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Abstract 
Human mesenchymal stromal/stem cells (MSC) isolated from aborted first trimester fetal 
bone marrow (BM) hold promise for use in tissue engineering applications and cell-based 
therapies due to their advantageous characteristics compared to their adult BM-MSC 
counterparts; faster growth kinetics, active telomerase, smaller size and higher differentiation 
potency. However, their isolation is restricted ethically and technically and therefore there is 
a need to identify a cell source with high therapeutic potential that is easily accessible in the 
clinic without ethical restrictions. The placenta is a potential source of readily-obtainable 
chorionic stem cells (CSC) throughout pregnancy. The aim of my thesis was to study the 
evolution of the CSC phenotype (i.e. change of stem cell characteristics) during gestation and 
to assess their capacity for bone repair in a mouse model of osteogenesis imperfecta (oim). I 
hypothesised that early fetal placental chorionic stem cells (e-CSC) were physiologically 
superior to their term counterparts, late chorionic stem cells (l-CSC), with advantages for use 
in fetal stem cell therapy of osteogenesis imperfecta (OI). 
 
In the first chapter I showed that e-CSC and l-CSC shared a common phenotype, which was 
intermediate between adult BM-MSC and human embryonic stem cells, with characteristics 
of both. I also showed the phenotype of CSC evolves during gestation with e-CSC displaying 
characteristics of an earlier state of stemness compared to l-CSC, such as smaller size, faster 
kinetics, unique expression of OCT4A variant 1 and higher levels of Nanog, Sox2, c-Myc and 
Klf4 expression, as well as the capacity to differentiate into lineages of the three germ layers 
through embryoid body formation.  
 
In the second chapter I showed the more primitive in vitro characteristics of e-CSC translated 
to higher tissue repair in vivo compared to l-CSC; accelerating healing when applied to a skin 
wound and increasing bone quality and plasticity following neonatal transplantation into the 
oim model. I subsequently used the oim model to assess the therapeutic potential of e-CSC 
for use in fetal cell therapy for OI. I showed compared to non-transplanted mice, oim 
transplanted with e-CSC had a two third reduction in fracture incidence, more ductile bones 
and increased trabecular bone volume. Prevention of fractures was attributed to the 
differentiation of exogenous cells to osteoblasts that expressed mature osteoblast genes and 
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synthesised human type 1 collagen (COL1A2). However, this beneficial effect may also have 
resulted from an indirect effect of the transplanted cells on the endogenous cells of the host 
mouse, since transplanted mice had upregulation of endogenous genes involved in 
endochondral ossification and osteoblast differentiation. 
 
Altogether, my thesis characterises early and late human fetal chorionic stem cells, providing 
insight into the ontogenesis of stemness phenotype during fetal development and shows the 
first trimester placenta is a practical source of stem cells that can be used to treat OI during 
bone development. 
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1.1.  Stem cells have properties useful for cell therapy 
1.1.1. Stem cells 
Stem cells from embryonic, fetal, neonatal and adult sources have huge potential for 
therapeutic applications. Embryonic stem cells (ESC) have been derived from the inner cell 
mass of embryos (Thomson, Itskovitz-Eldor et al. 1998; Adewumi, Aflatoonian et al. 2007), 
embryonic germ (EG) cells arise from cultured primordial germ cells (PGC) (Matsui, Zsebo 
et al. 1992; Resnick, Bixler et al. 1992; Shamblott, Axelman et al. 1998), and embryonic 
carcinoma (EC) cells are malignant counterparts of ESC, derived from teratocarcinomas 
(Martin 1980; Andrews 1984). Stem cells derived from embryonic sources can self-renew 
indefinitely in vitro and are pluripotential, capable of giving rise to cells from all three germ 
layers (ectoderm, mesoderm and endoderm). However, there are significant ethical concerns 
surrounding their use as well as risk of tumorigenicity if cells are not pre-differentiated prior 
to application. In contrast, somatic stem cells are found in various adult (bone marrow, fat, 
liver), neonatal (cord, amnion, chorion) and fetal tissues (blood, liver, bone marrow, placenta, 
amniotic fluid) (Friedenstein, Chailakhjan et al. 1970; Fortier 2005; Abdulrazzak, Moschidou 
et al. 2010). These cells can proliferate in vitro, but not indefinitely, are non-tumorigenic and 
have multipotent differentiation capacity, forming a restricted number of cell lineages. These 
cells may also provide beneficial trophic effects through cytokine and growth factor 
production and modulate the immune response (Vats, Bielby et al. 2005; Guillot, Cui et al. 
2007). 
 
1.1.2. Mesenchymal stem cells 
Adherent fibroblast-like stromal cells with osteogenic and clonal potential were first 
identified in adult bone marrow by Friedenstein et al. (Friedenstein, Petrakova et al. 1968; 
Friedenstein, Chailakhjan et al. 1970; Owen and Friedenstein 1988), and were subsequently 
termed mesenchymal stem cells (MSC) (Caplan 1991). MSC have since been isolated from a 
range of adult and fetal tissues and display distinct variations in cell size, growth rate, 
senescence, differentiation potency, immunosuppressive ability and gene expression profiles 
(Wagner, Wein et al. 2005; da Silva Meirelles, Chagastelles et al. 2006; Kern, Eichler et al. 
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2006; Guillot, Gotherstrom et al. 2007; Peng, Jia et al. 2008; Abdulrazzak, Moschidou et al. 
2010). The criteria to define an MSC is proposed as non-haematopoietic, plastic adherent, 
with multipotential differentiation to the mesenchymal lineages (bone, cartilage and adipose 
tissues) and expression of a specific panel of surface antigens; CD73 (SH3 and SH4), CD90 
(thy-1), CD105 (SH2) as well as lack of expression of the pan-leukocyte marker CD45, 
hematopoietic progenitor marker CD34, monocyte and macrophage hematopoietic cell 
marker CD14 (Dominici, Le Blanc et al. 2006). However, the exact definition of an MSC 
remains controversial, since cell surface epitopes can vary considerably depending on the 
extracellular environment (i.e. stem cell niche) (Kuhn and Tuan 2010) and although MSC are 
non-pluripotent, the transdifferentiation of MSC to non-mesodermal lineages has been widely 
reported (Poulsom, Alison et al. 2002). In addition, MSC possess immuno-modulatory 
properties through secretion of soluble factors such as indoleamine 2,3-dioxygenase, 
prostaglandin, nitric oxide, IL-6 and human leukocyte antigen (HLA)-G, as well as via cell-
cell interactions (Ghannam, Bouffi et al. 2010).  
 
 
 
Figure 1 – MSC migrate, differentiate and have trophic effects at sites of tissue injury 
MSC traffick through blood vessels to sites of tissue injury in response to migratory cues from 
chemokines (e.g. SDF-1), where they adhere and migrate across the endothelium and differentiate 
or release trophic factors to repair the tissue. Adapted from (Chavakis, Urbich et al. 2008). 
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MSC have generated substantial interest for clinical applications, such as in cell therapy, due 
to their ability to home to sites of injury (Chavakis, Urbich et al. 2008; Karp and Leng Teo 
2009), migrate across the transendothelial barrier (Schmidt, Ladage et al. 2006), undergo 
clonal expansion (Morrison and Kimble 2006), differentiate to specialised cells that replace 
damaged or defective cells (Pittenger, Mackay et al. 1999; Fuchs and Segre 2000) and also 
modulate the local tissue environment via paracrine anti-inflammatory, proangiogenic, anti-
apoptotic and immune suppressive effects that aid tissue repair (Caplan and Dennis 2006; 
Ghannam, Bouffi et al. 2010; Kuhn and Tuan 2010) (Fig.1). In addition, MSC from adult and 
fetal tissues have potential for allogeneic use due to their low immunogenicity in response to 
lack of expression of human leukocyte antigen (HLA) class II, modulation of a variety of 
immune cells, including T cells, B cells, natural killer cells, dendritic cells and neutrophils, 
and induction of regulatory T-cells that induce tolerance (Le Blanc, Tammik et al. 2003; 
Ghannam, Bouffi et al. 2010). 
 
1.1.3. Stem cell homing 
Schofield et al. first described the stem cell niche as a dynamic microenvironment that 
maintains stem cell quiescence and promotes proliferation and differentiation in response to 
local and systemic signals (Schofield 1978). Activation as well as trafficking and homing of 
MSC to sites of injury is controlled by release of inflammatory chemokines and cytokines as 
well as growth factors from injured tissues (Fox, Chamberlain et al. 2007; Chavakis, Urbich 
et al. 2008), which provide migratory cues and facilitate adhesion and transendothelial 
migration (Brooke, Tong et al. 2008). Stem cell therapy aims to use these natural homing 
mechanisms to direct transplanted cells to the target tissue and therefore identification of a 
cell source with high intrinsic migratory capacity would be advantageous. For example, fetal 
lung derived MSC had greater migratory capacity than adult stem cells to various stimuli, 
although the same was not found for hfMSC from bone marrow and therefore migratory 
potential may be source dependent (Maijenburg, Noort et al. 2010). 
 
Injured and inflamed tissues produce a variety of factors including hepatocyte growth factor 
(HGF) (Son, Marquez-Curtis et al. 2006), basic fibroblast growth factor (bFGF) (Schmidt, 
Ladage et al. 2006), platelet derived growth factor (PDGF) (Fiedler, Roderer et al. 2002; Zhu, 
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Mitsuhashi et al. 2006), bone morphogenic proteins BMP-2 and BMP-4 (Fiedler, Roderer et 
al. 2002), insulin-like growth factor I (IGF-1) (Li, Yu et al. 2007), and matrix 
metalloproteinases (MMPs) (Son, Marquez-Curtis et al. 2006). Importantly, stromal-derived 
factor (SDF-1 or CXCL12) is a dominant chemokine in the bone marrow and in combination 
with its receptor, CXCR4, has a key role in homing of MSC to various injured tissues (Ji, He 
et al. 2004; Wynn, Hart et al. 2004; Togel, Isaac et al. 2005; Son, Marquez-Curtis et al. 2006; 
Itoh, Satou et al. 2009). 
 
The interaction of SDF-1 and CXCR4 causes cytoskeleton rearrangements and integrin 
activation within the MSC, which results in their migration towards SDF-1, followed by 
transmigration across the endothelial barrier (Dar, Kollet et al. 2006). This SDF-1-CXCR4 
axis is thought to be essential for the migration of MSC to sites of fracture. For example, 
Granero Molto et al. used mice with a stabilised tibia fracture to show migration of MSC to 
the site of injury was dependent on the BM-MSC expression of CXCR4, since CXCR4- 
selected cells did not home to the fracture site (Granero-Molto, Weis et al. 2009). SDF-
1/CXCR4 signalling has also been shown to aid bone healing through recruitment of MSC. 
For example, AMD3100, a CXCR4 antagonist, reduced fracture repair (Toupadakis, Wong et 
al. 2012), whilst inhibition of SDF-1 using either a neutralizing antibody or a mouse partially 
lacking SDF-1 resulted in reduced bone formation and repair (Kitaori, Ito et al. 2009). 
Increasing the interaction of CXCR4 and SDF-1 could improve bone repair in cell based 
therapies.  
  
1.1.4. Stem cell self renewal 
Stem cell proliferation/clonal expansion can be either symmetric (giving rise to two 
unspecialised daughter stem cells) or asymmetric replication (giving rise to one stem cell and 
one committed/differentiated cell) (Morrison and Kimble 2006). Self renewal describes the 
proliferation of a stem cell to create more identical stem cells. The unlimited self renewal of 
ESC has been clearly demonstrated and attributed to c-Myc signalling (Rossant 2008; Smith, 
Singh et al. 2010; Wiese and Eilers 2011). However, controversy remains over the true ability 
of MSC to self renew, since we lack evidence that MSC proliferate indefinitely and instead 
Gemma Nicole Jones 
22 
 
show senescence and loss of initial multipotentiality (Sacchetti, Funari et al. 2007; Kuhn and 
Tuan 2010).  
 
The limited expansion potential of adult BM-MSC and low yield isolated from bone marrow 
aspirates, has meant obtaining sufficient numbers for use in regenerative medicine is difficult. 
There is research being carried out to maximise yield by adjusting the microenvironment of 
the cells to enhance proliferation, for example culturing in serum from donors of a young age 
(Lohmann, Walenda et al. 2012). Nevertheless, identifying a source of stem cells with greater 
expansion potential than adult MSC would allow greater numbers of cells to be generated for 
clinical use. BM-MSC have been found in the early fetus and compared to their adult 
counterparts have greater expansion potential due to faster kinetics and later senescence 
(Campagnoli, Roberts et al. 2001; Guillot, Gotherstrom et al. 2007).  Bone marrow human 
fetal MSC (hfMSC) also have greater proliferation capacity when compared to neonatal 
umbilical cord derived MSC (Zhang, Teoh et al. 2009). However, fetal bone marrow can only 
be collected after termination of pregnancy, which raises ethical issues and prevents their 
autologous use in cell-replacement therapies or tissue engineering settings. There is 
subsequently a need to identify a source of fetal stem cells with high proliferative capacity 
that can be collected without pregnancy termination. 
 
1.1.5. Stem cell differentiation 
The ability of MSC to differentiate to more specialised cells has resulted in their use in cell-
based tissue engineering and regenerative medicine (Fortier 2005). Adult BM-MSC were first 
shown to differentiate along osteogenic, chondrogenic and adipogenic lineages (Pittenger, 
Mackay et al. 1999) and have subsequently shown differentiation beyond mesodermal 
lineages (Poulsom, Alison et al. 2002). Bone marrow hfMSC have a broad differentiation 
potential beyond the mesodermal lineages, as well as basal expression of hESC markers 
(Campagnoli, Roberts et al. 2001; Guillot, Gotherstrom et al. 2007). Subsequent studies have 
shown other fetal stem cells as well as extra-embryonic stem cells are broadly multipotent, 
differentiating to some ectoderm and endoderm lineages as well as mesodermal and 
expressing an array of pluripotency genes (Table 1) (Abdulrazzak, Moschidou et al. 2010). 
However, unlike hESC these cells are not pluripotent and do not form tumours, which  
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Table 1 – Phenotype comparison of stem cells. Characteristics of fetal (blood, liver, bone marrow) and extra-embryonic (cord blood, Wharton’s jelly, 
amniotic fluid, amnion, chorion) derived stem cells compared to embryonic stem cells and adult bone marrow mesenchymal stem cells (BM-MSC). Listed are 
the cell phenotypes. E, embryonic; MSC, mesenchymal; H, haematopoietic; EP, epithelial; VSEL, very small embryonic like; P, pluripotent; M, multipotent; 
U, unipotent; n.d., not determined. (* these characteristics are not listed). Population doublings (PD) and doubling time (DT) shown for expansion over a, 50 
days; b, 8 passages; c, 14 passages; d, 5 passages. (Table taken from (Abdulrazzak, Moschidou et al. 2010)). 
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is critical for their safe therapeutic application. Full analysis of the pluripotency genes has yet 
to be determined for all sources and there remains debate in the literature as to whether the 
pluripotent isoform Oct4A is truly expressed by these cells or if instead Oct4B found in non-
pluripotent cells has been detected (Atlasi, Mowla et al. 2008; Ryan, Pettit et al. 2011). 
 
Bone marrow hfMSC have shown superior osteogenic differentiation capacity to adult BM-
MSC counterparts (Guillot, De Bari et al. 2008), which was attributed to the intermediate 
phenotype of the hfMSC between hESC and adult stem cells, with stemness characteristics of 
both (Guillot, O'Donoghue et al. 2006; Guillot, Gotherstrom et al. 2007). The hfMSC also 
showed greater osteogenic differentiation capacity, as shown by mineralisation of cellular 
scaffolds in immune-deficient mice, compared to perinatal MSC derived from umbilical cord 
(Zhang, Teoh et al. 2009). This may suggest primitive stem cell characteristics (i.e. stemness) 
are lost with increasing age of the tissue from which they are isolated. However, in this study 
cells were not derived from the same source, and therefore differences in stem cell phenotype 
may have been due to cell source rather than gestational age (in 't Anker, Noort et al. 2003).  
 
1.1.6. Trophic effects of stem cells 
MSC have the ability to produce a broad spectrum of soluble factors such as chemokines, 
cytokines and growth factors, which can aid tissue repair and also modulate the immune 
response. The immunosuppressive activity of MSC has been attributed to direct inhibition of 
T-lymphocyte (Bartholomew, Sturgeon et al. 2002; Di Nicola, Carlo-Stella et al. 2002) and 
natural killer cell proliferation (Sotiropoulou, Perez et al. 2006), but also indirect activation of 
monocytes (Beyth, Borovsky et al. 2005; Groh, Maitra et al. 2005) and regulatory T-
lymphocytes (Prevosto, Zancolli et al. 2007). These properties make MSC ideal for treatment 
of autoimmune diseases such as graft versus host disease (Trento and Dazzi 2010; Francois 
and Galipeau 2012), but also for use in cell therapy in combination with allogeneic cells.  
 
The paracrine and autocrine secreted factors from MSC influence the microenvironment to 
promote tissue repair via a combination of indirect trophic effects (Caplan and Dennis 2006). 
For example, the release of cytoprotective molecules such as anti-apoptotic factors can 
promote cell proliferation over cell death and reduce tissue fibrosis and scarring (Uemura, Xu 
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et al. 2006), whilst proangiogenic molecules can enhance angiogenesis to deliver more 
oxygen, micronutrients and inflammatory cells to the site of injury to aid tissue repair 
(Kinnaird, Stabile et al. 2004; Mirotsou, Jayawardena et al. 2011). Localised anti-
inflammatory factors also aid tissue repair by returning the tissue to its normal homeostatic 
function and preventing excessive detrimental inflammation (Ohnishi, Yanagawa et al. 2007). 
In cell therapy the secretion of soluble factors by MSC has been shown useful since MSC 
conditioned media alone improved cardiac function of acutely infracted hearts (Takahashi, Li 
et al. 2006) and increased chondrocyte proliferation and bone growth in the oim model 
(Otsuru, Gordon et al. 2012). Transplanted cells may also produce trophic factors that 
stimulate endogenous stem cell activity; increasing host cell commitment and enhancing 
tissue repair (Phinney 2007; Dominici, Rasini et al. 2009). The indirect paracrine action of 
MSC in cell-based therapies could be equally or possibly more useful to tissue repair than 
their direct differentiation. 
 
1.2. Developmental origin of stem cells 
Pluripotent epiblast stem cells distribute during gastrulation of the embryo into the three 
primary germ layers of the embryo, the primordial germ cells and the extra-embryonic 
mesoderm, which forms the umbilical cord and the mesenchymal part of the chorioallantoic 
placenta (Smith, Gesteland et al. 1994; Downs and Harmann 1997). In addition to the somatic 
cells found in the bone marrow, it was recently hypothesised that a sub-population of 
epiblast/germ line derived cells exist in murine bone marrow  descended from precursors of 
germ cells, primordial germ cells (PGC), due to their small morphology, high 
nuclear/cytoplasmic ratio, CD133+/Lin-/CD45- and expression of pluripotency markers 
OCT4, NANOG and SSEA4 (Kucia, Dawn et al. 2004; Wojakowski, Tendera et al. 2004; 
Kucia, Machalinski et al. 2006; Ratajczak, Mierzejewska et al. 2013). These cells were 
termed very small embryonic-like (VSEL) stem cells and similar cells have subsequently 
been found in human umbilical cord blood (Ratajczak, Zuba-Surma et al. 2008), human liver, 
heart and bone marrow (D'Ippolito, Diabira et al. 2004; Beltrami, Cesselli et al. 2007) and 
from in vitro cultures of various adult tissues (Vacanti, Roy et al. 2001; Kogler, Sensken et al. 
2004; Wernet, Trapp et al. 2010; Santourlidis, Wernet et al. 2011). 
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Kucia et al. hypothesised that epiblast/germ line derived cells were deposited in tissues prior 
to or during their migration through the developing blastocyst, which were then retained in a 
stem cell niche that maintained their stemness (Fig.2) (Kucia, Machalinski et al. 2006). The 
expression of pluripotency markers has been demonstrated for stem cells derived from human 
fetal tissues (Guillot, Gotherstrom et al. 2007; Zhang, Teoh et al. 2009; Ryan, Pettit et al. 
2011), although the presence of a subpopulation of fetal stem cells with a germ/epiblast 
developmental origin has yet to be elucidated. 
 
 
Figure 2 – The developmental deposition hypothesis of PGC during migration. 
During early embryogenesis early primordial germ cells (PGC; red) arise in the extra-embryonic 
mesoderm. It is hypothesised that whilst PGC migrate to the genital ridge and undergo methylation 
erasure some PGC are lost in the germ layers (endoderm, mesoderm and ectoderm), causing PGC 
derived stem cells to be retained in peripheral tissues of the fetus. 
Gemma Nicole Jones 
27 
 
1.3. Stem cells in regenerative medicine 
1.3.1. Tissue engineering 
Regenerative medicine describes a cross-disciplinary field of scientific research that aims to 
repair or replace damaged tissues or organs and restore their function. It combines a number 
of approaches including cell therapy, gene therapy and tissue engineering (Daar and 
Greenwood 2007). Tissue engineering combines living cells with non-living biocompatible 
materials to produce tissue like-structures (Langer and Vacanti 1993). Tissue engineering has 
made considerable progress in recent years, with translation to the clinic in some parts (e.g. 
cartilage repair), development of prototypes for other tissues (e.g. blood vessels) and even 
incorporation of new technologies (e.g. 3D printing) (Berthiaume, Maguire et al. 2011). 
However, hurdles for tissue engineering include scaling up production and obtaining 
sufficient cell numbers, identifying the appropriate cell source and matrices to use which are 
both safe and reliable, using adequate tissue differentiation protocols to avoid tumorigenic 
transformation of cells in vivo, preventing immune rejection of allogeneic cells and 
subsequent graft-versus host disease (Motaln, Schichor et al. 2010). First trimester bone 
marrow MSC have been used to seed tissue-engineered bone scaffolds, which were grafted in 
rats with critical-sized femoral defects and successfully resulted in closure of femoral defects 
by promoting woven and compact bone formation (Zhang, Teoh et al. 2010).  
 
1.3.2. Gene therapy 
Gene therapy aims to silence abnormal genes and/or increase normal gene expression where a 
genetic mutation is responsible for the disease pathology. Ex vivo gene delivery uses 
genetically modified autologous bone marrow MSC or induced pluripotent stem cells (iPSC) 
generated from skin fibroblasts of the patient. These cells are transduced with retroviral or 
adenoviral vectors of the normal gene along with tissue specific promoters, which are then 
transplanted back into the patient and deliver the normal gene (Deyle, Khan et al. 2012). This 
is an autologous approach therefore immune rejection is unlikely, however, the extraction of 
bone marrow is painful and MSC numbers are low. Whilst iPSC from skin are reprogrammed 
using transgenes, which has low efficiency, lacks stability of the pluripotent phenotype and is 
associated with viral induced tumorigenicity (Takahashi and Yamanaka 2006; Mukherjee and 
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Thrasher 2011). Therefore there is a need to isolate MSC from a more accessible source that 
can be banked for later autologous application, for example from extra-embryonic 
membranes normally discarded at birth or following prenatal diagnostics. 
 
Antisense gene approaches are required if the mutant RNA or protein results in the disease 
pathology. These approaches include oligodeoxynucleotides, ribozymes, hammerhead 
ribozymes, RNAi or siRNA to promote degradation of mutant mRNA transcripts. However, 
problems arise if there is wide genetic heterogeneity in the disease as the design of vectors 
specific to individual mutations is both complicated and time consuming (Niyibizi, Wang et 
al. 2004; Fuccio, Iorio et al. 2011; Ljunggren, Lindahl et al. 2011).  
 
1.3.3. Cell therapy 
In contrast, cell therapy has the potential to treat diseases without the need to tailor treatments 
for individual mutations. The rationale of cell therapy (Fig.1) is to introduce stem cells, 
which home to sites of injury (e.g. fractures), differentiate and replace defective cells with 
healthy cells (e.g. osteoblasts), that synthesise the correct protein (e.g. collagen type I) and 
also restore normal tissue function via trophic factors (e.g. anti-inflammatory, 
immunosuppressive and pro-angiogenic effects) (Guillot et al. 2008a). Cell therapy relies on 
the ability of stem cells to migrate to sites of injury, adhere and cross the transendothelial 
barrier, self-renew and hence expand to sufficient numbers for tissue repair, differentiate to 
specific cell lineages and secrete soluble factors to modulate the microenvironment and 
favour tissue repair (Chavakis, Urbich et al. 2008). In principle cell therapy could offer a long 
term treatment as stem cells have the ability to be stored long term in tissue niches (e.g. bone 
marrow) and be later activated when needed for tissue repair (Schofield 1978). However, the 
ability of transplanted stem cells to engraft and remain functional long term in host tissues is 
largely unknown. Several factors influence the efficiency of cell therapy, such as time of 
transplantation, dosing regimen, cell source, pre-conditioning of donor cells and potential of 
the cells to be banked according to good manufacturing practice (GMP) standards.  
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1.3.4. Fetal cell therapy 
Capitalizing on the small size of the fetus and the immature fetal immune system prenatal 
stem cell transplantation may have advantages over the postnatal approaches. The fetal 
environment is also permissive to endogenous stem cell migration during development, 
which may aid migration of donor cells to sites of tissue injury. For disorders that begin in 
utero and can be diagnosed during pregnancy, prenatal stem cell transplantation has 
advantages over postnatal approaches by preventing manifestation of the disorder earlier in 
life before damage or even perinatal death occurs (Le Blanc, Gotherstrom et al. 2005; Guillot, 
Abass et al. 2008; Panaroni, Gioia et al. 2009). In addition, a fetal-to-fetal approach to cell 
therapy may be optimal as fetal MSC are more primitive than adult MSC, showing greater 
expansion potential, smaller size, better osteogenic potential and greater immunogenicity 
(Guillot, Gotherstrom et al. 2007).  
 
1.3.5. Transplantation regime 
The route of injection has been found to influence cell therapy success with intra-venous 
(i.v.) transplantation of MSC showing higher engraftment and greater improvement in liver 
fibrosis than intrahepatic or intra-peritoneal (i.p.) injection (Zhao, Li et al. 2012), which may 
be due to phagocytosis of intra-peritoneal injected MSC by macrophages in the spleen 
(Wang, Shao et al. 2012). However, the venous route causes accumulation of cells in the 
lungs (Wang, Shao et al. 2012) and is considerably more technically challenging and invasive 
than the peritoneal route, in particular for prenatal cell therapy. Furthermore, in larger 
animals such as sheep i.v. transplantation is not superior to i.p. (Tanaka, Masuda et al. 2010), 
although this study used HSC. Therefore transplantation via the i.p. route is likely to be 
favoured in studies using prenatal or neonatal mice. 
 
1.3.6. Cell banking 
The potential to bank cells for both autologous and allogeneic application is likely to play an 
important role in bringing the translation of stem cell therapy to the clinic as a standardised 
treatment for a wide variety of disease pathologies. Stem cell banks for umbilical cord blood 
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have already been established worldwide and there are now numerous private stem cell banks 
that will bank various cells from dental pulp to menstrual blood. However, the safety and 
efficacy of using these alternative sources in the clinical setting have yet to be tested (Stacey 
2012). Recently, research has begun to investigate banking the extra-embryonic tissues 
normally discarded after birth. A facility with GMP production of human placenta derived 
MSC for human clinical trials has already been established (Brooke, Rossetti et al. 2009) and 
there is now a need to optimise, standardise and up-scale the production of these stem cells 
using large-scale bioreactors (Parolini, Alviano et al. 2010). Determining the optimal cell 
source for tissue banking and therapeutic application is also essential. The large size of the 
placenta tissues and accessibility at all clinics means they may become a fundamental MSC 
source for stem cell banking.   
 
1.4. Extra-embryonic stem cells potential use in cell therapy 
1.4.1. The extra-embryonic tissues 
Multipotent stem cells have been isolated from various fetal tissues; including bone marrow, 
blood and liver, as well as from extra-embryonic tissues such as umbilical cord, placenta and 
amniotic fluid (Table 1). Collection of fetal tissues in the first trimester is technically 
challenging and requires pregnancy termination, an obstacle to autologous applications. Fetal 
tissues are difficult to procure, the small size of the fetus limits total number of cells that can 
be collected and their clinical use is restricted by ethical legislations (In 't Anker, Scherjon et 
al. 2004; Michejda 2004; Miao, Jin et al. 2006). Whilst hfMSC from fetal blood can be 
collected by cardiocentesis during pregnancy, this procedure is highly invasive and carries a 
risk of miscarriage (Chan, Kumar et al. 2008). Fetal stem cell therapy could offer a promising 
alternative to current cell therapy using adult MSC (Abdulrazzak, Moschidou et al. 2010), but 
for the translation of fetal cell therapy to the clinic, it is essential to identify a cell source that 
is available in large numbers, without ethical or legal constraints surrounding their collection 
and use. For example, prenatal and perinatal stem cells that can be harvested from extra-
embryonic tissues. 
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The placenta and extra-embryonic membranes are readily obtainable within the clinic, being 
discarded at birth and also collectable during ongoing pregnancy from chorionic villous 
sampling (CVS), a routine prenatal diagnostic procedure (Ilancheran, Moodley et al. 2009). 
The extra-embryonic membranes surround not only the fetus, but also the amniotic fluid, 
which can also be collected during pregnancy via amniocentesis and at term. Amniotic fluid 
contains a heterogeneous population of cell types from the fetal amnion membrane, fetal skin 
and fetal alimentary, urogenital and respiratory tracts (Murphy and Atala 2013). Finally the 
umbilical cord, which transports fetal blood to the placenta via umbilical vessels, can be 
collected safely and non-invasively at birth for extraction of fetal blood containing 
haematopoietic stem cells, and also for collection of MSC from Wharton’s jelly; the 
connective tissue that surrounds the umbilical cord vessels (Weiss, Medicetty et al. 2006; 
Secco, Zucconi et al. 2008). 
 
The placenta is a large fetal-maternal organ that contains a maternal decidua layer, a fetal 
amnion layer composed of amniotic epithelial cells from the epiblast and amniotic 
mesenchymal stromal cells from the hypoblast, and a chorion layer containing both fetal and 
maternal cells (Fig.3). The chorionic tissue of the placenta is derived from both the outer 
trophectoderm layer of the embryo, which differentiates to cytotrophoblastic and 
synctiotrophoblastic cells and invades the maternal decidua, and also from the embryonic 
epiblast cells that are allocated to the extra-embryonic mesoderm during gastrulation and 
form the fetal mesenchymal part of the mature chorioallantoic placenta (Parolini, Alviano et 
al. 2008; Ilancheran, Moodley et al. 2009; Insausti, Blanquer et al. 2010; Murphy and Atala 
2013). The smooth chorion forms due to partial regression of the chorionic villi that surround 
the amniotic sac in early gestation and loosely fuses with the amnion at 17-20 weeks 
gestation to form the amnio-chorionic membrane (Ilancheran, Moodley et al. 2009).  
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1.4.2. Amniotic fluid 
Amniotic fluid can be collected at term (Murphy and Atala 2013), but in general is collected 
in the second trimester following routine amniocentesis. Just 2ml of amniotic fluid can 
contain up to 20,000 cells, 1% of which are stem cell factor c-Kit (CD117) positive and show 
a phenotype similar to hfMSC with characteristics intermediate of hESC and adult BM-MSC 
(De Coppi, Bartsch et al. 2007). Amniotic fluid stem cells (AFSC) are non-tumorigenic and 
have potential for application in the clinic due to their broad differentiation potential to a 
number of lineages from each of the three germ layers (e.g. hepatocytes, osteoblasts, and 
neurons). AFSC have been described as broadly multipotent, as opposed to pluripotent, 
 
Figure 3 – The placenta and extra-embryonic membranes 
The placenta is fully formed by 18-20 weeks gestation and contains chorionic villi carrying fetal 
blood to the maternal uterine vessels. The placenta is attached to the fetus at the chorionic plate via 
the umbilical cord, which contains umbilical veins and arteries as well as surrounding Wharton’s 
jelly. The extra-embryonic membranes comprise of amnion and smooth chorion, which are 
surrounded by the maternal decidua and enclose the fetus and amniotic fluid. Adapted from (Brown 
2007). 
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because they eventually senesce, so do not indefinitely self-renew, and they cannot 
differentiate to all the lineages of the 3 germ layers (Kaviani, Perry et al. 2001; Kaviani, 
Guleserian et al. 2003; Tsai, Lee et al. 2004; Tsai, Hwang et al. 2006; De Coppi, Bartsch et 
al. 2007; Cananzi, Atala et al. 2009; Ditadi, de Coppi et al. 2009). 
 
The application of AFSC has been demonstrated in vivo by their neuroprotective effect in a 
mouse model of ischemic stroke (Rehni, Singh et al. 2007) as well as their cardioprotective 
effects in rodent models of myocardial infarction (Bollini, Cheung et al. 2011; Lee, Wei et al. 
2011). The trophic mechanisms of tissue repair by AFSC have also been demonstrated by the 
increased proliferation and decreased apoptosis of tubular epithelial cells in the kidneys of 
mice with acute tubular necrosis (Perin, Sedrakyan et al. 2010). AFSC hold much promise for 
use in cell based therapies and tissue engineering, hence current research is now 
characterising and investigating the tissue repair capacity of stem cells derived from 
associated extra-embryonic tissues.  
 
1.4.3. Wharton’s jelly 
MSC isolated from umbilical cord tissue (i.e. Wharton’s jelly) have a similar phenotype to 
other fetal stem cells with high proliferative potential compared to adult BM-MSC (Schugar, 
Chirieleison et al. 2009) and expression of MSC genes as well as hESC genes, albeit at a 
considerably lower level (Fong, Richards et al. 2007; Fong, Chak et al. 2011).  The umbilical 
cord MSC (UC-MSC) can differentiate into lineages of all three germ layers including 
osteocytes (Wang, Wang et al. 2004), hepatocytes (Anzalone, Lo Iacono et al. 2010) and 
neurons (Mitchell, Weiss et al. 2003; Anzalone, Lo Iacono et al. 2010). These cells have a 
high harvest yield and can be used for allogeneic applications (Schugar, Chirieleison et al. 
2009). UC-MSC have also been used to suggest that primitive stem cell characteristics 
decline with age, since UC-MSC had lower osteogenic differentiation potency than hfMSC 
from first trimester bone marrow (Zhang, Teoh et al. 2009). Although differences may be due 
to the different tissue sources of origin rather than age.  
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1.4.4. Amnion 
Amniotic epithelial stem cells (AE) have been isolated from the amnion membrane which 
encloses the amniotic fluid. Similar to AFSC, AE show characteristics intermediate between 
MSC and hESC, expressing both mesenchymal and pluripotency markers (Yen, Huang et al. 
2005; Battula, Treml et al. 2008) with differentiation to some lineages from all three germ 
layers (Miki, Lehmann et al. 2005; Miki and Strom 2006; Ilancheran, Michalska et al. 2007). 
AE have also shown similarities to hESC through their formation with mouse ESC of 
xenogeneic chimeras (Tamagawa, Ishiwata et al. 2004), although importantly for clinical 
application AE were non-tumorigenic in SCID/beige mice (Miki, Lehmann et al. 2005). 
Similarly amnion derived MSC have shown capacity to differentiate beyond mesodermal 
lineages (In 't Anker, Scherjon et al. 2004; Soncini, Vertua et al. 2007) to neurogenic lineages 
(Sakuragawa, Kakinuma et al. 2004; Chang, Hwang et al. 2010; Manochantr, Tantrawatpan 
et al. 2010) and endodermal lineages including hepatocytes (Tamagawa, Oi et al. 2007), 
cardiomyocytes (Zhao, Ise et al. 2005) and endothelial cells (Alviano, Fossati et al. 2007). 
 
AE have also been isolated from the first trimester, but in contrast to CVS or amniocentesis, 
their collection requires pregnancy termination which restricts their clinical application. 
Interestingly, first trimester AE show a potentially more primitive phenotype than AE 
isolated at term. This was shown by a greater proportion of first trimester AE being positive 
for TRA-1-60 and TRA-1-81 with higher expression of Nanog and Sox2, but not Oct4 than 
their term counterparts (Izumi, Pazin et al. 2009). This suggests that primitive stem cell 
characteristics could be lost with increasing gestational age.  
 
1.4.5. Chorion 
The literature on term chorion-derived stem cells is insufficient with limited characterisation 
of immuno-phenotype and a focus primarily on isolation techniques and identification of their 
vascular niche within the placenta (Soncini, Vertua et al. 2007; Poloni, Rosini et al. 2008; 
Castrechini, Murthi et al. 2010; Bacenkova, Rosocha et al. 2011; Rus Ciuca, Soritau et al. 
2011). In addition many studies of term chorionic cells report cells of both fetal and maternal 
origin (In 't Anker, Scherjon et al. 2004; Soncini, Vertua et al. 2007), with some groups 
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isolating only maternal origin cells (Barlow, Brooke et al. 2008; Brooke, Rossetti et al. 2009; 
Semenov, Koestenbauer et al. 2010; Rus Ciuca, Soritau et al. 2011; Jaramillo-Ferrada, 
Wolvetang et al. 2012), and others failing to exclude maternal cell origin (Yen, Huang et al. 
2005; Miao, Jin et al. 2006; Castrechini, Murthi et al. 2010; Bacenkova, Rosocha et al. 2011; 
Fariha, Chua et al. 2011; Kim, Shin et al. 2011). Whilst studies that used chorionic villous 
from the chorionic plate of term placenta were able to isolate fetal origin stem cells, since this 
tissue is not in direct contact with the maternal decidual cells (Abumaree, Al Jumah et al. 
2012). Likewise work on first trimester chorionic stem cells has shown fetal origin by 
karyotyping (Poloni, Rosini et al. 2008), although not carried out in all studies (Portmann-
Lanz, Schoeberlein et al. 2006; Spitalieri, Cortese et al. 2009; Portmann-Lanz, Schoeberlein 
et al. 2010). 
 
Notwithstanding this problem of contaminating decidual maternal stem cells, comparisons of 
term placenta /chorionic stem cells with adult bone marrow MSC (Soncini, Vertua et al. 
2007; Brooke, Rossetti et al. 2009) have indicated that these cells may be more primitive than 
adult MSC with evidence of greater self renewal in vitro when growth kinetics were analysed 
(Barlow, Brooke et al. 2008; Jaramillo-Ferrada, Wolvetang et al. 2012), as well as expression 
of some pluripotency markers (Yen, Huang et al. 2005; Bacenkova, Rosocha et al. 2011; 
Fariha, Chua et al. 2011) and potential to differentiate beyond mesodermal lineages to 
hepatogenic (Kim, Shin et al. 2011) and neurogenic lineages (Portmann-Lanz, Schoeberlein 
et al. 2006; Portmann-Lanz, Schoeberlein et al. 2010). This suggests term placenta derived 
stem cells may be similar to fetal stem cells and have an intermediate phenotype. 
 
Late gestation placenta derived stem cells have already shown potential for use in cell based 
therapies. For example, they inhibited growth of multiple myeloma in bone and stimulated 
bone formation in an immune-deficient model of medullary myeloma bone disease (Li, Ling 
et al. 2011). Stem cells isolated from term placenta also had an anti-fibrotic effect in rats with 
carbon tetrachloride injured livers (Lee, Jung et al. 2010) and in a mouse model of lung 
fibrosis (Cargnoni, Gibelli et al. 2009). The same repair effects were seen ex vivo when the 
cells were applied to a perfused human lung (Nazarov, Lee et al. 2012). Term placenta stem 
cells were also capable of reversing hyperglycemia in streptozotocin-induced diabetic mice 
and differentiating to islet-like cell clusters that secreted insulin (Kadam, Muthyala et al. 
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2010). Term placenta stem cells have also demonstrated immuno-suppressive properties both 
in vitro in a mixed lymphocyte reaction (Karlsson, Erkers et al. 2012; Lee, Jung et al. 2012) 
and in vivo where neurtrophil infiltration was decreased in a mouse model of bleomycin-
induced lung fibrosis (Cargnoni, Gibelli et al. 2009). 
 
Fetal stem cells isolated from CVS can be collected in the first trimester as early as the 10th 
week of gestation, which allows sufficient time for cell expansion, differentiation, 
transduction, etc. for use in autologous prenatal cell therapy. This may be an advantage over 
the mid-trimester AFSC for preventing progression of congenital fetal diseases and 
subsequent organ damage as early as possible (Shaw, David et al. 2011). Similar to 
amniocentesis, CVS is an invasive procedure with a 1% miscarriage risk, which although 
low, may prevent banking of these cells in healthy pregnancies (Tabor and Alfirevic 2010). In 
terms of supply for allogeneic applications or cell banking, first trimester suction termination 
of pregnancy is the commonest operation in the world and although ethically contentious for 
clinical application, placenta would be an ideal source of stem cells to collect from pregnancy 
termination, being larger and easier to separate than other fetal tissues.  
 
Cultured first trimester chorionic derived stem cells show a phenotype similar to AFSC with 
a fibroblast-like morphology, greater cell expansion than adult BM-MSC, differentiation to 
osteocytes, adipocytes, chondrocytes and neuronal cells and expression of MSC markers as 
well as some markers found in hESC (Oct4 and Rex1) (Portmann-Lanz, Schoeberlein et al. 
2006; Poloni, Rosini et al. 2008; Spitalieri, Cortese et al. 2009). Immuno-regulatory capacity 
has also been shown for these cells, which inhibited proliferation of stimulated T-
lymphocytes (Poloni, Maurizi et al. 2012). First trimester chorionic stem cells have also 
demonstrated beneficial paracrine effects, showing release cytokines that reduced neurotoxin-
induced apoptosis in a Parkinson’s disease cell model (Nazarov, Lee et al. 2012). Although 
few studies have tested the survival and functions of the first trimester placenta stem cells in 
rodent models, their capacity to be expanded large-scale in human serum and maintain a 
stable karyotype means they are a promising source for regenerative medicine (Poloni, Rosini 
et al. 2008; Poloni, Maurizi et al. 2012). Whether the earlier gestational age of the chorionic 
stem cells translates to better tissue repair compared to stem cells isolated at birth needs to be 
answered in order to select the optimal source for cell therapy application. 
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1.5. Osteogenesis imperfecta 
1.5.1. The 11 types of OI 
Osteogenesis Imperfecta (OI), or brittle bone disease, is a genetic disorder of connective 
tissue caused by mutations in collagen type I or genes associated with its biosynthesis (Fig.4). 
OI occurs in 1 in 15,000–20,000 births (Marini 1998) and is defined as a heterogeneous 
group of disorders that vary in severity and result in bones being more prone to fracture. 
There is no cure for OI and current treatments merely manage the symptoms or offer 
temporary improvements in bone strength rather than treat the underlying cause (Van Dijk, 
Pals et al. 2010).  
 
There are 11 types of OI (Table 2) of which the clinical manifestations range in severity from 
the perinatal lethal type II to the mild non-deforming type I. OI patients are more susceptible 
to fractures due to reduced bone mass, which increases the brittleness and fragility of their 
bones (Stoss and Freisinger 1993; Cohen-Solal, Zylberberg et al. 1994; Dalgleish 1997; Van 
Dijk, Pals et al. 2010). Other symptoms of OI can include short stature, bone deformities 
 
Figure 4 - The biosynthesis of collagen type I 
The biosynthesis of collagen type I; col1α1 and col1α2 genes are transcribed and translated to 2 
proα1(I) and 1 proα2(I), assembled by molecular chaperones, then modified with 3-hydroxylation 
and folded to form collagen type I. Mutations in col1α1 and col1α2 genes cause type I-IV OI, 
mutations in molecular chaperones cause type X-XI OI and mutations in the 3-hydroxylation process 
result in type VII-IX OI. Arrows represent mutations. OI: Osteogenesis imperfecta. 
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including scoliosis and vertebral compressions, joint laxity, blue or grey sclera, 
dentinogenesis imperfecta, hearing problems, triangular shaped face, cardiopulmonary 
problems and reduced life expectancy (Basel and Steiner 2009). 
 
Table 2 - Types of OI, inheritance and clinical symptoms. OI types I-XI inheritance pattern 
causative genetic defect, disease severity, age of diagnosis and clinical symptoms presented; 
including incidence of fractures, stature, eye sclera colour and whether dental problems are present. 
OI: Osteogenesis Imperfecta. 
 
OI 
Severity Diagnosis 
Clinical Symptoms 
Genetic 
Defect 
 
Ref Fractures Stature 
Sclera 
Colour 
Dental 
Issues 
Autosomal Dominant Inheritance: 
I Mild 
Child-
adulthood 
A few 
Normal/ 
mildly short 
Blue No COL1A1  
(Sillence, 
Rimoin et al. 
1979) 
II Lethal In utero Multiple Short Dark NA 
COL1A1/ 
COL1A2 
(Sillence, 
Rimoin et al. 
1979) 
III Severe 
In utero/at 
birth 
Multiple Short Grey Yes 
COL1A1/ 
COL1A2 
(Sillence, 
Rimoin et al. 
1979) 
IV 
Mild-
moderate 
Birth-
adulthood 
Variable 
Moderately 
short 
Grey/ 
white 
Yes/No 
COL1A1/ 
COL1A2 
(Sillence, 
Rimoin et al. 
1979) 
V 
Moderate-
severe 
Birth-
adulthood 
Multiple 
with 
hypertrophic 
callus 
Short/mildly 
short 
Normal 
white 
No Unknown  
(Glorieux, 
Rauch et al. 
2000) 
Autosomal Recessive Inheritance: 
VI 
Moderate-
severe 
Birth-
adulthood 
Multiple 
Moderately 
short 
Normal 
white 
No SERPINF1 
 (Glorieux, 
Ward et al. 
2002) 
VII 
Moderate-
severe 
Birth Multiple Mildly short 
Normal 
white 
No CRTAP  
(Barnes, 
Chang et al. 
2006; Morello, 
Bertin et al. 
2006) 
VIII 
Severe-
lethal 
In utero/at 
birth 
Multiple Short 
Normal 
white 
Yes LEPRE1  
(Cabral, 
Chang et al. 
2007) 
IX 
Severe-
lethal 
Birth-
childhood 
Multiple 
Moderately 
short 
Normal 
white 
Yes PPIB  
(van Dijk, 
Nesbitt et al. 
2009) 
X Severe 
Birth-
childhood 
Multiple 
Moderately 
short 
Blue Yes 
SERPINH
1  
(Christiansen, 
Schwarze et 
al. 2010) 
XI Severe Birth Multiple Short 
Normal 
white 
No FKBP10  
(Alanay, 
Avaygan et al. 
2010) 
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1.5.2. Clinical management of OI 
Current clinical management of OI involves a multidisciplinary approach. Non-surgical 
methods aim to treat fractures through bracing, splinting and physiotherapy as well as 
improving hearing, dental and psychological issues, although this approach can increase 
mobilisation, joint movement and muscle function it cannot prevent fractures (Sillence, 
Morley et al. 1995; Niyibizi, Wang et al. 2004). Whilst surgery aims to prevent and correct 
deformities, such as using intramedullary telescopic rods to stabilise long bones (Cho, Kim et 
al. 2011), spine stabilisation to correct scoliosis and basilar impression surgery to correct 
migration of the spine (Bishop 2010; Monti, Mottes et al. 2010). However, surgery only 
stabilises the progression of deformity and is associated with risks during surgery as well as 
complications afterwards such as rod migration, increased risk of osteoporosis and 
immobilization (Esposito and Plotkin 2008). 
 
Pharmacological therapies, namely bisphosphonates, have become the standard treatment for 
children with OI. Bisphosphonates are internalised by osteoclasts and inhibit their bone 
resorption, thereby increasing bone mass, density and cortical width through accumulation of 
the defective bone matrix (Munns, Rauch et al. 2005; Russell, Lacey et al. 2011). However, 
controlled trials show the effectiveness of bisphosphonates reduces long term, with no 
significant improvements in growth, muscle strength, bone pain or lower extremity long bone 
fractures (Letocha, Cintas et al. 2005). Furthermore neither surgery nor bisphosphonates 
address the genetic mutations that affect collagen biosynthesis and subsequently lead to bone 
fragility.  
 
Some studies have shown growth hormone in combination with bisphosphonates may prove 
more effective than bisphosphonates alone, with greater bone mineral density and growth 
velocity measured in OI children, although fracture incidence was not improved (Antoniazzi, 
Monti et al. 2010). Alternatively antibodies, such as denosumab, anti-sclerostin and DKK1-
IgG, have also been shown to increase bone formation over bone resorption, thereby 
increasing matrix deposition and bone mass (Forlino, Cabral et al. 2011). However, the safety 
and long term efficacy of these methods is not yet known and the bone matrix deposited 
remains defective. 
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1.5.3. Rodent models of OI 
Rodent models of OI (Table 3) have provided a tool to not only better understand the 
disorder, but also to investigate the effectiveness of novel therapies, before they are brought 
to the clinic. The most popular rodent model, with over 57 publications to date, is the model 
of type III OI; osteogenesis imperfecta murine (oim). These mice have reduced growth, 
multiple fractures, skeletal deformities, enlarged growth plates and decreased bone strength, 
length and volume. Oim-/- (i.e. oim) are homozygous for a naturally occurring Glycine 
deletion at nucleotide 3983 of the Col1a2 gene. As a result these mice cannot produce 
pro2(I) collagen, causing the replacement of normal heterotrimeric COL1(1)2(2) with 
homotrimeric COL1(1)3, which accumulates in the extracellular matrix and causes bone 
fragility (Chipman, Sweet et al. 1993). 
 
Table 3 – OI murine models 
Murine models of OI, the type of OI they most resemble, the causative genetic mutation and how the 
mutation is inherited. OI: Osteogenesis imperfecta. M-MuLV: Moloney murine leukaemia virus. AD: 
autosomal dominant. AR: autosomal recessive. +/-: Heterozygous for mutation. -/-: Homozygous for 
mutation. 
Mouse Model 
OI 
Type 
Genetic Mutation Inheritance Reference 
Mov13+/- I M-MuLV insertion AD (Bonadio, Saunders et al. 1990) 
Mov13-/- II M-MuLV insertion AR (Bonadio, Saunders et al. 1990) 
Sp7-/- II Knock-out Sp7 AR (Baek, Lee et al. 2009) 
Transgenic II Col1a1 AD (Stacey, Bateman et al. 1988) 
Oim-/- III Glycine deletion col1α2 AR (Chipman, Sweet et al. 1993) 
Aga2+/- III Col1a1 substitution AD (Lisse, Thiele et al. 2008) 
Brtl+/- IV Knock-in col1α1 AD (Forlino, Porter et al. 1999) 
Brtl-/- IV Knock-in col1α1 AR (Forlino, Porter et al. 1999) 
OI-transgenic II-IV Human COL1A1 minigene AD (Khillan, Olsen et al. 1991) 
Crtap-/- VII KO Crtap AR (Morello, Bertin et al. 2006) 
Lepre1-/- VIII KO Lepre1 AR (Vranka, Pokidysheva et al. 2010) 
Ppib-/- IX KO Ppib AR (Choi, Sutor et al. 2009) 
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Other key rodent models investigated include the Mov13 mice, which were created by 
inhibition of Col1a1 allele transcription using the Moloney murine leukemia virus. 
Homozygote Mov13-/- have embryonic lethality, whereas heterozygote Mov13+/- mice display 
mild type I OI phenotype; reduced bone strength and increased tissue porosity, due to 
insufficient collagen fibril synthesis (Bonadio, Saunders et al. 1990). Knock-in type IV OI 
murine model Brittle (Brtl) mice have a Glycine349 to Cystine mutation in one col11 allele 
created using the Cre/lox recombination system. Heterozygote Brtl+/- mice have 30% chance 
of perinatal lethality, reduced body size, reduced bone mineral density, and long bone 
deformities and fractures. Whereas, homozygote Brtl-/- mice have no perinatal lethality, 
normal bone mineral density and only a moderately reduced body size due to homozygosity 
for the mutant allele resulting in a more homozygous extracellular matrix, which is 
subsequently better organised and therefore less brittle. Different mixtures of normal and 
mutant pro1(I) collagen chains may contribute to the range of severities seen in Brtl+/- mice 
as well as patients with type IV OI (Forlino, Porter et al. 1999).  
 
1.6. Prospective novel therapies for OI 
1.6.1. Gene therapy 
In contrast gene and cell therapy, improve bone fragility by acting during collagen formation 
to correct helical conformation and fibril assembly. Gene therapy aims to silence abnormal 
genes and/or increase normal gene expression. In autosomal recessive cases of OI (Table 2), 
where there is a deficiency in proteins required for post-translational modifications and 
folding (e.g. absence of 3-hydroxylation or deficiency in FKBP10 or Serpin H1 collagen 
chaperones), gene supplementation to over-express the normal collagen gene may be useful. 
Whereas in autosomal dominant OI types the defect is in the quantity or structure of type I 
procollagen; the presence of both mutant and normal procollagen chains results in matrix 
heterogeneity and the different severities of the OI phenotype. Therefore additional antisense 
gene approaches are required to promote degradation of mutant mRNA transcripts. However, 
the Col1α1 and Col1α2 genes span 51 and 52 exons respectively and over 800 different 
mutations have been reported within these genes to cause OI. Therefore the genetic 
heterogeneity of OI means vector design to specific mutations is both complicated and time 
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consuming (Niyibizi, Wang et al. 2004; Forlino, Cabral et al. 2011). Subsequently the reality 
of bringing gene therapy to the clinic as a standardised treatment for OI is unlikely in the near 
future and cell therapy holds the most promise for treating this disease. 
 
1.6.2. Cell therapy 
The potential of cell therapy for OI has been tested in various rodent models with different 
cells, methods of transplantation and analysis techniques (Table 4). The OI-transgenic 
murine model with a moderate (type IV OI) to severe (type II OI) phenotype was the first 
used to assess the potential of cell therapy to treat OI (Pereira, O'Hara et al. 1998). The mice 
had reduced growth, multiple fractures and reduced bone mineral and collagen content due to 
insertion of a mini-gene of human pro1(I) with a 41 exon deleted region that synthesised 
shortened pro1(I) chains causing degradation of normal pro1(I) chains (Khillan, Olsen et 
al. 1991). Pereira et al. infused wild type MSC isolated from bone marrow or whole bone 
marrow intra-peritoneal into 3 week old OI-transgenic after irradiation and showed donor 
cells were engrafted 1 and 2 months after transplantation in the bone, bone marrow, cartilage 
and other non-hematopoietic tissues such as the lung, brain, skin and spleen (Pereira, O'Hara 
et al. 1998). A small, but significant increase in collagen content and mineral content was 
also recorded in the transplanted mice, but how the donor cells contributed to these changes 
was not investigated. 
 
Subsequent experiments by Niyibizi’s group using the oim mouse model showed both 
engraftment of donor cells and differentiation down the osteogenic lineage. GFP tagged 
osteoprogenitors from wild type mouse bones were transplanted into neonatal oim via the 
superficial temporal vein and were detected on the oim endosteal bone surfaces, cortical 
bone, spongiosa, bone marrow and areas of active bone formation four weeks after 
transplantation. Differentiation of donor cells to osteoblasts and osteoprogenitors following 
transplantation was confirmed by gene expression analysis; transplanted bone had high 
expression of osteoblast-specific genes (e.g. Osteocalcin and Osterix), whereas 
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Table 4 - The history of cell therapy with murine models of OI 
In chronological order the cell therapy experiments carried out on murine models of OI; with details of the type of cells used, the mouse model, the age of 
transplantation and analysis, whether mice were irradiated before transplantation and the route of cell delivery. Results shown include whether transplanted 
cells engrafted and differentiated in the recipient bones and any change to bone properties or mouse phenotype recorded. OI: Osteogenesis imperfecta. WT: 
wild type. MSC: mesenchymal stromal/stem cells. E: embryonic day. i.p: intraperitoneal. i.v: intravenous. +/-: Heterozygous for mutation. -/-: Homozygous for 
mutation. 
Mouse 
Model 
Cells Age Irradiate Route 
Age 
Culled 
Results 
Ref Cells 
Engraft 
Donor Cell 
Differentiate 
Bone Pathology Phenotype  
OI-
transgenic 
WT bone 
marrow 
(whole/MSC) 
3 
weeks 
Yes i.p. 8-12 
weeks 
Yes Not measured Not measured Not measured (Pereira, O'Hara et al. 
1998) 
Oim-/- WT 
osteoprogenitors 
2 days Yes i.v. 2&4 
weeks 
Yes Yes Not measured Not measured (Wang, Li et al. 
2006) 
Oim-/- WT clonal bone 
marrow MSC 
2 days Yes i.v. 2&4 
weeks 
Yes Yes Not measured Not measured (Li, Wang et al. 
2007) 
Oim-/- Human fetal 
blood MSC 
E13.5 -
15 
No i.p. 2,4,8,12 
weeks 
Yes Yes Increase bone thickness, 
plasticity & length. 
Decreased  long 
bone fractures 
(Guillot, Abass et al. 
2008) 
Brtl+/- WT whole adult 
bone marrow 
E13.5 -
14 
No i.p. 8 weeks Yes Yes Increase bone strength No perinatal 
lethality 
(Panaroni, Gioia et al. 
2009) 
Oim-/- Human fetal 
blood MSC 
E13.5 -
15 
No i.p. 8 weeks Yes Yes Improved plasticity, matrix 
stiffness & organisation  
Decreased long 
bone fractures 
(Vanleene, Saldanha 
et al. 2011) 
Oim-/- Human fetal 
blood MSC 
3-5 
days 
No i.p. 8 weeks Yes Yes Decreased bone brittleness Decreased long 
bone fractures 
(Jones, Moschidou et 
al. 2012) 
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osteoprogenitor-specific genes were expressed more highly in the bone marrow (e.g. 
Osteopontin, Sox9 and Runx2) (Wang, Li et al. 2006). Although protein analysis did not find 
the presence of the missing COL1A2 protein, a subsequent study by the same group did find 
COL1(α1)2(α2) heterotrimers 4 weeks after injection of single cell-expanded marrow 
progenitor cells in neonatal oim (Li, Wang et al. 2007). This data shows transplantation of 
normal cells into a mouse model of OI results in their migration to bone and subsequent 
differentiation to functional osteoblasts. 
 
Since these studies clinical trials have used cell therapy to treat OI patients; four published, 
two completed and one presently recruiting with most studies carried out in the U.S.A and 
Sweden. One study showed transplantation of bone marrow MSC in OI children resulted in 
gains in body length and bone mineralization, although these effects were lost over time and 
donor cell engraftment was low at less than 2% (Horwitz, Gordon et al. 2002). This group is 
currently recruiting participants for further clinical trials to evaluate the safety and 
effectiveness of repeated infusions of MSC in children with OI. 
 
1.6.3. Fetal cell therapy 
The use of fetal stem cells to treat OI prenatally before irreversible damage is caused was 
shown in a clinical trial whereby allogeneic fetal liver derived MSC were transplanted in 
utero in a human fetus with OI. The transplantation led to better than expected results with no 
visible immune rejection, engraftment of cells in bone nine months later and regularly 
arranged and configurated trabecular bone. However, again engraftment was low at only up 
to 7% and results were confounded by concomitant use of bisphosphonates (Le Blanc, 
Gotherstrom et al. 2005).  
 
The potential of prenatal therapy to treat OI using human fetal MSC was assessed in the oim 
mouse model. Oim were transplanted prenatally at E13.5-15 with fetal MSC isolated from 
first trimester human fetal blood. At 8 weeks transplanted oim had an overall two-thirds 
reduction in long bone fractures when compared to age-matched oim controls with significant 
reduction in fracture incidence for all long bones at all time points (4, 8 and 12 weeks) 
analysed. Furthermore there was normalisation of growth plate height and increase in bone 
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length, strength and cortical thickness (Guillot, Abass et al. 2008). An independent study 
found that the dramatic reduction in fracture rate of these mice may be attributed to a 
reduction in bone brittleness, rather than increased bone strength (Vanleene, Saldanha et al. 
2011). 
 
Analysis of the mechanisms underlying these therapeutic effects revealed that the donor cells 
homed preferentially to bones, compared to other organs, where they were found in higher 
numbers at sites of fracture callus and active bone formation. Cells engrafted in bones, 
expressed late markers of osteoblasts (e.g. Osteocalcin) and produced the Collagen type 1 
alpha 2 (COL1A2) chain protein, which is absent in non-transplanted oim mice. This led to 
modification of the bone matrix composition, resulting in increased bone matrix stiffness and 
improved organisation of lamellar bone (Guillot, Abass et al. 2008; Vanleene, Saldanha et al. 
2011; Vanleene, Porter et al. 2012).  
 
However, engraftment levels of donor cells were low at only 3-5% and the long term effects 
of transplantation could not be measured due to strict severity limits on oim under British law 
(Guillot, Abass et al. 2008). In addition fetal MSC isolated from first trimester blood are 
collected either by cardiocentesis during termination of pregnancy, which is ethically and 
technically challenging and prevents autologous application, or from the umbilical cord 
during ongoing pregnancy, which is highly invasive and carries a risk of miscarriage (Chan, 
Kumar et al. 2008). 
 
A similar study was carried out in the Brtl mouse, a model of autosomal dominant OI, and 
similar effects were shown. Donor cells were found engrafted in bone 8 weeks after prenatal 
transplantation of wild type adult bone marrow into Brtl mice. These cells contributed to up 
to 20% of all collagen type I synthesised, which was associated with increased cortical 
thickness and improvements in bone stiffness, ultimate load and yield load. In addition 
transplantation in utero eliminated perinatal lethality seen in heterozygote Brtl+/- mice 
(Panaroni, Gioia et al. 2009).  
 
This study showed the potential of cell therapy to treat autosomal dominant types of OI in 
addition to recessive types. It also highlighted the possibility to treat perinatal lethal type II 
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OI with a prenatal approach. The improvements observed occurred despite just 1-2% 
engraftment of donor cells (Panaroni, Gioia et al. 2009). This engraftment rate was lower 
than that seen following fetal blood MSC transplantation in oim (3-5%) (Guillot, Abass et al. 
2008) or after fetal liver MSC transplantation in an OI fetus (7%) (Le Blanc, Gotherstrom et 
al. 2005). This suggests a fetal-to-fetal approach may have advantages over adult-to-fetal 
approach in terms of engraftment levels. 
 
In addition, human fetal MSC are more primitive than adult stem cells with higher kinetics 
and later senescence, longer telomeres, greater telomerase activity and expression of 
pluripotency markers (e.g. OCT4, NANOG, SSEA-4, SSEA-3, TRA-1-60, TRA-1-81 and 
REX1). Subsequently, they have greater expansion potential. Second, fetal MSC are smaller 
in size, which is likely to aid their ability to pass through the endothelial wall of the blood 
vessels, allowing improved migration to sites of injury. Fetal MSC also have a unique 
immune-privileged status. For example, liver derived fetal MSC did not elicit alloreactive 
lymphocyte proliferation either when undifferentiated, differentiated or IFN- stimulated to 
upregulate HLA I and HLA II (Gotherstrom, Ringden et al. 2003).  Finally, fetal MSC more 
readily differentiate to osteoblasts, which is critical to produce normal type I collagen fibrils, 
improve bone matrix organisation and subsequently improve the skeletal fragility caused by 
OI (Vanleene, Porter et al. 2012). 
 
1.7. The hurdles of cell therapy for OI 
1.7.1. Low engraftment of transplanted cells 
Although cell therapy shows great potential, several pitfalls constrain their clinical 
application. First the clinical effectiveness of cell therapy is challenged by low level of 
engraftment in target organs. For example, engraftment levels in a given bone chip ranged 
from 0.3-28% following neonatal transplantation of adult murine MSC in oim mice, despite 
irradiation of the recipient mice (Li, Wang et al. 2007). Whilst in utero transplantation of 
human fetal blood MSC in oim mice that were not irradiated was associated with 3-5% 
engraftment levels in bone (Guillot, Abass et al. 2008; Vanleene, Saldanha et al. 2011). 
Clinical experience is similar, with less than 2% engraftment of bone marrow MSC in 
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transplanted children with OI (Horwitz, Prockop et al. 1999; Horwitz, Prockop et al. 2001; 
Horwitz, Gordon et al. 2002), and up to 7% engraftment recorded following prenatal 
allogeneic fetal liver MSC transplantation in a human fetus with OI (Le Blanc, Gotherstrom 
et al. 2005).  
 
Donor cell engraftment levels are important to treat autosomal recessive OI types as they 
have a protein deficiency, but are more critical to treat autosomal dominant types of OI. This 
is because levels of differentiated donor cells must be high enough to significantly alter the 
ratio of normal to mutant proteins synthesised and counteract the structural instabilities 
caused by these abnormal pro-collagen proteins (Forlino, Cabral et al. 2011). The proof of 
this principle has been demonstrated in patients that are mosaic carriers of autosomal 
dominant OI and subsequently have both affected and normal somatic and germline cells. 
Despite 40-75% of their osteoblasts presenting a collagen I mutation the patients have normal 
skeletal growth, density and histology and often are only identified as a carrier when they 
have more than one child with OI (Cabral and Marini 2004). 
 
Direct differentiation of donor cells in the oim model has been implicated in the therapeutic 
benefits seen following transplantation (Wang, Li et al. 2006; Guillot, Abass et al. 2008; Li, 
Ling et al. 2011; Vanleene, Saldanha et al. 2011), therefore strategies to increase donor cell 
engraftment are critical. However, simply increasing the number of cells transplanted has 
been shown to have little effect on engraftment rate, with one study showing maximal 
engraftment levels in lethally irradiated mice at just 15% (Marino, Martinez et al. 2008). The 
importance of the CXCR4-SDF1 pathway in homing of MSC to fractures was shown in vitro 
whereby SDF-1 increased chemotaxis of MSC to injured bone dose dependently (Kitaori, Ito 
et al. 2009). Also work in a mouse model with a stabilised tibia fracture, showed only 
CXCR4+ MSC and not CXCR4- MSC migrated to the site of injury (Granero-Molto, Weis et 
al. 2009).  
 
A number of studies have reported strategies to manipulate stem cell homing by upregulating 
CXCR4 expression and subsequent migration towards SDF-1 gradients. For example, 
CXCR4 expression has been increased by IGF-1 (Li, Yu et al. 2007), hypoxic pre-
conditioning or pre-treatment with desferrioxamine (DFX) (Hung, Pochampally et al. 2007; 
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Hung, Pochampally et al. 2007), pre-treatment with PDGF (Fiedler, Etzel et al. 2004), IGF-I 
or IGF-II (Fiedler, Brill et al. 2006) or cytokine treatment: e.g. tumor-necrosis factor-alpha 
(TNFα) (Ohira, Itatsu et al. 2006) and interleukin (IL-6), which like IL-1, PDGF and TGFα 
are released during the early stages of fracture (Dimitriou, Tsiridis et al. 2005). Fetal MSC 
express high levels of intracellular CXCR4, but only a small number of cells present CXCR4 
on the cell surface. Priming human fetal blood MSC with SDF1 externalised CXCR4, and 
was associated with increased chemotaxis in vitro and a three-fold upregulation of 
engraftment in oim and wild type bone and bone marrow (Jones, Moschidou et al. 2012). 
Testing if the increased engraftment of donor cells translates to therapeutic benefits in the oim 
mouse model is the next step to optimising cell therapy for OI. 
 
1.7.2. Immune rejection of transplanted cells 
A second hurdle for cell therapy is the rejection of allogeneic cells by the host immune 
system. Fetal and adult MSC do not express HLA class II and express low levels HLA class 
I, therefore they are unlikely to elicit an immune reaction (Le Blanc 2003; Le Blanc, Tammik 
et al. 2003). In addition these cells have immune-suppressive properties, which prevents their 
rejection from the host immune system by inhibiting T, B, NK and dendritic cell proliferation 
and activating regulatory T cells (Trento and Dazzi 2010; Francois and Galipeau 2012). 
Allogeneic bone marrow MSC has been successfully injected in collagen-induced arthritic 
mice and prevented bone and cartilage damage (Augello, Tasso et al. 2007). Whilst HLA-
mismatched fetal liver MSC were transplanted in utero in a fetus with OI and engrafted and 
differentiated in vivo with no immunologic reaction against the donor cells (Le Blanc, 
Gotherstrom et al. 2005). However, before translation of stem cells to the clinic their 
immuno-modulatory properties should first be tested after expansion in clinical grade GMP 
conditions, since differences in immunosuppression and adhesion molecules were found in 
adult BM and adipose MSC after fetal bovine serum was replaced in the media with human 
platelet lysate (Menard, Pacelli et al. 2013). 
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1.7.3. Identification of a clinically translatable cell source 
Finally a major hurdle to the translation of cell therapy in the clinic is to find and test an 
appropriate cell source. Collection procedures to aspirate bone marrow and isolate adult MSC 
are often painful and highly invasive and cell numbers are low with only one estimated MSC 
per 250,000 bone marrow cells. The limited expansion potential of adult MSC is also a 
practical disadvantage in terms of clinical application. Stem cells from fetal organs and blood 
isolated after termination have higher expansion potential and more potent differentiation, but 
often require termination of pregnancy, hence their clinical use is restricted by ethical 
legislations (Guillot, Gotherstrom et al. 2007). Therefore, to bring cell therapy for OI closer 
to the clinic a more suitable cell source is required, such as cells isolated from extra-
embryonic fetal tissues like placenta and amniotic fluid, which are available in all clinics, are 
easy to physically manipulate and their use is unlikely to cause ethical controversy 
(Abdulrazzak, Moschidou et al. 2010). 
 
1.8. Aims and hypothesis 
Placental chorionic tissue is readily available in clinics and uniquely represents a cell source 
that can be safely collected without pregnancy termination in the first trimester and at term. It 
is therefore an ideal source to test the hypothesis that stem cells isolated earlier in gestation 
are more primitive than late gestation counterparts with advantages for use in regenerative 
medicine. The aim of this study was to first investigate whether early fetal placental chorionic 
stem cells (e-CSC) were physiologically superior to their late gestation counterparts (l-CSC) 
and secondly, if this was the case, to assess the capacity of e-CSC for bone repair in the oim 
mouse model to determine the potential of these cells for use in cell therapy of OI. 
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2.1. Cell culture techniques 
2.1.1. Placenta cell isolation and culture 
Human early chorionic stem cells (e-CSC) (n=5, 8+3 to 12+0 weeks gestational age) were 
previously isolated in the lab from placental chorionic villi (Fig.5A) after chorionic villous 
sampling prior to termination of pregnancy [Dr Dafni Moschidou]. Human late chorionic 
stem cells (l-CSC) were isolated from the placental chorionic plate (Fig.5B) of the extra-
embryonic membranes 
obtained from caesarean 
section deliveries (n = 5). The 
chorionic villous tissues (5 
cm2 for l-CSC and the totality 
of the sample for e-CSC) were 
separated from the amnion, 
minced mechanically, and 
trypsinized using 0.05% 
Trypsin EDTA (Invitrogen) 
for 20 min. Cells were 
subsequently centrifuged (5 
min at 1500 rpm), counted and 
plated (104 cells per cm2) in 
expansion media; high glucose 
Dulbecco’s modified Eagle’s 
medium (DMEM-LG) 
(Invitrogen) with 10% fetal 
bovine serum (BioSera) and 2 
mM L-glutamine, 50 IU/ml 
penicillin, 50 mg/ml 
streptomycin (Gibco BRL Life 
Technologies). Cells were 
incubated at 37oC in 5% CO2 
 
Figure 5 – Chorionic villous tissue is confined to the chorionic 
plate in late gestation. 
(A) Chorionic villi surround the gestational sac in the first 
trimester. (B) By term the chorionic villi have been confined to 
the chorionic plate as the amniotic cavity has expanded and 
fused with the chorion to form the amnio-chorionic membrane. 
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and serially passaged at 70-80% confluence. Cell passaging involved PBS washes, then 
trypsinization for 2 min, followed by centrifugation for 5 min at 1500 rpm and replating in 
expansion media at a 1:3 split. Cells were frozen using the same protocol, except instead of 
replating cells were frozen in freezing media; which contained 10% Dimethyl sulfoxide 
(DMSO; Sigma), 40% FBS and 60% expansion medium. Isolated cells were plastic adherent 
and c-KIT+ and all cells were used at passage 2-9. Ethical approval was given by the 
Research Ethics Committees of Hammersmith & Queen Charlotte’s Hospitals and the joint 
University College London Hospitals. Committees on the Ethics of Human Research 
(08/H0714/87).  
 
2.1.2. Osteogenic Differentiation 
Cells were plated at 104 cells per cm2 and grown in expansion media (see above) for 1 day. 
Expansion media was then replaced with high glucose DMEM supplemented with 10 mM β-
glycerophosphate, 0.2 mM ascorbic acid and 10-8 M dexamethasone, which was replaced 
every 3 days for 14 days. Then cells were fixed with 10% formalin and stained with von 
Kossa or alizarin red, or pelleted and extracted for RNA or protein (see below) for qRT-PCR 
or western blot analysis respectively. All analysis was compared to undifferentiated cells. 
RNA and cDNA was extracted as previously described and the qRT-PCR reactions were 
carried out as above for osteogenic specific primers (Table 5), normalised to GAPDH and 
compared to basal expression levels in non-differentiated cells. 
 
2.1.3. Adipogenic differentiation 
Cells were seeded at a concentration of 104 cells per cm2 on tissue culture plastic plates and 
cultured expansion media (see above) for 1 day. The media were then changed to high 
glucose DMEM supplemented with 0.5 M hydrocortisone, 0.5 M isobutyl methylxanthine 
and 60 M indomethacin (all Sigma-Aldrich), which was replaced every 3 days for 2 weeks. 
Then cells were pelleted for RNA or washed in PBS, fixed with 10% formalin, rinsed with 
60% isopropanol (BDH Laboratory Supplies), then stained for 10 minutes with oil-red-O 
(Sigma-Aldrich). Oil-red-O was prepared at a 1% concentration in isopropanol (BDH 
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Laboratory Supplies, Dorset, UK) then diluted in a 3:2 ratio of stock solution to distilled 
water. The cells were then washed 4 times with distilled water and photographed using an 
Olympus CK40-SLP microscope and an Olympus C3040-ADL camera (Olympus). RNA and 
cDNA was extracted as previously described and the qRT-PCR reactions were carried out as 
above with PPARγ specific primers (Table 5), normalised to GAPDH and compared to basal 
expression levels in non-differentiated cells. 
 
2.1.4. Neurogenic differentiation 
Cells were seeded at a concentration of 5000 cells/cm2 on tissue culture plastic plates and 
coverslips and cultured in expansion media (see above) for 1 day. The media were then 
changed to high glucose DMEM supplemented with 0.5% FBS, 1% penicillin/streptomycin, 
2mM L-glutamine and 0.1% baicalin (Sigma), freshly made. C17.2 mouse neural progenitor 
cells (from Henrik Hagberg and Pierre Gressens) were added in a co-culture setting to 
promote differentiation, using co-culture membrane inserts (Thermo Scientific Nunc, 
Loughborough, UK). The cells were allowed to differentiate for 5 days and assessed for 
expression of the neuronal markers -TUBULIN and MAP2 and for the NMDA receptor 
NR1 (Table 6) using confocal immunostaining, as previously described. Positive controls 
were differentiated neural progenitors [from Henrik Hagberg and Pierre Gressens] and 
negative controls were undifferentiated e-CSC and l-CSC cells.  
 
2.1.5. Hepatogenic differentiation 
Cells were seeded at a concentration of 5000 cells/cm2 on tissue culture plastic plates and 
coverslips coated with Matrigel (BD Biosciences) and cultured in high glucose DMEM 
supplemented with 1% penicillin/streptomycin (Invitrogen), 2mM L-Glutamine (Invitrogen) 
and 10% FBS for 3 days. The media were then changed to high glucose DMEM 
supplemented with 15% FBS, 1% penicillin/streptomycin, 2mM L-glutamine, 300μM 
monothioglycerol (Sigma), 20ng/ml hepatocyte growth factor (Peprotech), 10ng/ml 
oncostatin M (Peprotech), 10-7 dexamethasone (Sigma), 100ng/ml FGF4 (Peprotech) and 1X 
ITS (insulin, transferrin, selenium, Sigma). The cells were allowed to differentiate for 21 
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days and then fixed and stored in PBS for immuno-fluorescence. The differentiation media 
were collected and analysed for the presence of urea secreted by the differentiated cells. Urea 
was subsequently measured using the urea/ammonia determination kit (R-Biopharm AG, 
Darmstadt, Germany) according to the manufacturer’s instructions, with positive control 
being urea (as per manufacturer’s instructions) and negative control undifferentiated e-CSC 
and l-CSC. Cells were subsequently assessed for expression of the hepatocyte markers 
ALBUMIN and ALPHA FETO-PROTEIN (AFP) using confocal microscopy. Positive 
controls were HepG2 cells [from Wei Cui] and negative controls were undifferentiated e-
CSC and l-CSC cells.  
 
2.1.6. Cell size 
Size of passage 4-5 cells in suspension was determined using Image J software and calibrated 
with a haemocytometer. 
 
2.1.7. Growth Kinetics 
Cells were plated in triplicate at 104 cells per cm2 and counted in trypan blue to exclude dead 
cells in a haemocytometer every 2 days for 12 days without passaging.  Doubling time (DT) 
was calculated via the formula: DT=t/ (Log2[y/m]), with t=time in culture, y=number of cells 
at end of culture, m=number of cells at beginning of culture.  
 
2.1.8. Embryoid body formation and analysis 
As part of a collaborative work within the lab group [with Dr Dafni Moschidou and Aya 
Harada] undifferentiated e-CSC and l-CSC were induced to differentiate in vitro into EBs by 
incubating confluent cells with differentiation medium containing knockout Dulbecco’s 
modified eagle’s medium (Gibco BRL Life Technologies) supplemented with 1 mM L-
mercaptoethanol, 1% non-essential amino acids stock (all Gibco BRL Life Technologies) and 
20% FBS (BioSera). At confluence, cells were incubated with 1 mg/ml type IV collagenase 
(Invitrogen) before being dissociated into small clumps on low attachment Petri dish in 
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differentiating medium and allowed to develop into EBs for 12 days. EB suspensions were 
transferred to gelatin-coated coverslips before fixation in 4% PFA and analysis under 
confocal microscopy for expression of lineage markers from all three germ layers using 
specific primary (Table 6) then secondary antibodies (Table 7). Positive controls were EBs 
derived from induced pluripotent stem (iPS) cells, which originated from human amniotic 
fluid stem cells. 
 
2.1.9. Isolation and culture of fetal stem cells for transplantation 
Collection, isolation and culture of human early and late chorionic stem cells (e-CSC and l-
CSC) were carried out as described in Chapter 1. The e-CSC transplanted (n=1) was 9+5 
gestation age and l-CSC (n=1) was taken at term delivery. Human fetal blood (n=1) was 
collected previously by the group at 10+4 gestation age by cardiocentesis under ultrasound 
guidance during termination of pregnancy (Campagnoli, Roberts et al. 2001; Guillot, Abass 
et al. 2008; Guillot, Cook et al. 2008). Research was approved by the Research Ethics 
Committee of Hammersmith & Queen Charlotte’s Hospital. Cells were selected by plastic 
adherence and cultured in Dulbecco’s modified Eagle’s medium high glucose (DMEM-LG) 
(Sigma) supplemented with 10% fetal bovine serum (BioSera), 2mmol/l L-glutamine, 
50IU/ml penicillin, 50mg/ml streptomycin (Gibco-BRL). Cells were expanded at 70-80% 
confluence on plastic dishes and used at passage 4-8. 
 
2.2. RNA and DNA manipulation methods 
2.2.1.  RNA extraction and cDNA synthesis 
Total RNA was extracted from cells using RNeasy mini RNA isolation kit (Qiagen) followed 
by cDNA synthesis using Pd(N)6 random hexamers and M-MLV reverse transcriptase in the 
presence of dNTPs (Promega) (10 min, 25°C; 60 min, 42°C and 10 min, 75°C). 
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2.2.2. RT-PCR 
Reverse-transcriptase PCR (RT-PCR) was performed with cDNA using specific primers 
(Table 5), dNTPs, x10 buffer and Taq polymerase for 40 cycles according to the 
manufacturer’s protocol (Qiagen). 
 
2.2.3. qRT-PCR 
Quantitative real time polymerase chain reaction (qRT-PCR) was performed using SYBR 
green dye (Qiagen or Applied Biosystem) or Taqman® Gene Expression Master Mix 
(Applied Biosystem) and specific primers (Table 5), then analysed either with MJ-opticon or 
ABI Prism 7700 Sequence Detection system (Applied Biosystem). Samples were normalized 
against the internal control (GAPDH or β-ACTIN) to generate the 2-ΔCt for each sample. For 
pluripotency analysis the 2-ΔΔCt was plotted (log10 scale) relative to the expression level in 
human embryonic stem cells (hESC) line H9 [from Wei Cui]. For differentiation analysis the 
2-ΔΔCt of differentiated cells was plotted as a fold change from the basal level of gene 
expression. 
 
2.2.4. DNA extraction and SRY PCR 
Male gender of cells was determined by DNA extraction using TRIzol (Invitrogen), followed 
by ethanol precipitation, washing and DNA dissolution in 8mM NaOH. Then PCR was 
performed in the presence of dNTPs (Promega) and Taq polymerase (Bioline) with SRY 
specific primers (Table 5), followed by gel electrophoresis on 1.5% agarose with ethidium 
bromide (Sigma).  
 
2.2.5. FISH analysis 
No contamination by maternal cells was confirmed at passages 3-9 for SRY positive samples 
using XY FISH analysis. Cells were fixed on slides as previously described (Guillot, 
Gotherstrom et al. 2007), then digested with proteinase K before hybridization with human 
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specific centromeric mixture probe (CEP X/Y/18) according to manufacturer’s protocol 
(Vysis). Nuclei were counterstained with DAPI and viewed on a fluorescence confocal laser 
scanning microscope Leica TCS SP5 (X600 PL APO oil objective). A total of 100 cells per 
group were analysed. 
 
2.2.6. Analysis of H19 methylation 
Genomic DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen) and made free 
from RNA using RNase A (Invitrogen). The EpiTect Methyl qPCR assay (Qiagen) was used 
to digest DNA with methylation-sensitive and methylation-dependent enzymes to obtain 
fractions of unmethylated, partially methylated and hypermethylated DNA. The methylation 
status of H19 was then quantified using qRT-PCR and specific primers (Table 5), data were 
then normalised to the total amount of DNA. 
 
2.3. Protein detection methods 
2.3.1. Protein Extraction and Western Blot 
Total protein was extracted using RIPAE buffer containing protease inhibitor cocktail and 
PMSF (Sigma). Protein concentrations were determined using the BCA protein assay 
(Thermo-scientific), with bovine serum albumin as the standard. Proteins were run on an 8% 
SDS-PAGE, transferred to nitrocellulose, blocked with milk and incubated with primary 
anitbody COL1A2 (123kDa) (Table 6). Secondary HRP-linked anti-rabbit IgG (GE 
healthcare), followed by enhanced chemiluminescence (Thermo scientific) was used for 
detection (Table 7). Loading control used was β-actin (Santa Cruz). 
 
2.3.2.  Fluorescence immunostaining and confocal microscopy 
Cells were fixed in 4% followed by 8% PFA in 125mM HEPES, and then permeabilized in 
0.5% Triton X-100 in PBS.  Cells were then rinsed in PBS, incubated in 20μM Glycine in 
PBS, blocked with PBS+ (PBS supplemented with 1% BSA, 0.2% gelatin, 0.1% casein; pH 
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7.6) and incubated with primary antibodies (Table 6). Cells were then washed in PBS+, 
incubated with secondary antibodies (Table 7), washed, then mounted in VectaShield 
labelled with DAPI (Vector Labs) and visualized immediately. Fluorescence confocal laser 
scanning microscopy images were collected on a Leica TCS SP5 (X400 PL APO oil 
objective) and transferred to Adobe Photoshop (Adobe Systems) (Guillot, Gotherstrom et al. 
2007). 
 
2.3.3. Flow cytometry 
For intracellular FACS staining cells were detached, blocked with 1% bovine serum albumin 
(BSA; Sigma) in phosphate-buffered saline (PBS; Invitrogen) then fixed with 0.01% 
paraformaldehyde (PFA) (Sigma) and permeabilized with 0.5% Triton X-100 (Sigma). For 
cell surface and intracellular FACS staining detached cells were blocked with 1% BSA and 
incubated with specific anti-human primary antibodies (Table 6), either conjugated with PE, 
FITC or PE-Cy5 or unconjugated. For unconjugated antibodies, cells were subsequently 
washed with 1% BSA and incubated with secondary goat anti-murine IgM PE (Santa Cruz) 
(Table 7). All samples were analyzed in triplicate by FACScalibur flow cytometry (Becton 
Dickinson). Positive controls were hESC and negative controls were IgG or IgM primary 
antibody-specific isotype controls. 
 
2.4. Animal experiments 
2.4.1. Wound healing model 
All experimental protocols complied with UK Home Office guidelines. C57/Bl6 mice were 
housed in individual ventilated cages (IVC) in 12:12-hour light dark cycle (21oC) with water 
and chow. After hair removal from the dorsal surface of mice, they were given a dermal 
excision wound of 4-mm full-thickness under anesthesia. Each mouse was given two dermal 
excisions on each dorsal side (Rajkumar, Shiwen et al. 2006). Stem cells (e-CSC and l-CSC, 
106 cells in 30 l PBS) were applied to the left-side wounds and PBS alone applied to the 
right-side wounds. Seven days later, the mice were culled and the dermal tissues excised, cut 
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across the middle of the wound and fixed overnight in 10% neutral buffered formalin at 4C 
and embedded in paraffin, sectioned and subjected to hematoxylin and eosin staining for 
histological analysis.    
 
2.4.2. Breeding B6C3Fe a/a-Col1a2oim/Col1a2oim mice 
All experimental protocols complied with UK Home Office guidelines. Heterozygous male 
and female (B6C3Fe a/a-Col1a2oim/Col1a2oim) mice (Jackson Laboratory) were housed in 
individual ventilated cages (IVC) in 12:12-hour light dark cycle (21oC) with water and chow. 
Offspring were genotyped by overnight enzyme extraction of DNA from an ear notch, 
followed by PCR using oim specific primers (Table 5) and sequencing of the oim fragment 
(Beckman). Homozygous and wild type colonies were subsequently established. 
Homozygous oim mice showed multiple fractures and brittle bones. Progeny were weaned at 
30±1 day. 
 
2.4.3. Neonatal transplantation in the oim model 
All cells (e-CSC, l-CSC and hfMSC) were trypsinized, washed in PBS then injected 
intraperitoneal (106 cells in 10 l PBS) in homozygous oim neonates 3-4 days after birth. For 
SDF1 primed hfMSC, the cells were incubated with stromal-derived factor (SDF1) 30ng/ml 
in culture medium for 1 hour prior to transplantation. The mice were culled at 8 weeks of age 
for analysis. Controls were age-matched non-transplanted oim and wild type mice. 
 
2.5. Tissue analysis methods 
2.5.1. Three-point bending test 
Three-point bending tests were performed on 8 week old unfractured frozen and thawed 
femurs in a materials testing machine (5866 Instron) at a loading rate of 50 µm/s on two 
supports 9 mm apart until fracture at mid-diaphysis. Force deflection curves were analyzed 
with a custom program (Matlab, MathWorks) to measure the bending stiffness (slope of the 
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linear elastic deformation), the yield force (limit between the elastic and plastic deformation), 
the ultimate force (maximum force sustained), the total work to fracture (total area under the 
curve) and the plastic work to fracture (area under the curve from the yield point to fracture). 
 
2.5.2. Visualization of donor cells 
Presence of human donor cells was visualized in 3 different parts of non-fractured tibia: 
epiphysis, growth plate and diaphysis as well as from fracture callus in transplanted 8 week 
old oim and compared to non-transplanted oim as a negative control. Dissected tibias were 
decalcified in 10% EDTA pH7.4 and subsequently embedded in paraffin. Five micron 
sections were cut, deparaffinised in histoclear and rehydrated. Slides were then incubated 
with peroxidase blocking reagent (Dako), further blocked with PBS+ and goat serum, then 
stained with human-specific rabbit monoclonal Vimentin (Abcam) primary antibody (Table 
6). Slides were subsequently incubated with HRP-labelled anti-rabbit polymer followed by 
DAB+ substrate-chromogen (n=3 samples per group).  
 
2.5.3. Quantifying donor cell engraftment 
Femurs from transplanted 8 week old oim had the bone marrow flushed and were then 
dissected into callus if present (n=8), epiphysis (n=6) and diaphysis (n=6). Liver (n=6) was 
also used. RNA was extracted using TRIzol (Invitrogen) followed by cDNA synthesis with 
M-MLV reverse transcriptase (Promega). To calculate donor cell engraftment quantitative 
real time PCR (qRT-PCR) was performed using SYBR green dye and the ABI Prism 7700 
Sequence Detection System (Applied Biosystem) with human specific and human-mouse 
unspecific β-Actin primers (Table 5). Human: mouse chimerism was estimated as the ratio of 
human β-Actin to total human and mouse β-Actin in the total cDNA sample to give the 2-ΔCt 
value. Samples were considered positive with a human specific β-Actin Ct above 36 at a 
threshold of 0.13ΔRn. Primer specificity was confirmed by absence of amplification of non-
transplanted mouse cDNA (Guillot, Abass et al. 2008) 
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Presence of donor cells was estimated in non-fractured tibia bone marrow in transplanted 8 
week old oim. Dissected tibias were decalcified, paraffin embedded and sectioned as above 
(2.5.2). Sections were then deparaffinised in histoclear and rehydrated. Heat-induced epitope 
retrieval was performed in a steamer (Dako), followed by incubation with peroxidase 
blocking reagent (Dako), followed by PBS+ with 1 in 20 goat serum. Donor cells were 
visualised in the bone marrow using human-specific mouse monoclonal Vimentin (Dako) 
primary antibody (Table 6) and incubation with HRP-labelled anti-mouse polymer followed 
by DAB+ substrate-chromogen. Positive cells were counted in the bone marrow (n=4 
samples and n=4 sections for each group). Staining specificity was verified using non-
transplanted negative controls. 
 
2.5.1. Osteoblast gene expression by donor cells 
QRT-PCR was performed using SYBR green dye (Qiagen) and the MJ-Opticon with human 
specific Osteopontin and Osteocalcin primers (Table 5). Results with a Ct below 36 were 
normalised to human β-actin to give the 2-ΔCt value. Expression in 8 week old transplanted 
oim femurs (n=6) was compared to e-CSC (n=3) undifferentiated and grown in osteogenic 
permissive media for 2 weeks. Negative controls were non-transplanted oim (Guillot, Abass 
et al. 2008). 
 
2.5.2. Western blot 
Collagen was extracted from ground bone over 72hrs at 4oC in a lysis buffer of 6M guanidine 
HCl and 100mM Tris pH7.4 containing protease inhibitor cocktail. Proteins were precipitated 
with 10% TCA then resuspended in RIPAE buffer containing PMSF (Sigma) and run on an 
8% SDS-PAGE, transferred to nitrocellulose, blocked with milk and stained with COL1A2 
(129kDa) (Abcam), then with secondary antibody HRP-linked anti-rabbit IgG (GE 
healthcare), followed by enhanced chemiluminescence (Thermo scientific). Loading control 
used was β-ACTIN (43kDa) (Millipore). Detection of COL1A2 in transplanted oim bones 
was confirmed using wild type positive controls and non-transplanted oim negative controls 
(n=4 per group). 
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2.5.3. X-ray 
Tibias from 8 week-old mice (n=19 transplanted, n=20 oim, n=12 wild type) were fixed in 
formalin for 24 hours and stored in 70% ethanol prior to removal of soft tissues. Digital X-
ray images were obtained at a 10µm pixel resolution using a Faxitron MX20 variable kV 
point projection X-ray source and digital image system (Qados, Cross Technologies plc, 
Sandhurst, Berkshire, UK).  An X-ray image of a digital micrometer was used to calibrate 
ImageJ 1.41 software (http://rsb.info.nih.gov/ij/) prior to determination of cortical bone 
thickness and diameter at 5 locations along the mid shaft, and also to determine bone length.  
Relative bone mineral content (BMC) was determined by comparison with 1 mm diameter 
steel, aluminium and polyester standards included in each frame. 16 bit DICOM images were 
converted to 8 bit Tiff images using ImageJ and the image histogram stretched between the 
polyester (grey level 0) to steel (grey level 255) standards. Bone mineralization densities 
were represented by a pseudo colour scheme representing 16 equal intervals (Bassett, Boyde 
et al. 2010) [Results contributed by Dr Duncan Bassett]. 
 
2.5.4. Counting of fractures 
Fractures in the femur, tibia and humerus of both body sides were assessed at 8 weeks of age 
after dissection and were delineated by callus formation (n=120 transplanted bones, n=78 oim 
control bones). The number of mice with at least one long bone fracture and the fracture 
incidence (number of fractured bones/total bones assessed) were calculated by two 
independent observers blinded to whether mice were transplanted or not.  
 
2.5.5. Dynamic histomorphometry 
All mice were calcein injected 10 days and 3 days before sacrifice with 20mg/kg of calcein 
(Sigma). Tibia (n=7 transplanted, n=6 wild type, n=5 oim) were then fixed in formalin for 
24hrs and transferred to 70% ethanol, before being dehydrated in acetone for 48hrs, 
infiltrated over 6-9 days at -20oC and embedded in methylmethacrylate (MMA) (Chappard, 
Palle et al. 1987). Embedded samples were imaged on a Leica TCS SP5 confocal laser 
scanning microscope and analysed using ImageJ. Fluorescent images of calcein labels were 
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taken 500µm and 1000µm below the proximal growth plate of the trabecular and endo-
cortical regions respectively. The amount of mineralizing surface per total bone surface 
(MS/BS; %), the daily mineral apposition rate (MAR; µm/day) and the bone formation rate 
(BFR; µm3/µm2/days) were calculated. 
 
2.5.6. Static histomorphometry 
MMA embedded samples were cut into eight micron sections and stained using the 
Leucognost AP kit (Merck), according to the manufacturer’s instructions (n=6 transplanted, 
n=6 oim, n=5 wild type). Sections were analysed on a light microscope using the 
Osteomeasure system (OsteoMetrics Inc). Histomorphometric measurements of the % 
trabecular bone volume per total tissue volume (BV/TV) were performed on stained sections 
500µm from the end of the hypertrophic zone of the growth plate in the secondary spongiosa. 
For growth plate analysis dissected tibia were decalcified, paraffin embedded and 5µm 
sections were cut and stained with alcian blue 8GX (2%), Weigert’s haematoxylin and van 
Gieson, mounted and growth plate morphology analysed using Image J (n=14 transplanted 
oim, n=5 oim, n=5 wild type). 
 
2.5.7. Osteogenesis PCR array 
Total RNA was extracted from femoral epiphysis of 8 week old mice using the TRIzol 
(Invitrogen) protocol, followed by RNA clean up using the RNeasy Mini kit (Qiagen), then 
cDNA was synthesised using RT2 First Strand Kit (Qiagen). The RT2 Profiler mouse 
osteogenesis PCR array (Qiagen) was run and analysed according to the manufacturer’s 
instructions (n=3 mice for each group). To verify results further quantitative real time PCR 
was performed with RT2 qPCR Master Mix and primers (Table 5) and analysed with MJ-
opticon. Data was normalised against 2 housekeeping genes (β-Actin and Hsp90ab1) and the 
2-ΔCt of each sample calculated (n=8 transplanted oim, n=5 oim controls). 
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2.6. Statistical analysis 
Data were expressed as mean ± s.d (standard deviation) or mean ± s.e.m (standard error). 
Normally distributed data were analyzed by unpaired two-tailed Student’s t-test or one-way 
ANOVA followed by a Tukey’s post-hoc test. Data that did not have equal variance as 
confirmed by Bartlett’s test was analysed Welch’s t-test. Data that was non-parametric was 
analysed by Kruskal-Wallis or Mann-Whitney U test. P < 0.05 was considered significant. 
Two-tailed 2x2 Fisher exact was used for categorical comparisons. The frequency 
distributions of bone mineralization in 1024-pixel data sets were compared using the 
Kolomogorov-Smirnov test, where D≥6.01, P<0.05; D≥7.20, P<0.01; D≥8.62, P<0.001. Chi-
squared with Yates correction and to one degree of freedom was used to compare fracture 
incidence, where χ2≥3.84, P<0.05; χ2≥6.64, P<0.01; χ2≥10.83, P<0.001. 
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2.7. Primers 
Table 5 – List of primer sequences.  
List of primers used for RT-PCR and quantitative real time PCR and EpiTect Methyl qPCR assay. 
Gene  Forward  Reverse  Accession no.  
Aggrecan 
(Mouse) 
5’-GTTGGTTACTTCGCCTCCAG-
3’ 
5’-GTCCTCCAAGCTCTGTGACC-
3’ 
NM_007424 
β-ACTIN 
(Human) 
5’-CTGGAACGGTGAAGGTG 
ACA-3’ 
5’-AAGGGACTTCCTGTAACAAT 
GCA-3’ 
NM_001101 
β-ACTIN 
(Human-
Mouse) 
5’-GCTCCTCCTGAGCGCAAGTA-
3’ 
5’-GATGGAGGGGCCGGACT-3’ NM_001101 
NM_007393 
β-Actin (Mouse) 330001 PPM02945A Qiagen (http://www.qiagen.com/) NM_007393 
BMP2 (Human) 5’-TTCCACCATGAAGAATCTTT 
GGA-3’ 
5’-CCTGAAGCTCTGCTGAGGT 
GAT-3’ 
NM_001200 
BMP4 (Human) 5’-GTGAGGAGCTTCCACCA 
CGA-3’ 
5’-ACTGGTCCCTGGGATGTT 
CTC-3’ 
NM_130850 
BSP (Human) 5’-AAACGAAGAAAGCGAAGCA 
GAA-3’ 
5’-GCTGCCGTTGCCGTTTT-3’ NM_004967 
CK19 (Human) 5’-GGCCACACGGAGCAGCT 
CCA-3’ 
5’-CGCCTGGATATGCGCCAGCT-
3’ 
NM_002276 
CK3 (Human) 5’-
CGTACAGCTGCTGAGAATGA-3’ 
5’-CTGAGCGATATCCTCATACT-
3’ 
NM_057088 
c-KIT (Human) 5’-CACCGAAGGAGGCACTTA 
CAC-3’ 
5’-GGAATCCTGCTGCCACACA-
3’ 
NM_000222 
C-MYC 
(Human)  
5’-TTGTACCTGCAGGATCTGAG-
3’  
5’-CTTGTTCCTCCTCAGAGTCG-
3’  
NM_002467  
Col1α1 
(Mouse) 
330001 PPM03845F Qiagen NM_007742 
Col2α1 
(Mouse) 
5’-CCTCCGTCTACTGTCCAC 
TGA-3’ 
5’-ATTGGAGCCCTGGATGA 
GCA-3’ 
NM_0011135
15 
Col10α1 
(Mouse) 
330001 PPM05135F Qiagen NM_009925 
Dmp1 (Mouse) 330001 PPM04680E Qiagen NM_016779 
FRAGILIS 
(Human) 
5’-CTCAAGGAGGAGCAGGA 
AGT-3’ 
5’-TGAAGAGGGTGTTGAAC 
AGG-3’ 
NM_006435 
GAPDH 
(Human)  
5’-TCTGCTCCTCCTGTTCGACA-
3’  
5’-AAAAGCAGCCCTGGTGACC-
3’  
NM_002046  
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GATA6 
(Human) 
5’-ACCACCTTATGGCGCAGA 
AAC-3’ 
5’-TTTTTCATAGCAAGTGGTCT 
GGG-3’ 
NM_005257 
H19 (Human) Catalogue number: MePH28624-1B Qiagen (http://www.qiagen.com) NC_000011 
Hsp90ab1 
(Mouse) 
330001 PPM04803E Qiagen NM_008302 
Igf1 (Mouse) 330001 PPM03387E Qiagen NM_010512 
KLF4 (Human) 5’-CACATTAATGAGGCAGCC 
ACC-3’  
5’-AAGTCGCTTCATGTGGGA 
GAG-3’  
NM_004235  
NANOG 
(Human)  
5’-CCAACATCCTGAACCTCAGC 
TAC-3’  
5’-GCCTTCTGCGTCACACCATT-
3’  
NM_024865  
NANOS3 
(Human) 
TaqMan Hs00928455_s1* Applied Biosystems 
(http://www.appliedbiosystems.com) 
NM_0010986
22 
NESTIN 
(Human) 
5’-TCCAGGAACGGAAAATC 
AAG-3’ 
5’-GCCTCCTCATCCCCTACTTC-
3’ 
NM_006617 
OC (Human) 5’-CCTCACACTCCTCGCCCT 
ATT-3’ 
5’-CCCTCCTGCTTGGACACAAA-
3’ 
NM_199173 
OCT4A 
(Human) 
5’-GTATTCAGCCAAACGACC 
ATC-3’ 
5’-CTGGTTCGCTTTCTCTTTCG-
3’ 
NM_002701 
OCT4A v1 
(Human) 
5’- CCGCCGTATGAGTTCTG 
TGG-3’ 
5’- AGAGTGGTGACGGAGAC 
AGG-3’ 
NM_002701 
OP (Human) 5’-GCCGACCAAGGAAAACTCA 
CTA-3’  
5’-CAGAACTTCCAGAATCAGCC 
TGTT-3’  
NM_0010400
58  
OSX (Human) 5’-CCCCACCTCTTGCAACCA-3’ 5’-GGCTCCACCACTCCCTTC 
TAG-3’ 
NM_152860 
OSX (Mouse) 5’-AGGCACAAAGAAGCCATAC-
3’ 
5’-AATGAGTGAGGGAAGGGT-3’ NM_130458 
PAX6 (Human) 5’-AGATTCAGATGAGGCTC 
AAA-3’ 
5’-AATTGGTTGGTAGACACTGG-
3’ 
NM_000280 
PCE (Human) 5’-TTCGCTGGGTCTGGGACTT-3’ 5’-CATCCTCAGGGTCACCTG 
GTT-3’ 
NM_002593 
PHEX (Mouse) 330001 PPM41830E Qiagen NM_011077 
PTHRP 
(Mouse) 
5’-GAACATCAGCTACTGCATG 
ACAAG-3’ 
5’-TCTGATTTCGGCTGTGTGG 
ATC-3’ 
NM_008970 
Runx2 (Mouse) 5’-CCGGCCACTTCGCTAACTT-3’ 5’-TGGTGCTCGGATCTACAG 
GAA-3’ 
NM_009820 
SMAD3 
(Mouse) 
330001 PPM04461B Qiagen NM_016769 
SOX2 (Human) 5’- CACACTGCCCCTCTCACA 5’- CATTTCCCTCGTTTTTCTTT NM_003106  
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CAT-3’  GAA-3’  
Sox9 (Mouse)  330001 PPM05134C Qiagen NM_011448 
SRY  (Human) 5’-TGGCGATTAAGTCAAATT 
CGC-3’  
5’-CCCCCTAGTACCCTGACAA 
TGTATT-3’  
NM_003140 
SSEA1 
(Human) 
5’-CACAACTGTTCCCGATTCAC-
3’ 
5’-AGCCACAGTCCTTCCACTCT-
3’ 
NM_002033 
STELLA 
(Human) 
TaqMan Hs01931905_g1* Applied Biosystems NM_199286 
SYCP1 
(Human) 
5’-ACAGCGAAAAGCCATTCA 
GGA-3’ 
5’-GCCTGGTTTCTTCCCGTTC 
ATA-3’ 
NM_003176 
VASA (Human) TaqMan Hs00987130_m1* Applied Biosystems NM_0011665
33 
 
2.8. Antibodies 
Table 6 – List of primary antibodies 
List of primary antibodies used, the host species developed in, dilution used, supplier and application 
for either immuno-fluorescence (IF), flow cytometry (FC), immuno-histochemistry (IH) and western 
blot (WB). 
Antibody Host 
Species 
Application Dilution Supplier 
AFP Mouse IF 1:100 Abcam (http://www.abcam.com) 
ALBUMIN Mouse IF 1:100 Abcam 
Β-ACTIN Rabbit WB 1:5000 Santa Cruz 
Β-TUBULIN Mouse IF 1:100 Chemicon (http://www.millipore.com) 
Β-TUBULIN Mouse WB 1:5000 Abcam 
BLIMP1 Goat IF 1:5 Santa Cruz (http://www.scbt.com) 
CD105 Mouse IF 1:50 BD Biosciences 
(http://www.bdbiosciences.com) 
CD14 Mouse IF 1:100 Dako Cytomation (http://www.dako.com) 
CD24-FITC Mouse FC 1:10 Abcam 
CD29 Mouse IF 1:100 Abcam 
CD34 Mouse IF 1:100 Dako Cytomation 
CD44 Mouse IF 1:50 Abcam 
CD45 Mouse IF 1:100 Dako Cytomation 
CD73 Mouse IF 1:50 BD Biosciences  
CD90 Mouse IF 1:100 Abcam 
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C-KIT-PE Mouse FC 1:10 R&D Systems (http://www.rndsystems.com) 
C-MYC-PE Mouse FC 1:20 R&D Systems 
COL1A2 Rabbit WB 1:1000 Abcam 
CXCR4-PE Mouse FC 1:10 R&D Systems 
DAZL Goat IF 1:10 Santa Cruz 
FRAGILIS Goat IF 1:20 Santa Cruz 
GATA4 Rabbit IF 1:100 Abcam 
HLAI Mouse IF 1:100 Dako Cytomation 
HLAII Mouse IF 1:100 Dako Cytomation 
KLF4 Mouse IF 1:2 Stemgent (http://www.stemgent.com) 
LAMININ Rabbit IF 1:100 Sigma (http://www.sigmaaldrich.com) 
MAP2 Mouse IF 1:100 Abcam 
NANOG Rabbit IF 1:20 Abcam 
NANOS 3 Goat IF 1:20 Santa Cruz 
NESTIN Mouse IF 1:50 Chemicon (http://www.millipore.com) 
NMDAR1 Rabbit IF 1:50 Abcam 
OCT-4A Mouse IF 1:2 Santa Cruz  
OCT-4A-PE Mouse FC 1:10 R&D Systems  
PUM2 Goat IF 1:20 Santa Cruz 
REX1  Rabbit  IF  1:100  Stemgent  
SOX2  Rabbit  IF  1:100  Abcam  
SOX2-PE  Mouse  FC  1:10  R&D Systems  
SSEA1 Mouse IF 1:50 Chemicon 
SSEA3  Rat  IF  1:50  Abcam  
SSEA3 -PE Mouse  FC  1:5  Dev. Studies Hybridoma Bank 
(http://dshb.biology.uiowa.edu)  
SSEA4  Mouse  IF  1:50  Abcam  
SSEA4-PE  Mouse  FC  1:10  R&D Systems  
STELLA Rabbit IF 1:50 Santa Cruz 
TNAP Mouse IF 1:50 Abcam 
TRA-1-60  Mouse  IF, FC  1:10  Santa Cruz  
TRA-1-81  Mouse  IF, FC  1:10  Santa Cruz  
VASA 
(DDX4) 
Rabbit IF 1:50 Abcam 
VIMENTIN  Mouse  IF, IH 1:100  Dako Cytomation 
VIMENTIN Rabbit IH 1:150 Abcam 
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Table 7 – List of secondary antibodies 
List of secondary antibodies used, the host species developed in, application for either immuno-
fluorescence (IF), flow cytometry (FC) and western blot (WB), dilution used, supplier and conjugated 
fluorescent marker. 
Antibody Host 
Species 
Applicatio
n 
Dilution Conjugate
d marker 
Supplier 
IgG-anti-goat Donkey IF 1:100 FITC Jackson ImmunoResearch Inc 
(http://www.jacksonimmuno.c
om) 
IgG-anti-goat Donkey FC 1:100 FITC Santa Cruz 
(http://www.scbt.com) 
IgG-anti-goat Donkey WB 1:10000 HRP Santa Cruz 
IgG-anti-
mouse 
Donkey IF 1:100 FITC Jackson ImmunoResearch Inc  
IgG-anti-
mouse 
Donkey  FC 1 in 100 Cy™3 Jackson ImmunoResearch Inc 
IgG-anti-
mouse 
Donkey  WB 1 in 
15000 
HRP Jackson ImmunoResearch Inc 
IgM-anti-
mouse 
Goat IF 1:100 FITC Santa Cruz 
IgM-anti-
mouse 
Donkey FC 1:100 PE Santa Cruz 
IgG-anti-
rabbit 
Donkey IF 1:1000 FITC Jackson ImmunoResearch Inc 
IgG-anti-
rabbit 
Donkey WB 1:10000 HRP Santa Cruz 
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CHAPTER 3 – Results 
Human fetal chorionic stem cells 
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3.1. Chorionic stem cells have a phenotype intermediate of MSC and 
hESC 
3.1.1. Introduction 
 
The literature shows fetal and extra-embryonic stem cells express both markers of MSC and 
hESC and have a broadly multipotent differentiation potential, forming mesodermal lineages 
and some lineages from the endoderm and ectoderm germ layers (Abdulrazzak, Moschidou et 
al. 2010). It was therefore hypothesised that fetal and extra-embryonic stem cells present an 
intermediate phenotype between embryonic and adult stem cells with characteristics of both. 
Extra-embryonic stem cells derived from mid-trimester amniotic fluid have been extensively 
characterised and offer support for this hypothesis (De Coppi, Bartsch et al. 2007), whereas 
the phenotype of chorionic stem cells from early (e-CSC) and late (l-CSC) gestations has yet 
to be fully elucidated. Therefore I aimed to characterise the immunophenotype and 
differentiation potential of e-CSC and l-CSC to determine if they too presented an 
intermediate phenotype. 
 
3.1.2. Results 
 
Both early and late chorionic stem cells (e-CSC and l-CSC respectively) were isolated based 
on their plastic adherence from first trimester placental chorionic villous tissue and term 
placenta chorion respectively. Cells were cultured in DMEM supplemented with 10 % FBS 
and maintained at sub-confluence by passaging with Trypsin-EDTA. Both populations were 
c-KIT+ (Fig. 6A), as reported for AFSC (Moschidou, Drews et al. 2012; Moschidou, 
Mukherjee et al. 2012), grew in monolayers and showed a spindle shaped cytoplasm 
morphology (Fig.6B). Therefore the chorionic stem cells at the morphological level were 
similar to the previously described mid-trimester AFSC. 
 
The fetal origin of the cells was confirmed by the presence of the SRY gene in male samples 
(Fig.6C). Fluorescence in situ hybridisation (FISH) analysis showed that all nuclei in male 
samples contained the X and Y chromosome in both e-CSC and l-CSC populations, 
identifying cells as being of fetal origin, with no contaminating maternal cells (Fig. 6D). 
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Figure 6 - e-CSC and l-CSC are of fetal origin. 
(a) Confocal immuno-fluorescence for c-KIT in early and late gestation chorionic stem cells (e-CSC and 
l-CSC respectively). Positive control amniotic fluid stem cells (AFSC) shown. Nuclei stained with DAPI 
(blue). n=4 per group. (b) Cell morphology at passage 4-5. (c) PCR for Y chromosome specific SRY. 
Positive (male cells) and negative (female cells) controls shown. (d) FISH analysis for X (FITC) and Y 
(Texas Red) chromosomes indicated with green and red arrows respectively. 100 cells were counted (n 
= 1). All scale bars 100 µm.  
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Both e-CSC and l-CSC share a common morphology as well as immunophenotype with 
mesenchymal stem cells (MSC) (Dominici, Le Blanc et al. 2006), immunophenotype of bone 
marrow hfMSC is given in Appendix 1A. This is shown through exclusion of hematopoietic 
and endothelial cells in the e-CSC and l-CSC populations, as demonstrated by absence of 
CD14, expressed on monocytes and macrophages, CD34, which marks hematopoietic 
progenitors and endothelial cells and CD45, a pan-leukocyte marker (Dominici, Le Blanc et 
al. 2006). The positive control for CD14, CD34 and CD45 were human umbilical vein 
endothelial cells (HUVEC), which stained positive for all three markers as shown in 
Appendix 1B. In addition both e-CSC and l-CSC populations showed expression of MSC-
associated markers CD105, CD73, CD44 and the matrix protein VIMENTIN as well as CD29 
and CD90, although CD29 and CD90 are also found in human embryonic stem cells (hESC) 
(Carpenter, Rosler et al. 2004; Lian, Lye et al. 2007) (Fig.7). The positive control used was 
bone marrow hfMSC, which showed positive expression for all six markers as shown in 
Appendix 1A [Confocal immuno-fluorescence of bone marrow hfMSC was carried out with 
assistance from Dr. Dafni Moschidou]. No quantification or flow cytometry analysis was 
carried out on these markers since confocal immuno-fluorescence indicated all cells in the 
population were positive and therefore have an MSC phenotype. 
CD90CD73
l-C
S
C
e-
C
S
C
CD29CD44CD14 CD34 CD45 CD105 Vimentin
 
Figure 7 - e-CSC and l-CSC have a similar immunophenotype. 
Confocal immuno-fluorescence for endothelial marker (CD14), hematopoietic markers (CD34 and 
CD45), MSC-associated markers (CD105, CD73 and CD44), matrix protein (vimentin) and markers 
found in pluripotent cells as well as MSC (CD29 and CD90) stained with FITC (green). Nuclei stained 
with DAPI (blue). Scale bar 100 µm. n = 4 per group. 
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Similar to hfMSC (Gotherstrom, Ringden et al. 2004) both e-CSC and l-CSC present low 
levels of intracellular human leukocyte antigen I (HLA-I i.e. HLA-ABC) and no expression 
of HLA II (HLA-DP, DQ, DR) (Fig.8). Low/null expression of these major 
histocompatibility  (MHC) antigens suggests e-CSC and l-CSC may have low 
immunogenicity and may subsequently have potential for allogeneic clinical use (Le Blanc, 
Tammik et al. 2003). Positive controls used for the MHC antigens were HUVECs that had 
been induced to express HLA I and II using IFN-γ, shown in Appendix 1C.   
 
However, in contrast to MSC, pluripotency markers typical of undifferentiated hESC were 
expressed by a subset of cells in both the e-CSC and l-CSC populations (Fig.9A). In 
particular an OCT4A specific antibody was used to prevent false positive detection of the 
OCT4B isoform commonly found in other cell types (Cauffman, Van de Velde et al. 2005; 
Lee, Kim et al. 2006; Atlasi, Mowla et al. 2008). OCT4A expression was further verified by 
the nuclear localisation of the protein in the cells, whilst OCT4B is known to be cytoplasmic 
 
Figure 8 – cells have low expression of HLA antigens 
Confocal immuno-fluorescence for expression of human leukocyte antigens; HLA I and HLA II in e-
CSC and l-CSC shown by FITC (green). Nuclei stained with DAPI (blue). Scale bar 100 µm. n = 4 
per group. 
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(Cauffman, Van de Velde et al. 2005). Both chorionic stem cell populations were also 
heterogeneous for the expression of a subset of proteins involved in stemness and 
pluripotency (Skottman, Mikkola et al. 2005; Adewumi, Aflatoonian et al. 2007) including 
SOX2, KLF4, NANOG, REX1, c-MYC, SSEA4, SSEA3, TRA-1-60, and TRA-1-81 
(Fig.9A). The expression of these proteins in undifferentiated hESC [from Dr. Wei Cui] was 
also confirmed (Fig.9B). 
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Figure 9 - e-CSC and l-CSC contain a subpopulation expressing hESC markers. 
(a) Representative confocal immunofluorescence images for OCT4, SOX2, KLF4, NANOG, REX1, 
SSEA4, SSEA3, TRA-1-60 and TRA-1-81 stained with FITC (green). Positive cells indicated with green 
arrow, negative cells with white arrow. Nuclei stained with DAPI (blue). (b) Positive controls (hES cell 
line H9) OCT4A, SOX2, KLF4, NANOG, REX1, SSEA4, SSEA3, TRA-1-60, and TRA-1-81. All genes 
stained with FITC (green). Nuclei stained with DAPI (blue). All scale bars 25 µm. n = 4 per CSC 
group. n = 1 hES cell sample. 
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In parallel with my findings our group also showed using flow cytometry that the subset of 
cells positive for pluripotency genes was similar sized in the e-CSC and l-CSC populations. 
For example CD24, a marker of undifferentiated hESC, not expressed in MSC (Assou, Le 
Carrour et al. 2007; Lian, Lye et al. 2007), was found in 34.2% ± 3.5 s.e.m and 36.0% ± 10.0 
of the e-CSC and l-CSC respectively.  As well as CD24, a similar sized subpopulation of 
cells were positive for OCT4A (63.1 % ± 5.1 s.e.m vs. 70.2 % ± 6.6), SOX2 (62.2 % ± 4.2 
s.e.m vs. 66.1 % ± 3.3), c-MYC (52.3 % ± 11.2 vs. 61.6 % ± 11.4), SSEA4 (83.1 % ± 8.2 vs. 
69.6 % ± 22.3), SSEA3 (63.7 % ± 6.6 vs. 66.1 % ± 3.3), TRA-1-60 (59.4 % ± 10.6 vs. 62.8 % 
± 12.1), TRA-1-81 (61.8 % ± 3.2 vs. 62.8 % ± 12.1) in e-CSC and l-CSC respectively [Data 
published in (Jones, Moschidou et al. 2012) from Dr. Dafni Moschidou].  
 
An MSC is defined as a multipotent cell that can differentiate to the specialised cells of the 
mesodermal germ layer (bone, fat and cartilage) (Dominici, Le Blanc et al. 2006). Both e-
CSC and l-CSC differentiated to bone as shown by alizarin red staining of calcium deposition 
and von Kossa staining of mineralisation after cells were grown in osteogenic permissive 
media (Fig.10). The chorionic stem cells also differentiated to fat, evident from lipid droplet 
formation after growth in adipogenic permissive media (Fig.11), indicating an MSC 
phenotype. 
 
Alizarin Red Von Kossa
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Figure 10 - Osteogenic differentiation of e-CSC and l-CSC. 
Alizarin red staining (calcium deposits) and von Kossa staining (mineralisation) of cells grown 
in osteogenic permissive media for 2 weeks. Scale bar 100 µm. n = 3 per group. 
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In addition to differentiation to mesodermal 
lineages, both e-CSC and l-CSC were also 
capable of differentiation into the ectodermal 
lineage, indicating the cells to be broadly 
multipotent. After 5 days of neuronal 
differentiation e-CSC and l-CSC changed 
morphology and expressed the neuronal 
markers -TUBULIN, the microtubule-
associated protein 2 (MAP2) and the NMDA 
receptor NR1 (Fig.12), indicating that both 
cell populations have the potential to 
differentiate into neural-like cells. 
 
 
Figure 11 - Adipogenic differentiation of CSC. 
Oil Red O staining (lipid droplets) of e-CSC and 
l-CSC grown in adipogenic permissive media for 
3 weeks. Scale bar 100 µm. n = 4 per group. 
 
Figure 12 - Neurogenic differentiation of e-CSC and l-CSC. 
Morphology and expression of neuronal markers -TUBULIN, MAP2 and NMDA receptor NR1 
shown with FITC (green) of e-CSC and l-CSC after 5 days neurogenic differentiation. Nuclei stained 
with DAPI (blue). All scale bars 100 µm. n = 2 per group. 
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However, differentiation to the endodermal lineage was not found as culture of e-CSC and l-
CSC in hepatic-permissive medium over 21 days failed to induce expression of the hepatic 
markers ALBUMIN and alpha-fetoprotein (AFP) as visualized by confocal immunostaining 
(Fig.13A). Further confirmation of the absence of functional hepatic cells was shown by the 
lack of urea in the culture medium (Fig.13B). 
 
Figure 13 - Growth of e-CSC and l-CSC in hepatogenic differentiation media. 
(a) ALBUMIN and AFP immuno-fluorescence of e-CSC and l-CSC grown 3 weeks in hepatogenic 
permissive media. Positve control is HepG2 cells [from Wei Cui]. All genes stained with FITC (green) 
and nuclei with DAPI (blue). Scale bars 100 µm. n = 3 per CSC group. (b) Presence of urea (mmol/l) 
in hepatogenic differentiation media (diff) of e-CSC and l-CSC. Positive (urea; according to the 
manufacturer’s instructions) and negative controls; non-differentiated (non-diff) e-CSC and l-CSC 
shown. Data. n.s. (not significant), Student’s t test. Mean  s.e.m. n = 4 per CSC group. 
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3.1.3. Discussion 
Here I have shown e-CSC and l-CSC present an intermediate immunophenotype between 
hESC and adult BM-MSC, expressing MSC markers and containing a sub-fraction of cells 
that express pluripotency genes. Both populations also have a broadly multipotent 
differentiation capacity, forming tissues of the ectodermal as well as mesodermal lineages, 
but not the endodermal lineage. 
 
My findings verify previous research that demonstrated, albeit qualitatively, the mesodermal 
differentiation potential of e-CSC (Portmann-Lanz, Schoeberlein et al. 2006; Poloni, Rosini 
et al. 2008) and l-CSC (Li, Zhang et al. 2005; Yen, Huang et al. 2005; Soncini, Vertua et al. 
2007; Barlow, Brooke et al. 2008; Brooke, Rossetti et al. 2009) to the osteogenic and 
adipogenic lineages. I also show neurogenic differentiation of e-CSC and l-CSC, verifying 
previous reports that they can differentiate beyond the mesodermal lineages to neural 
progenitors and oligodendrocytes (Portmann-Lanz, Schoeberlein et al. 2006; Poloni, Rosini et 
al. 2008; Portmann-Lanz, Baumann et al. 2010; Portmann-Lanz, Schoeberlein et al. 2010). 
The potential of term placenta derived stem cells to treat neurological diseases has recently 
been investigated and shows the cells could differentiate to a neural phenotype under niche 
conditions (Martini, Jeremias Tda et al. 2013) and were able to cross the blood-brain barrier 
to engraft in models of cerebral artery occlusion after intravenous transplantation 
(Kholodenko, Yarygin et al. 2012). Similarly, a recent study using first trimester placenta 
stem cells has shown their formation to neural progenitors that can engraft in the brain of an 
animal model with hypoxia-ischemia and improve motor activity (Park, Koh et al. 2011).  
 
I found neither e-CSC nor l-CSC differentiated to hepatocytes, which is in contrast to others 
that have shown stem cells isolated from both early and term placental tissue can form cells 
of the endodermal lineage including hepatocytes (Shin, Lee et al. 2010; Kim, Shin et al. 
2011; Lee, Jung et al. 2012) as well as cardiomyocytes (Schmidt, Mol et al. 2006; Okamoto, 
Miyoshi et al. 2007; Weber, Zeisberger et al. 2011), vascular endothelial cells (Nur Fariha, 
Chua et al. 2012) and pancreatic cells (Kadam, Muthyala et al. 2010; Susman, Soritau et al. 
2010). The discrepancies in findings may be the result of different culture conditions and 
methods used, but it should also be noted that a number of studies, mainly those on term 
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placental stem cells, may be confounded by contamination with or overgrowth of 
maternal/decidual cells (In 't Anker, Scherjon et al. 2004). This was verified in some by 
characterising the cells (Soncini, Vertua et al. 2007; Barlow, Brooke et al. 2008; Brooke, 
Rossetti et al. 2009; Semenov, Koestenbauer et al. 2010; Rus Ciuca, Soritau et al. 2011; 
Jaramillo-Ferrada, Wolvetang et al. 2012) and not tested for in others (Yen, Huang et al. 
2005; Miao, Jin et al. 2006; Portmann-Lanz, Schoeberlein et al. 2006; Spitalieri, Cortese et al. 
2009; Castrechini, Murthi et al. 2010; Bacenkova, Rosocha et al. 2011; Fariha, Chua et al. 
2011; Kim, Shin et al. 2011). Here the presence of the male specific SRY gene was used to 
show CSC isolated from male samples were of fetal as opposed to maternal origin. We 
further confirmed with FISH that the male CSC populations did not contain a mixture of fetal 
and maternal cells and were therefore not contaminated with maternal cells. 
 
The expression of key pluripotency factors in both the e-CSC and l-CSC population indicates 
that although these cells share many features with MSC they also share some characteristics 
found in pluripotent hESC and may therefore have an intermediate phenotype. I have referred 
to the cells as chorionic stem cells (CSC) and not as MSC to avoid confusion. The 
endogenous expression of pluripotency markers in addition to MSC markers has also been 
shown for amniotic fluid stem cells (De Coppi, Bartsch et al. 2007; Moschidou, Mukherjee et 
al. 2012; Moschidou, Mukherjee et al. 2012), as well as amnion derived MSC (Miki, 
Mitamura et al. 2007; Izumi, Pazin et al. 2009), but the data is limited for the chorionic stem 
cells with studies only showing expression of a few pluripotency associated genes in e-CSC  
(Poloni, Rosini et al. 2008; Spitalieri, Cortese et al. 2009; Sung, Hong et al. 2010; Arakawa, 
Aoki et al. 2012) and l-CSC (Yen, Huang et al. 2005; Semenov, Koestenbauer et al. 2010; 
Bacenkova, Rosocha et al. 2011; Fariha, Chua et al. 2011; Kim, Shin et al. 2011; Rus Ciuca, 
Soritau et al. 2011; Koo, Park et al. 2012). Here I show [in combination with flow cytometry 
data from Dr. Dafni Moschidou] that a panel of pluripotency markers are expressed by a sub-
fraction of both CSC populations. This sub-fraction was similar sized in both e-CSC and l-
CSC, which suggests the proportion of cells expressing pluripotency genes is maintained 
throughout gestation. However, whether the expression levels were maintained throughout 
gestation is investigated next. 
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3.2. Phenotype features of e-CSC are more primitive than l-CSC 
3.2.1. Introduction 
Fetal stem cells from various tissues such as bone marrow, liver and blood as well as from 
extra-embryonic tissues including amniotic fluid, amnion, chorion and Wharton’s jelly appear 
to have a more primitive phenotype than adult BM-MSC, which may be due to the younger 
age of the tissues they were isolated from (Abdulrazzak, Moschidou et al. 2010). The 
comparison of first trimester fetal BM-MSC to neonatal UC-MSC (Zhang, Teoh et al. 2009) 
and adult BM-MSC (Guillot, Gotherstrom et al. 2007) has shown fetal stem cells have an 
earlier state of stemness (e.g. smaller size, faster proliferation and greater differentiation 
potency), which may be advantageous for use in regenerative medicine. 
 
Studies using placenta derived stem cells have shown both first trimester (Poloni, Rosini et al. 
2008; Meraviglia, Vecellio et al. 2012) and term stem cells (Barlow, Brooke et al. 2008; 
Jaramillo-Ferrada, Wolvetang et al. 2012) have greater expansion potential than adult BM-
MSC. However, a direct comparison of their phenotypes has yet to be carried out. I 
hypothesised that the chorionic stem cells isolated early in pregnancy would present a more 
primitive phenotype than those isolated at term. Accordingly my aim was to compare the 
phenotype of e-CSC and l-CSC when cultured in vitro in terms of cell size, growth kinetics, 
differentiation potential and pluripotency gene expression. 
 
 
3.2.2. Results 
Cell size was measured in equivalent passage cells (4-5) (i.e. a similar number of population 
doublings) to prevent senescence and subsequent cell enlargement confounding results. On 
average e-CSC were smaller in size than l-CSC (16.5 µm ± 0.1 s.e.m vs. 24.0 µm ± 0.1, 
P<0.01) (Fig.14A and 14B). Kinetic analysis revealed that e-CSC grew faster than l-CSC 
(population doubling time 48.6 h ± 3.7 s.e.m vs. 120.7 h ± 27.2, P<0.05) (Fig.15A) and 
subsequently generated greater cell numbers when grown beyond confluence (5.0 PD ± 0.6 
s.e.m vs. 2.3 PD ± 1.3 over 288 hours, P<0.05) (Fig.15B). In combination with our previous 
findings that e-CSC also senescenced later than l-CSC, growing respectively to 17 passages 
compared to 11 passages without reduced growth (Jones, Moschidou et al. 2012), these 
results show e-CSC has greater expansion potential than l-CSC. 
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Figure 14 - e-CSC are smaller in size than l-CSC. 
(a) Image of cells in suspension used for cell size analysis. Scale bar 100 µm. (b) Average cell size in 
µm of e-CSC (black) and l-CSC (red) when in suspension. ** P<0.01, Student’s t test, n = 3 different 
samples per cell group. Mean  s.e.m.  
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Figure 15 - e-CSC grow faster than l-CSC. 
(a) Average growth rate in hours taken for cell population to double during exponential growth 
phase; i.e. population doubling time (DT). e-CSC (black), l-CSC (red). (b) Cell kinetics measured by 
average cumulative population doublings of e-CSC (▲) and l-CSC (▼) when seeded at low density 
and grown beyond confluence for 288 hours. * P<0.05; ** P<0.01, Student’s t test, n = 3 different 
samples per cell group. Mean  s.e.m. 
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Qualitatively the osteogenic differentiation of e-CSC over 14 days of culture in osteogenic 
permissive conditions appeared greater than l-CSC, due to more intense alizarin red and von 
Kossa staining (Fig.8). I subsequently used quantitative real time PCR to semi-quantify the 
upregulation of late osteogenic genes and bone matrix related genes in e-CSC and l-CSC after 
2 weeks in vitro differentiation. Relative expression of each gene was normalized by its 
expression in non-differentiating growth medium (basal level) after normalization to Gapdh 
(2-Ct). Results showed only differentiated e-CSC expressed Osteocalcin (OC; 5.2 fold 
upregulation ± 4.6 s.e.m) and differentiated e-CSC compared to l-CSC had higher expression 
of Osteopontin (OP; 17.5 fold upregulation ± 5.6 vs. 0.3 fold upregulation ± 0.3, P<0.05), 
Bone sialo-protein-II (BSP; 67.8 fold upregulation ± 5.0 vs. 9.7 fold upregulation ± 11.1, 
P<0.05) and Bone morphogenic protein-2 (BMP2; 7.5 fold upregulation ± 1.2 vs. 0.5 fold 
upregulation ± 0.3, P<0.01) (Fig.16A). At the protein level, type I collagen (COL1A2) was 
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Figure 16 - e-CSC have greater osteogenic differentiation than l-CSC. 
(a) Quantitative real time PCR of fold increased expression of osteogenic genes after osteogenic 
differentiation; Osteopontin (OP), Procollagen endopeptidase enhancer (PCE), Osteocalcin (OC), 
Osterix (OSX), Bone sialo-protein-II (BSP) and bone morphogenic protein-2 (BMP2). Expression 
normalised to GAPDH and basal expression levels of differentiation genes (i.e. 2-ΔΔCt). e-CSC (black) 
and l-CSC (red). Data. * P<0.05, Student’s t test. Mean  s.e.m. n = 3 per cell group. (b) Western 
blot of COL1 for e-CSC and l-CSC not differentiated (non-diff) and differentiated to bone for 2 weeks 
(diff). Positive control (AFSC differentiated to bone for 4 weeks) and negative control shown. 
Loading control is β-actin. 
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absent in non-differentiated cells, but present in differentiated e-CSC and l-CSC samples, 
with e-CSC showing 3.2 times more protein (Fig.16B). This shows e-CSC has a greater 
osteogenic potency than l-CSC.  
 
In addition to greater osteogenic differentiation e-CSC also produced considerably more Oil 
Red O-positive lipid vacuoles than l-CSC when cultured in adipogenic permissive medium 
for three weeks (Fig.11). Quantification of adipocyte differentiation regulator peroxisome 
proliferator-activated receptor gamma (PPAR) using real time PCR analysis confirmed the 
higher adipogenic differentiation potential of e-CSC as expression was greater in 
differentiated e-CSC than l-CSC (5.7 fold upregulation ± 1.4 s.e.m vs. 1.7 fold upregulation ± 
0.4 s.e.m, P<0.05), after normalization to Gapdh and basal cell expression (Fig.17). The 
upregulation of PPARγ in l-CSC was typical of previous reports for this cell type (Kim, Park 
et al. 2012).  
At the protein level OCT4A was expressed in both e-CSC and l-CSC (Fig.9A), however 
pseudogenes not involved in maintaining pluripotency are found in the Oct4A isoforms and 
may have resulted in a false positive result (Pesce and Scholer 2000; Lee, Kim et al. 2006; 
Atlasi, Mowla et al. 2008; Ryan, Pettit et al. 2011). To avoid pseudogene detection RT-PCR 
was performed using specific primers for Oct4A variant 1 previously reported to be negative 
in e-CSC (Ryan, Pettit et al. 2011), and results showed expression in e-CSC, but not l-CSC, 
indicating a more primitive phenotype of e-CSC (Fig.18A). However, both e-CSC and l-CSC 
expressed the other  Oct4A variants when primers that also detected Oct4A variant 2 and 3 
were used (Fig.18B), explaining the detection of OCT4A protein in both cell populations.  
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Figure 17 - e-CSC have greater adipogenic differentiation than 
l-CSC. 
Quantitative real time PCR of fold increased expression of 
adipocyte differentiation regulator peroxisome proliferator-
activated receptor gamma (PPARγ) after 3 weeks of adipogenic 
differentiation. Expression normalised to GAPDH and basal 
expression levels of differentiation genes (i.e. 2-ΔΔCt). e-CSC 
(black) and l-CSC (red). Data. * P<0.05, Student’s t test. Mean  
s.e.m. n = 3 per cell group. 
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Transcript levels of the other reprogramming factors Sox2, c-Myc, Klf4 as well as Nanog 
were subsequently quantified and showed expression levels were considerably lower relative 
to hESC for Nanog (2.5 % ± 0.1 and 0.6 % ± 0.1; Fig.18C) and Sox2 (8.5 % ± 1.0 s.e.m and 
4.6 % ± 0.5; Fig.18D) However, expression levels were markedly higher in both e-CSC and 
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Figure 18 - e-CSC express higher levels of pluripotency genes than l-CSC. 
(a) RT-PCR for Oct4A variant 1. Gapdh and positive and negative controls shown. (b-f) Quantitative 
real time PCR for (b) Oct4A all variants, (c) Nanog, (d) Sox2, (e) c-Myc and (f) Klf4 for e-CSC (black) 
and l-CSC (red) as percentage expression of human embryonic stem cells (hESC). * P<0.05; *** 
P<0.001, Student’s t test. Mean  s.e.m. n = 4 per cell group.  
  Gemma Nicole Jones 
86 
 
l-CSC relative to those found in hESC for c-Myc (2,472 % ± 785.9 vs. 556.4 % ± 106.7, 
respectively; Fig.18E) and Klf4 (2,906 % ± 277.3 vs. 1,940 % ± 305.8, respectively; 
Fig.18F). When we compared e-CSC to l-CSC, all five pluripotency markers were expressed 
at greater relative levels in e-CSC; Oct4A (P<0.05), Sox2 (P<0.05), c-Myc (P<0.05), Klf4 
(P<0.05) and Nanog (P<0.001), indicating a e-CSC may have a more primitive phenotype. 
 
To investigate if endogenous 
expression of pluripotency 
markers translates to an 
ability to differentiate 
beyond mesodermal 
lineages, I [in combination 
with Dr Dafni Moschidou 
and Aya Harada] tested the 
capacity of e-CSC and l-
CSC to form embryoid 
bodies (EBs) in vitro with 
differentiation to cells from 
the three germ layers. We 
showed that only e-CSC, but 
not l-CSC, formed EBs 
when grown in EB-
permissive media, which 
may be linked to lack of 
Oct4A variant 1 expression 
in l-CSC. In contrast e-CSC formed EBs with a complex and compact morphology and a 
defined peripheral lining after 12 days of differentiation [Data published in (Jones, 
Moschidou et al. 2012) from Dr. Dafni Moschidou and Aya Harada]. I showed the expression 
of differentiation markers representative of all three germ layers using confocal microscopy 
for NESTIN and MAP2 (ectoderm), GATA4 (mesoderm), AFP (endoderm) and LAMININ, 
which was expressed in the peripheral lining of the EBs (Fig.19). Teratoma formation was 
not tested for in these cells. 
 
Figure 19 - e-CSC uniquely form embryoid bodies (EBs) with 
tri-lineage differentiation. 
Confocal immuno-fluorescence of e-CSC EBs for expression of 
NESTIN, MAP2, GATA4, AFP and LAMININ stained with FITC 
(green). Nuclei stained with DAPI (blue). Scale bars 25 μm. n = 1 
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3.2.3. Discussion 
Here I show ontological differences between chorionic stem cells isolated at different 
gestational ages with a decline in primitive characteristics seen in l-CSC compared to e-CSC. 
This suggests that there is an evolution of the stem cell phenotype during pregnancy, with an 
increase in cell size and a decrease in kinetics and differentiation potency paralleling a down 
regulation of expression levels of early “stemness” genes. 
 
My findings support previous work, which showed bone marrow hfMSC in contrast to their 
adult counterparts were smaller, grew faster and senesced later, despite sharing a common 
immunophenotype with expression of mesenchymal, adhesion and lineage markers in the 
whole population (Guillot, Gotherstrom et al. 2007). Others have previously reported that 
early placental MSC or e-CSC have increased proliferative potential when compared to adult 
bone marrow MSC (Poloni, Rosini et al. 2008; Meraviglia, Vecellio et al. 2012) due to the 
maintenance of long, stable telomeres without telomerase activity (Poloni, Maurizi et al. 
2011). Telomere length was also shown to be maintained in l-CSC without telomerase 
(Nazarov, Lee et al. 2012). Our data indicates that human fetal chorionic stem cells retain 
their immunophenotype with age, but lose associated primitive characteristics, not only from 
fetal to adult, but also from fetal to neonatal.  
 
The absence of Oct4A variant 1 expression in l-CSC at the transcript level and 
downregulation of other pluripotency markers may be pivotal to the decline of primitive 
characteristics seen in these cells when compared to their early gestational counterparts. 
Oct4A variant 1 transcript is expressed in the nuclei of undifferentiated hESC, EC cells and 
PGC and is responsible for maintaining “stemness”, whilst the other pseudogenes are found 
in the cytoplasm and have no known function (Pesce and Scholer 2000; Lee, Kim et al. 2006; 
Atlasi, Mowla et al. 2008). In particular the lack of Oct4A variant 1 in l-CSC may explain the 
inability of l-CSC to form embryoid bodies (EBs) as Oct4A variant 1 is critical to retain 
pluripotentiality (Atlasi, Mowla et al. 2008; Ryan, Pettit et al. 2011). From a technical view, 
OCT4A was detected at the protein level in the nuclei of both e-CSC and l-CSC using 
OCT4A-specific antibodies; this is likely to reflect lack of specificity of the available 
antibody for the variant 1 isoform, potentially also binding to variants 2 and 3 (Ryan, Pettit et 
al. 2011). This was confirmed through qRT-PCR analysis that showed expression of Oct4A in 
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both e-CSC and l-CSC when primers that amplified all 3 of the Oct4A variants were used. 
Therefore the cell populations differ in expression of Oct4A variant 1 only. 
 
Although Oct4A variant 1 was not detectable in l-CSC, other pluripotency associated markers 
were found in both e-CSC and l-CSC populations at both the transcript and protein level. 
Significantly both cell populations contained a similar proportion of cells expressing these 
markers, however, expression of key pluripotency markers (Oct4A, Klf4, Sox2, c-Myc and 
Nanog) decreased in l-CSC compared to e-CSC. This indicates a downregulation of 
expression with increased gestational age rather than a reduced number of cells expressing 
these early developmental markers. A similar result has been shown in amniotic epithelium 
stem cells, whereby expression of NANOG and SOX2 was higher in first trimester amnion 
than term, although levels of OCT4 were unchanged (Izumi, Pazin et al. 2009). While there is 
little literature on this in human chorionic stem cells (Sung, Hong et al. 2010), work to date 
on whole chorion tissues indicates a down regulation of telomerase activity over gestation, 
supporting the decline of primitive stem cell characteristics with age in this tissue (Kyo, 
Takakura et al. 1997). 
 
Despite both e-CSC and l-CSC expressing early developmental markers and differentiating 
beyond the mesodermal lineages to neural progenitors, only e-CSC formed EBs, which was 
validated with typical morphology and expression of markers from the three germ layers. The 
lack of EB formation in the l-CSC indicates a reduced potency of these cells compared to the 
e-CSC and may be due to the absence of Oct4A variant 1 in the l-CSC or may be a result of 
sub-optimal culture conditions for this cell type. Recent work from our group has shown that 
similar to e-CSC, first trimester amniotic fluid stem cells (AFSC) grown in MSC media can 
form EBs with differentiation to some lineages of all three germ layers (Moschidou, 
Mukherjee et al. 2012), whereas mid trimester AFSC do not have the capacity to form EBs 
under the same conditions (Moschidou, Mukherjee et al. 2012). This loss of potency with 
increased gestational age was attributed to the first trimester AFSC being phenotypically 
more primitive than their mid trimester counterparts, with expression of Nanog, Sox2, Klf4, 
Ssea3, Tra-1-60 and Tra-1-81 (Moschidou, Mukherjee et al. 2012; Moschidou, Mukherjee et 
al. 2012), which reflects what I have shown with the CSC. In addition single cell analysis 
showed first trimester AFSC contained cells that were smaller in size than the mid trimester 
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AFSC and this subfraction of small cells highly expressed Ssea3, Tra-1-60 and Tra-1-81 
(Moschidou, Drews et al. 2012). These results indicated expression of pluripotency markers 
may decrease with gestation due to either the loss of the high expressing subfraction of 
primitive cells with gestational age or the increase in size and decrease in primitive 
characteristics of this subfraction of cells. These results together with my data offer strong 
support that there is a decline in stemness with increased gestational age. Investigation into 
the heterogeneity of the CSC populations is now needed at a single cell level, to address how 
the molecular signature of the populations change with fetal development and if a primitive 
subfraction of cells is present in the parental populations. 
 
Semi-quantitative analysis of the adipogenic and osteogenic differentiation of e-CSC and l-
CSC compared the upregulation of lineage specific genes and protein and confirmed that l-
CSC had a reduced adipogenic and osteogenic potency. These findings parallel previous 
findings that, despite not comparing the same tissue type, found MSC from fetal bone 
marrow had higher osteogenic potency than term umbilical cord blood (Zhang, Teoh et al. 
2009). Likewise results from our group have shown the osteogenic potency of fetal BM-MSC 
was higher than adult BM-MSC (Guillot, Gotherstrom et al. 2007) and others have shown 
greater differentiation potency of first trimester placenta derived stem cells compared to term 
decidua derived MSC along ectoderm lineages (Park, Koh et al. 2013). However, one study 
reported a restricted plasticity of e-CSC, with less efficient adipocyte and osteocyte 
differentiation than adult bone marrow MSC and instead had preference towards endothelial 
differentiation (Meraviglia, Vecellio et al. 2012). This difference is likely to reflect different 
methods of culture and differentiation that may have inadvertently reduced the differentiation 
potency of the e-CSC, potentially by not maintaining cells at sub-confluence. 
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3.3. Chorionic stem cells may share a developmental origin with PGC 
3.3.1. Introduction 
Primordial germ cells (PGC) are the most primitive cell to be specified during development 
and are found at the beginning of gastrulation where they reside in extra-embryonic 
mesoderm prior to migration along the genital ridge, upon which they differentiate to mature 
germ cells in the gonads (Shin, Zuba-Surma et al. 2009). Kucia et al. hypothesised that cells 
isolated from adult and fetal tissues that have pluripotency characteristics may share an origin 
with PGC (Kucia, Machalinski et al. 2006; Ratajczak, Machalinski et al. 2007). Investigation 
of very small embryonic-like (VSEL) cells, isolated from cord blood (Kucia, Wu et al. 2007), 
adult bone marrow (Hua, Pan et al. 2009; Hua, Yu et al. 2009) as well as mouse fetal liver 
(Shin, Liu et al. 2010), has revealed similarities to PGC in morphology, expression of 
pluripotency genes and methylation status and were therefore proposed to have a PGC origin. 
Since I have shown expression of pluripotency markers in the chorionic stem cells I aimed to 
investigate if e-CSC and l-CSC might also share a developmental origin with PGC.  
 
3.3.2. Results 
At the transcript level both e-CSC and l-CSC expressed markers found in PGC (Fig.20) as 
has been previously shown for first trimester amniotic fluid stem cells (AFSC) (Moschidou, 
Mukherjee et al. 2012). These included c-kit, a regulator of PGC survival and growth (De 
Miguel, Cheng et al. 2002; Hoyer, Byskov et al. 2005), which is expressed in PGC, neural 
crest stem cells and haematopoietic stem cells during embryogenesis (Motohashi, Aoki et al. 
2007). As well as other markers which commonly define PGC: Stella, which is thought to 
maintain pluripotentiality (Bowles, Teasdale et al. 2003; Payer, Saitou et al. 2003), Fragilis 
and Nanos3, which have roles in PGC migration (Tsuda, Sasaoka et al. 2003; Tanaka, 
Yamaguchi et al. 2005) as well as SSEA1, an early marker found in PGC and human 
embryonic germ (hEG) cells but not hESC (Henderson, Draper et al. 2002; Park, Kim et al. 
2004). Vasa is expressed by PGC in the gonadal ridge and also by post-migratory PGC 
(Castrillon, Quade et al. 2000), Vasa was only detected in the e-CSC and not l-CSC 
populations at the transcript level (Fig.20). These results suggest both populations may 
contain cells of pre-migratory PGC origin, whilst e-CSC may also contain cells of post-
migratory PGC origin. Positive controls for PGC markers are shown in Fig.20 /Appendix 2. 
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Confocal immuno-
fluorescence confirmed 
the expression of PGC 
markers at the protein 
level for STELLA, 
FRAGILIS, NANOS3 
and SSEA1 and also 
demonstrated expression 
of DAZL and PUM2, 
which co-localise in hEG 
cells (Moore, Jaruzelska 
et al. 2003) (Fig.21). The 
presence of PGC proteins 
was confirmed by 
comparison to first 
trimester AFSC (shown in 
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Figure 20 - e-CSC and l-CSC express PGC proteins. 
Representative confocal immuno-fluorescence for protein expression of FRAGILIS, SSEA1, TNAP, 
NANOS3, BLIMP1, PUM2, STELLA, DAZL and VASA stained with FITC (green). Nuclei stained with 
DAPI (blue). Scale bar 100 μm. For positive control see Appendix 2C. n = 4 per cell group. 
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Figure 21 - e-CSC and l-CSC express PGC genes. 
Gel electrophoresis band following RT-PCR for expression of 
PGC genes in e-CSC and l-CSC. + shows positive controls used 
for each gene: first trimester AFSC was control for Stella, 
Fragilis, Nanos3, Ssea1 and Gapdh loading control; second 
trimester AFSC was control for c-kit; mouse testes was control 
for Vasa (for loading controls see Appendix2A and 2B). n = 3 per 
cell group. 
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Appendix 2C), which have high expression of a number of PGC markers and have been 
compared to the seminoma cell line TCam-2, which have characteristics of fetal germ cells 
(Nettersheim, Gillis et al. 2011; Moschidou, Mukherjee et al. 2012).   
 
Flow cytometry showed there was a similar sized subpopulation of cells in both e-CSC and l-
CSC respectively positive for STELLA (29%  14 and 27%  4), FRAGILIS (32%  5 and 
38%  12), NANOS3 (25%  9 and 34%  10), SSEA1 (61%  1 and 53%  4), as well as 
DAZL (30%  10 and 41%  12) and PUM2 (30%  8 and 33%  14) (Fig.22A and 22B). 
Whereas only a small proportion of cells expressed VASA, specific to the germ cell lineage 
(Castrillon, Quade et al. 2000), in both e-CSC and l-CSC (25% ± 10 and 17% ± 5 
respectively) with RT-PCR failing to detect Vasa transcripts in the l-CSC population  
(Fig.20). Also only a small proportion of e-CSC and l-CSC respectively expressed TNAP, 
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Figure 22 – A sub-fraction of cells express 
markers of primordial germ cells. 
(a) Representative flow cytometry for PGC 
markers; STELLA, FRAGILIS, NANOS3, 
SSEA1, DAZL, PUM2, VASA, TNAP and 
BLIMP1 (isotype control in black). (b) Flow 
cytometry for percent of e-CSC (black) and l-
CSC (red) populations positive for STELLA, 
FRAGILIS, NANOS3, SSEA1, DAZL, PUM2, 
VASA, TNAP and BLIMP1. For positive 
control see Appendix 2D. n = 3 per cell group. 
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used to denote early PGC (MacGregor, Zambrowicz et al. 1995; McLaren 2003) (20%  12 
and 22%  14) and BLIMP1, not found in hEG cells (Durcova-Hills, Tang et al. 2008), but a 
key marker in PGC that prevents dedifferentiation into pluripotent stem cells (Ohinata, Payer 
et al. 2005) (13%  1 and 15%  1) (Fig.22A and 22B). Positive controls for flow cytometry 
were first trimester AFSC, which express the PGC markers in a large sub-population of cells 
(Moschidou, Mukherjee et al. 2012), these are shown in Appendix 2D. Down-regulation of 
Blimp1 in e-CSC and l-CSC may be responsible for the high expression levels of its targets c-
Myc and Klf4, which were at least five times higher than expressed by hESC (Fig.18E and 
18F). 
 
PGC reside in extra-embryonic tissues prior to migration along the genital ridge where they 
undergo epigenetic reprogramming including erasure of methylation on H19 (Hajkova, 
Erhardt et al. 2002; Arnaud 2010). To determine to which developmental stage of PGC e-
CSC and l-CSC are most similar, we investigated the methylation status of H19. We found 
H19 was both hypermethylated and unmethylated in both e-CSC (50%  0 hypermethylated 
and 50%  0 unmethylated, n=3) and l-CSC (70%  8 hypermethylated and 30%  8 
unmethylated, n=3) (Fig.23), which was similar to the H19 methylation status of first 
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Figure 23 - Partial methylation of H19 in e-CSC and l-CSC. 
DNA methylation status of imprinted gene H19 as percent total input DNA hypermethylated (black), 
unmethylated (light grey) and intermediately methylated (dark grey). Reference control is first 
trimester AFSC. n = 3 per cell group. 
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trimester AFSC, which was used as a reference control since bisulfite sequencing shows H19 
methylation at a 1:1 ratio of methylated and unmethylated regions (Moschidou, Mukherjee et 
al. 2012). These results may indicate that e-CSC and l-CSC contain cells of PGC origin 
which have been retained in placental tissue prior to the start of genital ridge migration, at a 
time when imprint erasure has not yet started. 
 
3.3.3. Discussion 
This work offers support for Kucia et al.’s  hypothesis that cells isolated from adult and fetal 
tissues that have pluripotency characteristics may share an origin with PGC (Kucia, 
Machalinski et al. 2006; Ratajczak, Machalinski et al. 2007). This has been shown for murine 
fetal liver and adult bone marrow derived VSEL cells (Shin, Liu et al. 2010), and may also be 
true for  umbilical cord blood VSEL cells (Kucia, Halasa et al. 2007) as well as human fetal 
bone marrow and lung stem cells (Hua, Pan et al. 2009; Hua, Yu et al. 2009) and potentially 
hESC (Zwaka and Thomson 2005). During fetal development PGC reside at the junction 
between embryonic and extra-embryonic tissues, then migrate through the primitive streak to 
give rise to extra-embryonic mesoderm (Donovan 1998). Erasure of H19 methylation occurs 
during PGC migration. As we have demonstrated e-CSC and l-CSC maintained both 
methylated and unmethylated regions on H19 and expressed a wide array of markers 
associated with pre-migratory PGCs (OCT4, c-KIT, STELLA, FRAGILIS, NANOS3) 
(Hayashi, de Sousa Lopes et al. 2007; Saiti and Lacham-Kaplan 2007). Therefore the cells 
may originate from PGCs deposited in the extra-embryonic tissues before migration and 
hence before methylation was erased. 
 
Notwithstanding this, we also showed that e-CSC and l-CSC contain a sub-fraction of cells 
expressing post-migratory PGC markers (VASA, DAZL), which demonstrates the 
heterogeneity of the chorionic stem cell populations (Hayashi, de Sousa Lopes et al. 2007; 
Saiti and Lacham-Kaplan 2007). Placental stem cells are known to reside in a vascular niche 
(Castrechini, Murthi et al. 2010), therefore these cells may have been deposited later in PGC 
development following their mobilisation into the peripheral blood as shown for VSELs 
(Ratajczak, Liu et al. 2011). Further investigation is needed, potentially using an in vivo 
model, to precisely trace the lineage of PGCs and determine if this hypothesis is true.  
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The size of the subpopulation positive for PGC markers in e-CSC and l-CSC remained fairly 
consistent, which may result from the surrounding tissue niche maintaining a fairly stable, 
albeit heterogeneous, population of cells. In contrast the comparison of first and second 
trimester AFSC, showed distinct populations of cells (Moschidou, Drews et al. 2012); with 
the majority of first trimester AFSC expressing all the PGC markers (Moschidou, Mukherjee 
et al. 2012), whereas only a small fraction of the second trimester AFSC were positive for the 
PGC markers, in particular expression of STELLA and VASA was decreased (Moschidou, 
Mukherjee et al. 2012). The loss of the PGC-expressing subfraction in AFSC with increased 
gestational age may be due to the amniotic fluid niche being more dynamic than the placenta 
and subsequently unable to maintain the primitive subpopulation of cells.  
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CHAPTER 4 – Results 
Therapeutic benefits of e-CSC in a model of osteogenesis 
imperfecta 
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4.1. Greater tissue repair capacity of e-CSC compared to l-CSC 
4.1.1. Introduction 
In the first chapter I have shown in vitro that e-CSC has advantages for regenerative medicine 
in terms of differentiation potency and growth kinetics compared to l-CSC due to a more 
primitive phenotype. Others have shown a greater in vitro osteogenic capacity of first 
trimester bone marrow hfMSC compared to neonatal UC-MSC, translated to a more robust 
mineralization of cellular scaffolds in vivo, an advantage for use in tissue engineering (Zhang, 
Teoh et al. 2009). I subsequently aimed to test if the superior in vitro phenotype of e-CSC 
compared to l-CSC translated to higher tissue repair capacity in vivo using two different 
murine models. 
 
Firstly I used a mouse model of skin wound repair where it was known that the addition of 
stem cells promoted healing of dermal wounds and the rate of tissue repair could be measured 
(Direkze, Forbes et al. 2003; Fathke, Wilson et al. 2004; Ishii, Sangai et al. 2005; Mori, 
Bellini et al. 2005). Secondly I used the mouse model of type III OI (oim) (Chipman, Sweet 
et al. 1993) that has a deletion in the Col1a2 gene resulting in bone fragility, which can be 
quantified using the 3-point bending test. This model has previously shown marked 
therapeutic improvements following transplantation of first trimester blood hfMSC (Guillot, 
Abass et al. 2008; Vanleene, Saldanha et al. 2011). 
 
4.1.2. Results 
To compare the tissue repair capacity of e-CSC and l-CSC, a skin wound mouse model was 
used, which consisted of wild type mice given 4 full thickness dermal excisions on their 
dorsum. Skin wounds were treated with local application of either e-CSC or l-CSC in PBS or 
PBS alone [Animal experiments carried out with the help of George Bou-Gharios at the 
Kennedy Institute of Rheumatology, University of Oxford]. Morphological analysis of H&E 
sections of the wound beds seven days later showed that the healing process for the e-CSC-
treated wounds was more advanced (i.e. more closely resembled the normal skin 
morphology) than for either PBS or l-CSC-treated wounds (Fig.24A). This indicated e-CSC 
promoted greater tissue repair than l-CSC. It was evident by a lower number of infiltrated 
cells in the e-CSC-treated wounds compared to PBS-treated wounds (53 cells  3 s.e.m vs. 66 
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cells  4, respectively, calculated in a 100 μm2 surface, P<0.05). In contrast, l-CSC-treated 
wounds did not significantly differ from the controls (70 cells  6) (Fig.24B). Similarly, the 
epithelial thickness of the wound beds was thinner for the wounds covered with e-CSC 
compared to controls (46 μm  7 s.e.m vs. 76 μm  5, respectively, P<0.01), whilst l-CSC-
treated wounds did not significantly differ from the controls (81 μm  11) (Fig.24C). 
 
 
Secondly the capacity of e-CSC and l-CSC to improve bone pathology in a mouse model of 
osteogenesis imperfecta (oim mice) was compared by measuring the mechanical properties of 
the bone. Oim mice have significantly lower overall bone quality (i.e. total work) than wild 
type mice (0.90 mJ  0.09 s.e.m for non-transplanted oim mice vs. 7.91 mJ  0.61 for wild 
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Figure 24 - e-CSC have better tissue repair capacity in vivo than l-CSC. 
(a) Cross-section of normal skin and skin wounds 7 days after 4mm dermal biopsy in mice 
transplanted with e-CSC or l-CSC or PBS (Control); stained with haematoxylin and eosin. Indicated 
is collagen (white arrow), granulated cells (black arrow) and epithelial thickness (dashed line). In the 
same model of wound repair, (b) number of granulated cells in the wound bed (per 100µm2) and (c) 
epithelial thickness across wound in µm. Data. * P<0.05; ** P<0.01, n.s. (not significant), Student’s t 
test. Mean  s.e.m. n = 4 cell samples per cell source. n = 8 mice per group. 
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type mice, P<0.0001) and lower bone plasticity (i.e. work from yield to fracture) than wild 
type mice (0.62 mJ  0.08 s.e.m for non-transplanted oim mice vs. 7.91 mJ  0.61 for wild 
type mice, P<0.0001). E-CSC and l-CSC (106 cells in PBS) were transplanted i.p. into oim 
neonates (n = 15 per transplanted group and n = 30 for non-transplanted oim) and culled 8 
weeks later for analysis. Compared to non-transplanted control oim, transplantation of e-CSC 
led to an improvement of overall bone quality (1.86 mJ  0.42, P<0.05) (Fig.25A) and bone 
plasticity (1.54 mJ  0.40, P<0.01) (Fig.25B), whilst oim mice transplanted with l-CSC did 
not show any significant improvements (1.16 mJ  0.14 for total work, and 0.89 mJ  0.12 
for work from yield to fracture) (Fig.25A and 25B respectively). This suggests under these 
conditions of transplantation e-CSC have the capacity to improve the bone pathology of oim 
mice, whilst l-CSC do not. However, more samples would be required to determine if there is 
a significant difference between the two transplantation groups. [Three-point bending 
experiments carried out with the help of Maximilien Vanleene in the Department of 
Bioengineering, Imperial College London]. 
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Figure 25 - e-CSC improve oim bone mechanical properties more than l-CSC. 
(a) Mechanical 3-point bending data in a mouse model of bone brittleness (oim) for overall bone 
quality shown by total energy input in millijoules to fracture and for (b) femoral plasticity shown by 
energy input in millijoules from yield to fracture. Results shown per mouse for wild type (WT; green), 
non-transplanted oim (oim; blue) and oim transplanted with e-CSC (e-CSC; black) and l-CSC (l-
CSC; red). n = 17 wild type, n = 30 non-transplanted oim, n = 15 per transplanted group.. 
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Human donor cell engraftment was visualised by DAB staining on paraffin-embedded tibial 
sections of 8 week old oim using human specific Vimentin. Both cell populations had similar 
engraftment in the bone marrow; ranging from 1.7-3.9% for e-CSC transplanted oim and 1.6-
3.6% for l-CSC transplanted oim with average engraftments of 2.6% and 2.4% respectively 
(Fig.26). This was verified by quantitative real time PCR (qRT-PCR), which quantified the 
ratio of human specific β-actin to total human and mouse β-actin expressed. Results showed 
no significant difference in engraftment of human cells between e-CSC and l-CSC 
transplanted oim in the bone marrow as well as the bone (Fig.27A). 
 
Therefore differences in the bone parameters of transplanted oim are likely to result from 
differences in the intrinsic donor cell properties. Flow cytometry showed a higher proportion 
of e-CSC expressed STRO-1, a marker associated with early osteoprogenitors (Gronthos, 
Zannettino et al. 1999; Tare, Khan et al. 2009), than l-CSC (77.4% vs. 32.8%) (Fig.27B). 
Greater numbers of osteoprogenitors corresponded to greater expression of human specific 
osteogenic genes after transplantation in the bones of oim transplanted with e-CSC compared 
to l-CSC; Bgn 0.25 2-ΔCt ± 0.07 s.e.m vs. 0.07 2-ΔCt ± 0.03, P<0.05 respectively; Phex 0.47 2-
ΔCt ± 0.12 s.e.m vs. 0.08 2-ΔCt ± 0.03, P<0.01 respectively (Fig.27C). Bsp, a gene responsible 
for synthesis of structural proteins of the bone matrix was not different between the two 
transplanted groups. 
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Figure 26 - Transplanted e-CSC and l-CSC engraft in the bone marrow of oim. 
Visualisation of human donor cells with DAB staining (brown) of human specific vimentin in the tibial 
bone marrow of oim neonatally transplanted with e-CSC (e-CSC) and l-CSC (l-CSC), compared to age 
matched non-transplanted oim controls (OIM). Zoomed in bone marrow cell shown. Nuclei counter 
stained with Haematoxylin (blue). Scale bar 10μm. n = 4 per group. 
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Figure 27 – Transplanted e-CSC have higher osteogenic potency than l-CSC. 
(a) Donor cell engraftment in bone marrow and bone; 2-ΔCt of human specific β-actin normalised to 
human-mouse non-specific β-Actin in oim mice transplanted with e-CSC (black) or l-CSC (red). n = 8 
mice per group. (b) Flow cytometry for the proportion of osteoprogenitors (STRO-1+ cells; red) in the e-
CSC and l-CSC populations before transplantation (n = 1 per group) (isotype control in black). (c) 
Expression of human ossification genes; Biglycan (BGN), Bone sialo-protein II (BSP) and Phosphate 
regulating endopeptidase homolog (PHEX) in transplanted oim, normalised to expression of human 
specific β-actin (2-ΔCt). Data. n.s. (not significant), * P<0.05; ** P<0.01, Student’s t test. Mean  s.e.m. 
n = 8 mice per group for BGN and PHEX, n = 12 mice analysed per group for BSP. 
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4.1.3. Discussion 
I showed that compared to l-CSC, e-CSC had accelerated tissue repair in dermal excision 
skin wounds and resulted in an improvement in the bone quality and plasticity of bones in 
oim mice. This demonstrates in vivo that e-CSC have a greater tissue repair capacity than l-
CSC and suggests the more primitive characteristics of these cells are advantageous for use in 
regenerative medicine.  
 
Accelerated dermal wound healing was evident after just 7 days in e-CSC transplanted mice, 
but not in the l-CSC transplanted mice, with production of new collagen and reduced 
epithelial thickness at the wound site. The advancement of tissue repair may be in response to 
paracrine signals from the e-CSC, which potentially produced more anti-inflammatory 
cytokines, growth factors or proangiogenic molecules than l-CSC, to enhance repair by the 
endogenous cells (Ankrum and Karp 2010). Healing of skin wounds has been shown to 
accelerate in response to increased production of type I collagen (Direkze, Forbes et al. 2003; 
Fathke, Wilson et al. 2004; Ishii, Sangai et al. 2005; Mori, Bellini et al. 2005), primarily 
produced from resident cells indicating a paracrine effect of transplanted cells may be 
beneficial (Higashiyama, Nakao et al. 2011). However, adult bone marrow derived cells have 
also been shown to differentiate into dermal cells following transplantation that directly 
contributed to tissue repair (Badiavas, Abedi et al. 2003; Kataoka, Medina et al. 2003). 
Therefore the mechanisms of tissue repair of skin wounds has yet to be elucidated, but may 
be a combination of direct donor cell differentiation and paracrine action on the host cells. 
 
The transplantation of e-CSC in the osteogenesis imperfecta model (oim) resulted in 
improved oim bone plasticity compared to controls, not seen for l-CSC transplanted oim. The 
improvement in bone plasticity was in line with previous studies which transplanted first 
trimester blood hfMSC prenatally in oim mice (Guillot, Abass et al. 2008; Vanleene, 
Saldanha et al. 2011). The change in bone mechanics seen in e-CSC transplanted oim and not 
l-CSC transplanted mice corresponded with greater expression of human specific osteogenic 
differentiation genes, despite a similar level of donor cell engraftment, indicating e-CSC had 
higher osteogenic differentiation in vivo. This offers support for my findings in vitro that 
demonstrated a greater osteogenic potency of e-CSC compared to l-CSC and matches the 
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findings of Zhang et al. that showed higher osteogenic differentiation in vitro and in vivo of 
bone marrow hfMSC compared to neonatal UC-MSC (Zhang, Teoh et al. 2009). 
 
The osteoblast differentiation of transplanted cells in the oim model and subsequent 
improvements in disease pathology has been previously shown for adult bone marrow 
derived cells and blood hfMSC (Wang, Li et al. 2006; Li, Wang et al. 2007; Guillot, Abass et 
al. 2008; Vanleene, Saldanha et al. 2011). The greater osteogenic potency of e-CSC 
compared to l-CSC may be due to a higher number of early osteoprogenitors within the 
population. Previous research, albeit with hematopoietic stem cells (HSCs), has shown 
correlations with engraftment levels and number of progenitor cells transplanted (Glass, 
Uharek et al. 1997). I hypothesised that pre-selection of STRO-1+ cells could equalise the 
therapeutic effects seen between e-CSC and l-CSC. However, preliminary tests showed 
separation using magnetic beads yielded low numbers of STRO-1+ cells and expansion of the 
positive fraction after separation was not possible as the cell population reverted back to its 
original heterogeneous state containing both STRO1+ and STRO1- cells. Therefore I focused 
on the effect of e-CSC cells in the oim model as they contained a higher endogenous fraction 
of osteoprogenitors as well as advantages for regenerative medicine including higher 
population expansion in vitro and a greater capacity for tissue repair in vivo. 
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4.2. Transplanted e-CSC engraft and differentiate to osteoblasts 
4.2.1. Introduction 
 
Our group has previously shown that in utero transplantation of first-trimester blood hfMSC 
in oim resulted in donor cells preferentially engrafting at sites of active bone formation and 
remodelling, as well as at sites of fracture healing (Guillot, Abass et al. 2008). More recently, 
examining the cellular mechanisms and mechanical modifications underlying the 
improvement of the oim phenotype, our group showed that donor cells differentiated into 
functional mature osteoblasts, expressing mature osteoblast genes and producing the normal 
Collagen type 1 alpha 2 (COL1A2) chain protein, which is absent in non-transplanted oim 
mice. This was associated with reduced bone brittleness, indicating that the normal collagen 
produced from donor cells prevented long bone fracture occurrence by improving the 
mechanical integrity of the bone at the molecular and whole bone level (Vanleene, Saldanha 
et al. 2011). 
 
In chapter 4.1 I showed e-CSC and l-CSC engrafted in the bone and bone marrow and 
expressed some human specific osteogenic genes. Here I have focused on investigating the 
fate of transplanted e-CSC, in terms of in which part of the bone the cells homed to and if e-
CSC differentiated to functional osteoblasts that expressed late osteoblast markers and 
produced the COL1A2 protein. 
 
4.2.2. Results 
 
Tibia were analysed using DAB staining of human specific Vimentin 8 weeks after e-CSC 
were transplanted and donor cells were localized in the articular cartilage of the epiphysis, the 
primary spongosia of the growth plate, the periosteum of the diaphysis and in the primary 
spongosia of fracture calluses (Fig.28). This shows transplanted cells migrated to the bone 
and survived there 8 weeks after transplantation. 
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Quantitative real time PCR (qRT-PCR) showed that donor cell engraftment in transplanted 
oim was highest in the epiphysis, the site of active bone formation. This was 7.1 fold 
(P<0.05) higher than in the non-fractured diaphysis where bone formation is less active, and 
 
Figure 28 - Transplanted e-CSC engraft in oim bone. 
Visualisation of human donor cells with DAB staining (brown) of human specific vimentin in the tibial 
epiphysis, growth plate, diaphysis and fracture callus of oim neonatally transplanted with e-CSC (e-
CSC), compared to age-matched non-transplanted oim controls (OIM). Zoomed in human MSC in the 
fracture callus shown. Nuclei counter-stained with Haematoxylin (blue). Scale bars all 100µm. AC; 
articular cartilage, SOS; secondary ossification site, HC; hyaline cartilage, M; metaphysis, PS; 
primary spongosia, P; periosteum, CB; cortical bone, E; endosteum. n = 3 per group. 
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Figure 29 - Donor e-CSC localize to where bone formation is 
most active. 
Quantitative real time PCR of donor cell engraftment 
calculated as the 2-ΔCt of human specific β-actin normalised to 
human-mouse non-specific β-actin in the femoral epiphysis 
(Epi), diaphysis (Dia); with (+Fr) and without fracture callus 
(-Fr), and in the liver (Liv). ** P<0.01, ***P<0.001; One-way 
ANOVA followed by Tukey’s post hoc test. Error bars are 
s.e.m. n = 6 for Epi, -Fr, Liv. n = 9 +Fr. 
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11.7 fold (P<0.05) higher than engraftment in the liver (Fig.29). Donor cells also 
preferentially homed to sites of bone repair, where engraftment was 4 fold (P<0.05) higher 
than engraftment in the liver. Engraftment in fractured and non-fractured diaphysis was not 
significantly different, but interestingly more mice were positive for human cDNA in the 
diaphysis if a fracture callus was present; 90% compared to 60%.  
 
To determine if transplanted cells underwent osteogenic differentiation, in vivo expression 
using qRT-PCR was determined for human specific Osteopontin (OP); a major interfacial 
extracellular matrix protein found in bone and secreted by osteoblasts (McKee and Nanci 
1996) and also for Osteocalcin (OC); an osteoblast specific gene (Lian, Stein et al. 1989) 
with an important role in osteoblast differentiation (Ryoo, Hoffmann et al. 1997). Results 
showed expression of human OP and OC in the transplanted mouse bones (0.38 2-ΔCt ± 0.08 
s.e.m and 0.85 2-ΔCt ± 0.18, respectively), which was greater than expression in e-CSC after 
WT OIM e-CSC
140K
100K
50K
40K
COL1A2
-ACTIN
A B
E
xp
re
ss
io
n 
of
 h
um
an
 g
en
es
(2
-
C
t  o
f h
um
an

-a
ct
in
)
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
OP OC
differentiated cells
basal cells
e-CSC Tx bone
* *
 
Figure 30 - Donor e-CSC differentiate to functional osteoblasts in vivo. 
(a) Quantitative real time PCR of expression of human specific Osteopontin (OP) and Osteocalcin 
(OC) normalised to human specific β-actin (2-ΔCt) in the femurs of e-CSC transplanted oim (e-CSC Tx 
bone, n = 6; black) and compared to the basal expression level of e-CSC (basal cells, n = 3; stripes) 
and expression level of cells grown in osteogenic permissive media for 2 weeks (differentiated cells, n 
= 3; checks). * P<0.05; One-way ANOVA followed by Tukey’s post hoc test. Error bars are s.e.m. (b) 
Western blot of COL1A2 protein in the femurs of e-CSC transplanted oim (e-CSC) compared to age 
matched wild type (WT) control and non-transplanted oim (OIM). Loading control is β-ACTIN. n = 4 
per group. 
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growth in osteogenic permissive media for 2 weeks (0.05 2-ΔCt ± 0.03, P<0.05 and 0.06 2-ΔCt 
± 0.04, P<0.05, respectively) and greater than the low/null basal expression level of the 
undifferentiated cells (P<0.05) (Fig.30A). Western blot of the COL1A2 protein, missing in 
oim (Chipman, Sweet et al. 1993), showed a substantial amount of COL1A2 in transplanted 
oim (Fig.30B). This confirmed osteogenic differentiation of e-CSC to functional osteoblasts. 
 
4.2.3. Discussion 
I showed donor e-CSC preferentially engrafted at sites of active bone formation and repair, 
and differentiated to functional osteoblasts, shown by expression of late osteoblast genes and 
production of the COL1A2 protein. Osteoblast differentiation of blood hfMSC and bone 
marrow MSC after transplantation in oim has been previously shown by production of the 
missing COL1A2 protein (Li, Wang et al. 2007; Vanleene, Saldanha et al. 2011) and 
expression of osteoblast markers (Wang, Li et al. 2006; Guillot, Abass et al. 2008). 
Production of normal COL1A2 by blood hfMSC was associated with improvements in the 
mechanical and biochemical matrix properties of the oim bone, including an increase in 
lamella bone and some improvement in maturation of matrix apatite crystals, which led to 
reduced bone brittleness and 85% decreased femoral fracture incidence (Vanleene, Saldanha 
et al. 2011). I have verified that e-CSC, a source of clinically translatable stem cells, 
engrafted and differentiated in vivo to osteoblasts that contributed to collagen production. 
Whether these mice also had an improvement in therapeutic outcome was investigated next. 
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4.3. Transplantation of e-CSC in oim improves disease pathology 
4.3.1. Introduction 
OI, or brittle bone disease, is a debilitating inherited skeletal dysplasia characterised by 
multiple fractures and osteopenia and has a range of severities across the 11 known types 
depending on the causative mutation in collagen type I or genes involved in its biosynthesis 
(Stoss and Freisinger 1993; Cohen-Solal, Zylberberg et al. 1994; Dalgleish 1997; Van Dijk, 
Pals et al. 2010). The current ‘gold standard’ treatment of OI is bisphosphonates, which 
temporarily improves bone strength by inhibiting bone resorption, but does not significantly 
improve growth or bone pain beyond a year (Letocha, Cintas et al. 2005) and does not reduce 
fracture incidence long term (Antoniazzi, Monti et al. 2010; Ward, Rauch et al. 2011). A 
number of studies have shown the engraftment and differentiation of transplanted cells in 
rodent models of OI, but have failed to investigate if the cell therapy also had therapeutic 
benefits (Pereira, O'Hara et al. 1998; Wang, Li et al. 2006; Li, Wang et al. 2007). Recent 
work from our lab has shown transplantation of hfMSC from first-trimester blood in oim 
mice led to a striking two-third reduction in long bone fractures as well as improvements in 
bone pathology and mechanical properties (Guillot, Abass et al. 2008; Vanleene, Saldanha et 
al. 2011). However, the collection of fetal blood is ethically and technically challenging 
(Chan, Kumar et al. 2008), therefore I aimed to test if the transplantation of e-CSC in oim 
could also improve the OI disease pathology (i.e. the manifestation of the disorder). 
 
4.3.2. Results 
To assess the therapeutic benefits of e-CSC when transplanted in oim mice, the fracture 
incidence compared to non-transplanted oim was calculated. Eight weeks after e-CSC were 
transplanted 11/20 oim mice (55%) had no long bone (femur, tibia and humerus) fractures 
whereas all non-transplanted oim mice (n = 13) had at least one long bone fracture or more 
(Fig.31A). The fracture incidence in long bones, calculated as the number of fractured tibia, 
femur and humeri over the total number of bones, was significantly reduced from 29.5% 
(23/78 total bones) in non-transplanted oim to 10.0% (12/120 total bones) in e-CSC 
transplanted oim. This corresponded to a 66% decrease in fracture rate (X2=21, P<0.001) 
(Fig.31B). Parallel work in the lab found tail fractures were also reduced by 29.2% (X2=33.8, 
P<0.001) in e-CSC transplanted oim compared to oim controls, suggesting bones throughout 
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the oim mice were more resistant to fractures after transplantation [Publication in progress. 
Data from Bhalraj Singh Kalirai]. 
The transplanted oim bones had improved bone plasticity and overall quality compared to 
oim controls (Fig.25) due to an increased post-yield strain as shown by the representative 3-
point bending load-displacement curve (Fig.32A). Further investigation of the load-
displacement data showed that the bones of e-CSC transplanted oim were not only more 
plastic, but also more ductile due to a reduction in stiffness in the pre-yield region and an 
increase in maximum deflection before fracture (Fig.32A). Bone stiffness of e-CSC 
transplanted oim was reduced by an average of 16% compared to non-transplanted oim 
femurs (29.7 N/mm ± 2.1 s.e.m vs. 35.3 N/mm ± 1.7 s.e.m respectively, P<0.05) (Fig.32B), 
while the maximum deflection was increased in transplanted compared to control oim by an 
average of 24% (0.26 mm ± 0.02 s.e.m vs. 0.21 mm ± 0.01, P<0.05 respectively) (Fig.32C). 
However, the maximal load sustained by transplanted and non-transplanted oim femurs prior 
to fracture was similar (4.5 N ± 0.3 vs. 4.8 N ± 0.3) (Fig.32D). In contrast, wild type 
compared to oim bones were stiffer (73.6 N/mm ± 2.0, P<0.001) (Fig.32B), with greater 
maximum deflection (0.88 mm ± 0.07, P<0.001) (Fig.32C) and sustained higher loads before 
fracture (14.0 N ± 0.5, P<0.001) (Fig.32D). Thus the material properties of bones from 
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Figure 31 - e-CSC transplanted oim show reduced long bone fractures. 
(a) Percentage of mice with at least one long bone fracture. (b) Fracture rate; total proportion of 
fractured femur, tibia and humerus over total number of bones per mouse. Data. *** P<0.001 
Fisher’s exact test or Chi squared test respectively. Error bars are s.e.m. n = 13 oim, n = 20 
transplanted mice. 
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transplanted oim were not intermediate between the properties of wild type and oim bone. 
Instead bones from transplanted oim were of similar strength to non-transplanted oim, but 
displayed greater plasticity and ductility which may explain their reduced fracture 
susceptibility. [Three-point bending experiments carried out with the help of Maximilien 
Vanleene in the Department of Bioengineering, Imperial College London]. 
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Figure 32 - e-CSC transplanted oim bones have greater ductility 
(a) Three-point bending load (N) displacement (mm) curves shown up to the critical fracture point. (b) 
Bending stiffness of femurs (slope of the linear elastic deformation; N/mm). (c) Total energy deflected 
during bending (energy displacement extension to the point of fracture; mm). (d) Load to fracture 
(maximum force sustained by femur prior to fracture; N). All mice were 8 weeks old and either wild 
type (WT; green), non-transplanted oim (OIM; blue) or e-CSC transplanted oim (e-CSC; black). Data. 
n.s. not significant, * P<0.05, *** P<0.001; Student’s t-test. Error bars are s.e.m. n = 14 WT, n = 34 
oim, n = 22 transplanted mice. 
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Figure 33 - Engraftment levels correlate with 
reduced oim bone stiffness. 
Correlation per mouse of donor cell engraftment 
(2-ΔCt) in the femoral epiphysis against the stiffness 
(N/mm) of the femur calculated from the three 
point bending test. Linear line of best fit given. n 
=10 transplanted oim.  
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Engraftment in the femoral epiphysis was inversely correlated with bone stiffness (R2=0.64, 
y= -0.96x + 41.43, P<0.01 deviation from zero), indicating that bone flexibility increases 
with increasing numbers of donor cells (Fig.33). 
 
Tibial length was unaffected by transplantation being similar in transplanted oim compared to 
control oim (15.1mm ± 0.1 and 15.2mm ± 0.1 respectively), with both being shorter than wild 
type tibia (17.0mm ± 0.1, P<0.001) (Fig.34A). The diameter of the tibia at the mid-diaphysis 
was also similar in transplanted and control oim (1.01 mm ± 0.01 and 1.05mm respectively) 
but less than in wild types (1.28 mm ± 0.02, P<0.001) (Fig.34B). Cortical bone thickness was 
less in oim than wild type (17.9% ± 0.5 and 20.4% ± 0.3, P<0.001 respectively), and was not 
increased in e-CSC transplanted oim (17.2% ± 0.5 s.e.m) (Fig.34C). [X-ray 
microradiography carried out with the help of J.H. Duncan Bassett in the Department of 
Medicine, Imperial College London]. 
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Figure 34 - Bone length and cortex thickness are not changed by transplantation. 
(a) Tibia length (mm) of 8 week old wild type (WT; green), non-transplanted oim (OIM; blue) and e-
CSC transplanted oim (e-CSC; black). (B) Tibia diameter (mm) at the mid shaft for each group 
across all osseous tissues including cancellous bone (light grey) and compact cortical bone (dark 
grey). (C) Height of tibial cortex (compact bone) at the mid shaft shown as a percentage of all 
osseous tissues in the tibia. Data. n.s. not significant, *** P<0.001; Student’s t-test. Error bars are 
s.e.m. n = 12 WT, n = 20 oim, n = 19 transplanted mice. 
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Cortico-endosteal bone formation rate (BFR) was greater in wild type mice compared to oim 
(2.4 µm3/µm2/day ± 0.21 s.e.m vs. 1.54 µm3/µm2/day ± 0.23, P<0.05 respectively) (Fig.35A). 
This difference resulted from an increased mineral apposition rate (MAR) at the cortico-
endosteal interface (2.6 µm/day ± 0.3 vs. 1.7 µm/day ± 0.3, P<0.05 respectively) (Fig.35B), 
because there was no difference in mineralizing surface (92% ± 2 vs. 90% ± 2, respectively) 
(Fig.35C). The MAR and mineralizing surface, however, did not differ between transplanted 
and non-transplanted oim mice (Fig.35A, 35B and 35C). 
 
Total bone mineral content (BMC) of combined trabecular and cortical bone compartments 
did not differ between transplanted and non-transplanted oim mice, both of which BMC was 
reduced compared to wild-type (P<0.001) (Fig.36A and Fig.36B). [X-ray microradiography 
and BMC analysis carried out with the help of J.H. Duncan Bassett]. Trabecular bone volume 
(bone volume/ total volume; BV/TV), however, was increased in transplanted compared to 
non-transplanted oim mice (4.1% of total bone volume ± 0.6 vs. 2.0% ± 0.4 respectively, 
P<0.05), but remained lower than in wild type mice (11.9% ± 0.9) (Fig.36C). [BV/TV data 
generated with Hassan Abdulrazzak]. 
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Figure 35 – Cortico-endosteal bone formation not affected by transplantation. 
(a) Bone formation rate (BFR;µm3/µm2/days) for the endosteal cortex calculated from dual calcein 
labelling in 8 week old wild type (WT; green), non-transplanted oim (OIM; blue) and e-CSC 
transplanted oim (e-CSC; black). (b) Mineral apposition rate (MAR) in µm per day for the endosteal 
region of the tibial cortex. (c) Percentage mineralizing surface per total bone surface (MS/BS) for the 
cortico-endosteal. Data. n.s. not significant, * P<0.05; Student’s t-test. Error bars are s.e.m. n = 6 
WT, n = 5 oim, n = 7 transplanted mice. 
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Figure 36 - Transplantation increased trabecular bone, but not bone mineral content. 
(a) Digital X-ray images of tibia from 8 week old wild type (WT), non-transplanted oim (OIM) and 
oim transplanted with e-CSC (e-CSC), where grey level has been pseudocoloured according to a 16-
colour palette; ranging from black (low mineralization density) to white (high mineralization 
density). (b) Bone mineral content shown as relative frequency (%) across 16 equal intervals of 
mineralisation density (0 grey scale: no mineralisation; 256 grey scale: maximum mineralisation). 
Data. *** P<0.001; Kolomogorov-Smirnov test. n = 12 WT, n = 20 oim, n = 19 transplanted mice. 
(c) Percentage of trabecular bone volume in the tibial metaphysis calculated over the total bone 
volume.  Data. * P<0.05, *** P<0.001; Student’s t-test or. Error bars are s.e.m. n = 5 WT, n = 6 
oim, n = 6 transplanted mice. 
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BFR in the trabecular bone was not significantly different between transplanted and non-
transplanted oim (0.58 µm3/µm2/day ± 0.03 s.e.m vs. 0.52 µm3/µm2/day ± 0.03 respectively) 
with wild type having a faster BFR than oim (1.10 µm3/µm2/day ± 0.1 s.e.m, P<0.001) 
(Fig.37A). Transplanted and control oim also had a similar trabecular MAR (0.86 µm/day ± 
0.04 s.e.m vs. 0.89 µm/day ± 0.04, P<0.05 respectively), whilst wild type had a greater MAR 
than oim (1.62 µm/day ± 0.09 s.e.m, P<0.001) (Fig.37B). MS/BS did not differ between 
transplanted oim, non-transplanted oim and wild type mice (Fig.37C). 
 
 
4.3.3. Discussion 
Therapeutic benefits of e-CSC in the oim mice were evident from a two-third decrease in 
long bone fracture incidence compared to non-transplanted controls, following a single 
neonatal infusion of e-CSC. Fracture reduction in e-CSC transplanted mice was attributed to 
an increase in bone plasticity as well as greater bone ductility compared to non-transplanted 
controls. Changes to the bone mechanical properties of transplanted oim were most likely 
mediated by the exogenous cells since higher engraftment levels in bones correlated with 
decreased bone stiffness. Fracture reduction was comparable to that seen in oim transplanted 
with blood hfMSC (Guillot, Cook et al. 2008; Vanleene, Saldanha et al. 2011), although the 
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Figure 37 - Trabecular bone formation was not affected by e-CSC transplantation. 
(a) Bone formation rate (BFR; µm3/µm2/days) for trabecular bone calculated from dual calcein 
labelling. (b) The MAR of the tibial trabecular bone. (c) MS/BS percentage for the tibial trabecular 
bone. Data. n.s. not significant, *** P<0.001; Student’s t-test. Error bars are s.e.m. n = 6 WT, n = 5 
oim, n = 7 transplanted mice. 
  Gemma Nicole Jones 
115 
 
reduction in stiffness of e-CSC transplanted oim highlights a difference from the previous 
study whereby bone parameters of blood hfMSC transplanted mice were intermediate 
between wild type and oim. 
 
The trabecular bone volume (BV/TV) of oim is lower than wild type mice due to the impaired 
osteoblast differentiation of oim (Kalajzic, Terzic et al. 2002; Li, Jiang et al. 2010), which 
results in a high numbers of preosteoblasts that support greater osteoclast bone resorption (Li, 
Jiang et al. 2010). Oim mice transplanted with e-CSC had a higher BV/TV than non-
transplanted oim, despite bone formation rate remaining the same, which could be due to 
differentiation of exogenous cells to normal osteoblasts that better regulate bone remodelling. 
 
BMC measured at the whole bone scale did not increase in oim after transplantation of e-
CSC, despite changes in bone mechanical properties. Others have shown the importance of 
the collagen matrix organization on bone mechanical properties (Gupta, Schratter et al. 2005; 
Zebaze, Jones et al. 2011) and recently we have shown using nanoindentation that compared 
to wild type mice, oim have greater mineralization of a poorly organized matrix (Vanleene, 
Porter et al. 2012). Therefore exogenous cells may have affected the bone mineralization or 
improved organization of bone matrix collagen fibres in the oim bones at the microscopic 
matrix scale, potentially in response to production of normal COL1A2.  
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4.4. Transplantation of e-CSC upregulates endogenous ossification genes 
4.4.1. Introduction 
I have shown, along with others (Wang, Li et al. 2006; Li, Wang et al. 2007; Guillot, Abass et 
al. 2008; Vanleene, Saldanha et al. 2011), evidence in support of a direct contribution to 
tissue repair by donor cells via their osteogenic differentiation. However, transplantation may 
also affect the activity of endogenous cells via paracrine action (Dominici, Le Blanc et al. 
2006; Phinney and Prockop 2007). Paracrine effects have been attributed to the release of 
various factors from the transplanted MSC, such as growth factors, anti-apoptotic factors, 
anti-inflammatory cytokines or pro-angiogenic molecules, but may also arise from cell-cell 
contacts that activate cell signalling or allow exchange of cytoplasmic components (Ankrum 
and Karp 2010). Evidence of a paracrine mechanism of action was recently reported in oim 
mice transplanted with adult BM-MSC, which had increased endogenous chondrocyte 
proliferation that led to increased lumbar vertebrae length (Otsuru, Gordon et al. 2012). I 
therefore aimed to investigate if transplantation of e-CSC affected endogenous osteogenesis 
or chondrogenesis activity in the oim mice.  
 
4.4.2. Results 
The mouse osteogenesis array (SABiosciences) was used to analyse changes in endogenous 
osteogenesis gene expression. The array results showed the femoral epiphysis of e-CSC 
transplanted mice compared to non-transplanted oim controls had a global increase in 
expression of genes involved in intramembranous ossification (Fig.38). For example, 
transplanted mice compared to oim controls had a 2.8 fold (P<0.05) increase in Phex and a 
2.9 fold (P<0.05) increase in Dmp1; genes co-expressed by osteoblasts and osteocytes that 
regulate bone mineralization via FGFR signalling pathways (Lorenz-Depiereux, Bastepe et 
al. 2006; Martin, Liu et al. 2011). In addition, Bgn, which has a role in osteoblast 
differentiation and mineralisation of the matrix (Wang, Harimoto et al. 2010), and Serpinh1, 
which acts as a molecular chaperone in collagen biosynthesis (Christiansen, Schwarze et al. 
2010) were upregulated in transplanted oim (2.6 fold, P<0.05, and 3.5 fold, P<0.05 
respectively). This corresponded to higher expression of extracellular matrix proteins in 
transplanted mice, including a 3.2 fold increase in Col1α1 (P<0.01), involved in fibril 
formation of the abundant collagen type I (Stacey, Bateman et al. 1988; Dalgleish 1997) 
(Fig.38). 
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Figure 38 – Changes to endogenous 
osteogenesis and chondrogenesis. 
Fold changes in gene expression in the 
femoral epiphysis of oim transplanted 
with e-CSC when compared to non-
transplanted oim controls, generated 
from a mouse osteogenesis PCR array 
(SABiosciences). Data. * P<0.05. n = 3 
per group. 
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Array results were confirmed by qRT-PCR and showed Runx2 expression, essential for 
differentiating mesenchymal stem cells to osteoblasts (Ducy, Zhang et al. 1997; Komori, 
Yagi et al. 1997; Otto, Thornell et al. 1997), was also increased in transplanted mice 
compared to non-transplanted oim (2.1 x10-2 2-ΔCt ± 0.2 x10-2  vs. 1.3 x10-2 2-ΔCt ± 0.3 x10-2 
respectively, P<0.05) (Fig.39). However, the downstream transcription factor Osterix, 
required for osteoblast differentiation (Karsenty and Wagner 2002) was found to be similar in 
both e-CSC transplanted oim non-transplanted controls (3.7 x10-2 2-ΔCt ± 0.5 x10-2  vs. 3.3 
x10-2 2-ΔCt ± 0.7 x10-2 respectively). Whereas Igf1, which regulates both osteoblasts 
(Giustina, Mazziotti et al. 2008) and osteoclastogenesis via induction of RANK-L synthesis 
(Mochizuki, Hakeda et al. 1992; Niu and Rosen 2005) and is reported to increase linear bone 
growth (Yakar, Rosen 
et al. 2002) was 
upregulated in 
transplanted mice 
(0.43 2-ΔCt ± 0.05 for 
transplanted oim vs. 
0.21 2-ΔCt ± 0.02 for 
oim controls, P<0.05). 
This suggests 
transplanted e-CSC 
may have an effect on 
the systemic 
hormones such as GH 
or PTH that regulate 
local production of 
Igf1 in bone 
(Giustina, Mazziotti 
et al. 2008).  
 
These results show that transplantation of e-CSC affects the levels of endogenous ossification 
genes. The expression of these genes correlated with their co-activators and trans-activation 
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Figure 39 – Transplantation increases endogenous intramembranous 
ossification genes 
Expression of genes involved in intramembranous ossification; Dmp1, 
Phex, Biglycan (Bgn), Col1α1, Runx2, Osterix (Osx) and Igf1. Results 
are given as 2-ΔCt normalised to mouse β-actin and Hsp90ab1 for non-
transplanted oim (OIM; blue) and oim transplanted with e-CSC (e-
CSC; black). Data. * P<0.05, ** P<0.01; Student’s t-test. Error bars 
are s.e.m. n = 5 oim, n = 8 transplanted mice. 
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targets as expected when mice were analysed on an individual basis. This included the co-
activators Dmp1 and Phex which were closely associated (R2=0.91, P<0.001) (Fig.40A), as 
were the ECM genes Col1α1 and Bgn (R2=0.93, P<0.001) (Fig.40B). I also show a strong 
correlation between Igf1 and Bgn expression (R2=0.89, P<0.001), highlighting the importance 
of Igf1 in regulating genes activated during intramembraneous ossification (Fig.40C).  
 
The PCR array also showed upregulation of genes involved in early stage endochondral 
ossification (Fig.38). These included a 2.7 fold increase of Sox9 expression (P<0.01), 1.6 fold 
increase of Twist1 (P<0.05), 6.8 fold increase of Col2α1 (P<0.01) and 3.3 fold increase of 
Col11α1 (P<0.05). In addition late hypertrophic chondrocyte differentiation genes were 
upregulated by 4.4 fold for Col10α1 (P<0.05), 2.9 fold for Dmp1 (P<0.05) and 2.6 fold for 
Alkaline phosphatase (P<0.05) (James, Stanton et al. 2010), whilst chondrocyte assembly 
gene Comp was also upregulated by 1.7 fold (P<0.05) (Haleem-Smith, Calderon et al. 2011) 
(Fig.38). 
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Figure 40 - Endogenous intramembranous genes have linked expressions. 
Correlation of gene expression per mouse (given as 2-ΔCt normalised to mouse β-actin and Hsp90ab1) 
of (a) Dmp1 and Phex, (b) Col1α1 and Bgn and (c) Igf1 and Bgn. Linear line of best fit given. 
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The array results were 
again confirmed by qRT-
PCR for the key 
transcription factor of 
chondrogenesis Sox9 (5.6 
x10-2 2-ΔCt ± 0.1 x10-2 s.e.m 
for transplanted oim vs. 2.1 
x10-2 2-ΔCt ± 0.01 x10-2 for 
oim controls, P<0.05) (Bi, 
Deng et al. 1999). The 
subsequent upregulation in 
transplanted oim compared 
to oim controls was also 
confirmed for the Sox9 
transactivation target 
Col2α1 (Bell, Leung et al. 
1997; Lefebvre, Huang et 
al. 1997) (0.11 2-ΔCt ± 0.01 
vs. 0.04 2-ΔCt ± 0.01 
respectively, P<0.05) and key cartilage matrix component Aggrecan (Muir 1995; Tsuji, 
Shimada et al. 2000) (4.8 2-ΔCt ± 0.8 vs. 1.1 2-ΔCt ± 0.4 respectively, P<0.01), found in 
proliferating chondrocytes. However, expression of the Sox9 target Pthrp, which inhibits 
chondrocyte maturation (Huang, Zhou et al. 2000; Huang, Chung et al. 2001; Amano, Hata et 
al. 2009) was similar in transplanted and non-transplanted oim (5.2 x10-4 2-ΔCt ± 0.7 x10-4 
s.e.m vs. 4.8 x10-4 2-ΔCt ± 0.5 x10-4, respectively). Importantly Smad3, which has been 
reported to inhibit maturation of chondrocytes through mediating TGF-β signalling 
(Ferguson, Schwarz et al. 2000) was downregulated in e-CSC transplanted mice compared to 
oim controls (1.8 x10-2 2-ΔCt ± 0.1 x10-2  vs. 4.4 x10-2 2-ΔCt ± 1.1 x10-2 respectively, P<0.05). 
This corresponded to increased expression in transplanted mice compared to non-transplanted 
oim, of chondrocyte maturation regulator Col10α1 (Arias, Nakamura et al. 1997) (1.0 2-ΔCt ± 
0.2 vs. 0.2 2-ΔCt ± 0.1 respectively, P<0.01) (Fig.41). 
 
G
en
e 
ex
pr
es
si
on
 (2
-
C
t )
0.0001
0.001
0.01
0.1
1
10
100 OIM
e-CSC
col21 pthrpsox9 col101acan smad3
*
**
**
**
 
Figure 41 – Transplantation upregulates endogenous 
endochondral ossification genes. 
Expression of genes involved in endochondral ossification; Sox9, 
Col2α1, Aggrecan (Acan), Col10α1, Smad3 and Pthrp. Results are 
given as 2-ΔCt normalised to mouse β-actin and Hsp90ab1 for non-
transplanted oim (OIM; blue) and oim transplanted with e-CSC 
(e-CSC; black). * P<0.05, ** P<0.01; Student’s t-test. Error bars 
are s.e.m. n = 5 oim, n = 8 transplanted mice. 
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As expected Sox9 correlated positively with its transactivation target Col2α1 (R2=0.84, 
P<0.001) (Fig.42A) (Zhao, Eberspaecher et al. 1997). Likewise Runx2 expression was 
closely linked with the expression of Col10α1 (R2=0.76, P<0.001), which is known to be 
transactivated by Runx2 during chondrocyte maturation as well as osteoblast differentiation, 
(Zheng, Zhou et al. 2003) (Fig.42B).  
 
Analysis of growth plate height confirmed previous findings (Guillot, Abass et al. 2008) that 
oim have larger growth plates than wild type mice (153μm ± 7 s.e.m vs. 137μm ± 9 
respectively, P<0.05).  Interestingly, e-CSC transplanted oim had a growth plate that was 
substantially wider (184μm ± 6) than the oim controls (P<0.05), primarily the result of a 
larger hypertrophic zone (84μm ± 4 for e-CSC transplanted oim vs. 60μm ± 7 for oim 
controls, P<0.01) (Fig.43A and Fig.43B). When the relative proportions of the growth plate 
zones were calculated, the hypertrophic zone formed a larger proportion of the total growth 
plate in the transplanted mice than non-transplanted (46.4% ± 1.1 vs. 39.5% ± 3.2 
respectively, P<0.05), in which the hypertrophic zone was similar to wild type mice (41.7% 
±1.2) (Fig.43C). This finding was consistent with gene expression studies that showed 
transplanted oim had a 10:1 ratio of late hypertrophic chondrocyte marker Col10α1 to 
proliferating chondrocyte marker Col2α1, whereas in non-transplanted oim the ratio was 4:1 
(P<0.05). 
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Figure 42 - Chondrogenesis genes have linked expressions. 
Correlation of gene expression per mouse (given as 2-ΔCt normalised to mouse β-actin and 
Hsp90ab1) of (a) Sox9 and Col2α1 and (b) Col10α1 and Runx2. Linear line of best fit given. 
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Figure 43 – Transplanted oim have more hypertrophic chondrocytes. 
(a) Tibial growth plate architecture of 8 week old wild type (WT), non-transplanted oim (OIM) and 
transplanted oim (e-CSC). Chondrocyte matrix is stained blue and contains a reserve zone (RZ) of 
cells undergoing clonal expansion, a proliferative zone (PZ) containing columns of proliferating 
chondrocytes, and a hypertrophic zone (HZ) of differentiating chondrocytes. Scale bar is 20µm. n = 3 
per group. (b) Average widths of the tibial growth plate RZ (white), PZ (light grey) and HZ (dark 
grey). Significance shown for total growth plate and HZ height. Data. * P<0.05, ** P<0.01; Student’s 
t-test. Error bars are s.e.m. (c) Ratio of zones (RZ, PZ, and HZ) within the growth plate. n = 5 WT, n 
= 5 oim, n = 14 transplanted mice. 
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As expected, there was a positive correlation (R2=0.75, P<0.01) between Col10α1 expression 
and the size of the hypertrophic zone of chondrocytes in the growth plate, shown per mouse 
(Fig.44). Importantly the size of the hypertrophic zone also positively correlated with 
increased bone plasticity in transplanted oim (R2=0.64, P<0.01) (Fig.45). This suggests 
changes to the mechanical properties of the bone may be due to the paracrine effect of 
transplanted cells on endogenous chondrogenesis in addition to the direct differentiation of 
donor cells. 
 
4.4.3. Discussion 
I have shown changes in the expression of endogenous endochondral ossification genes in e-
CSC transplanted oim, which corresponded with increased chondrocyte differentiation and 
may in part be responsible for the increased plasticity of the transplanted oim bones. 
Therefore my findings suggest e-CSC transplantation may have a paracrine effect on 
endogenous endochondral ossification. I have shown upregulation in transplanted oim of 
endogenous chondrogenesis genes including chondrogenesis regulator Sox9 (Bi, Deng et al. 
1999) and Runx2, implicated in chondrocyte maturation through Col10α1 transactivation 
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Figure 44 - Hypertrophic zone size corresponds 
to endogenous Col10a1 expression. 
Correlation of gene expression (given as 2-ΔCt 
normalised to mouse β-actin and Hsp90ab1) of 
Col10α1 and width of the hypertrophic zone (HZ) 
of the growth plate. Linear line of best fit given. 
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Figure 45 - Changes in chondrogenesis 
correlate with changes in bone plasticity. 
Correlation of bone plasticity (total energy 
input from yield to fracture in millijoules) and 
width of the hypertrophic zone (HZ) of the 
growth plate. Linear line of best fit given. 
  Gemma Nicole Jones 
124 
 
(Zheng, Zhou et al. 2003). Whilst expression of chondrocyte maturation inhibitor Smad3 
(Ferguson, Schwarz et al. 2000) was downregulated in transplanted mice. These changes 
were associated with a larger zone of hypertrophic chondrocytes within the growth plate and 
more plastic bones. However, the physiological significance is questionable as there was no 
change in linear growth in the e-CSC transplanted oim compared to non-transplanted animals. 
 
The larger growth plate of e-CSC transplanted oim compared to oim controls is in contrast to 
previous data with first trimester blood hfMSC that instead showed normalisation of growth 
plate height in prenatally transplanted oim compared to controls (Guillot, Abass et al. 2008). 
This may suggest different mechanisms of action between different transplanted cell sources. 
For example, recent work by Horwitz et al. in oim mice suggested different sources of cells 
contributed through different mechanisms when used in cell therapy, with non-adherent bone 
marrow cells differentiating to osteoblasts that produced normal collagen, whilst bone 
marrow MSC increased lumbar vertebrae length via paracrine mechanisms on chondrocyte 
proliferation at the growth plate, possibly through release of soluble growth factors (Otsuru, 
Gordon et al. 2012). 
 
Transplanted oim also had upregulation of endogenous genes associated with osteoblast 
differentiation, including Dmp1, Phex and Bgn (Lorenz-Depiereux, Bastepe et al. 2006; 
Wang, Harimoto et al. 2010; Martin, Liu et al. 2011). Oim have lower BV/TV than wild type 
mice due to an impaired osteoblast differentiation (Kalajzic, Terzic et al. 2002; Li, Jiang et al. 
2010). Therefore the increased BV/TV found in the transplanted oim may result from an 
indirect effect of the transplanted e-CSC on endogenous osteoblast differentiation. Others 
have also shown an effect of transplantation on endogenous osteoblast activity, for example 
transplantation of osteogenic differentiated MSC in SCID mice resulted in increased bone 
being produced by host cells (Zhou, Fan et al. 2012), and endogenous osteoblast numbers and 
bone formation was increased after transplantation of term placental stem cells in a SCID-rab 
mouse model of medullary myeloma-associated bone loss (Li, Ling et al. 2011). 
 
From these findings I show that e-CSC has potential to treat OI and I hypothesise that e-CSC 
function in the oim model via a combination of direct osteoblast differentiation and indirect 
regulation of endogenous osteogenesis and chondrogenesis.  
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4.5. Improved donor cell chemotaxis translates to therapeutic benefits 
4.5.1. Introduction 
The clinical effectiveness of fetal cell therapy is challenged by low levels of engraftment in 
target organs. For example, I found engraftment of e-CSC and l-CSC reached a maximum of 
3.9% and 3.6% respectively in oim bone marrow, which is similar to the maximum of 5% 
engraftment of blood hfMSC in oim (Guillot, Abass et al. 2008; Vanleene, Saldanha et al. 
2011). The importance of the SDF1-CXCR4 chemotaxis axis has been shown for engraftment 
of hematopoietic stem cells (Tocci, Roberts et al. 2003) and for MSC migration to sites of 
tissue injury (Kucia, Jankowski et al. 2004; Son, Marquez-Curtis et al. 2006; Granero-Molto, 
Weis et al. 2009). Studies have shown adult MSC lack expression of CXCR4 (Von Luttichau, 
Notohamiprodjo et al. 2005), although this finding is not consistent (Ponte, Marais et al. 
2007). Data from our group has shown all blood hfMSC express intracellular CXCR4, which 
is externalised when exposed to SDF1. Results showed increased in vitro migration of blood 
hfMSC to SDF1 as well as to oim bone and bone marrow when cells were first primed with 
SDF1. This was verified in vivo and showed SDF1 primed blood hfMSC had higher levels of 
bone engraftment compared to the non-primed cells [Data from Dr. Moschidou et al. 
published in (Jones, Moschidou et al. 2012)]. I subsequently investigated if the increased 
engraftment of donor cells in oim resulted in a better therapeutic outcome. 
 
4.5.2. Results 
By 8 weeks of age all control oim (16/16) had at least one long bone fracture (tibia, femur, 
humerus). Whereas only 27.8% (5/18 mice, P<0.001) of 8 week old oim transplanted 
neonatally with human fetal MSC (hfMSC) from first trimester blood had a fracture. When 
cells were primed with SDF1 prior to transplantation, the percentage of mice with fractures 
was lower still, with only 18.2% (4/22 mice, P<0.001 compared to oim controls) having a 
fracture (Fig.46A). The fracture incidence (number of fractured bones/total bones) of oim 
transplanted with SDF1 primed blood hfMSC was reduced compared to control oim (4.5% 
fractures vs. 27.1%, respectively, χ2=32.8, P<0.001) and was lower than oim transplanted 
with unprimed cells (8.3% fractures, χ2=18.3, P<0.001 compared to oim controls), although 
significance was not reached (Fig.46B). This corresponded to a 69% and 83% decrease in 
fracture rate in oim transplanted with unprimed and primed blood hfMSC respectively. 
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Figure 46 - Enhanced engraftment of FBL CXCR4+ has therapeutic benefits. 
(a) Percentage of 8 week old oim mice with at least one long bone fracture following transplantation 
of human fetal blood MSC (FBL; pink) or human fetal blood MSC primed with SDF1, 30ng/ml for 1 
hour (FBL CXCR4+; yellow) or not transplanted (OIM; blue). (b) Fracture rate; total proportion of 
fractured femur, tibia and humerus over total number of bones per mouse. Data. n.s. not significant, 
*** P<0.001; Fisher’s exact test or Chi squared test respectively. n = 16 oim, n = 18 FBL 
transplanted mice. n = 22 FBL CXCR4+ transplanted mice. 
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Figure 47 - Enhanced engraftment of FBL CXCR4+ improves bone mechanics. 
(a) Mechanical 3-point bending data for overall bone quality shown by total energy input in 
millijoules to fracture and for (b) femoral plasticity shown by energy input in millijoules from yield 
to fracture. Results shown per mouse for non-transplanted oim (OIM; blue) and oim transplanted 
with human fetal blood MSC (FBL; pink) or human fetal blood MSC primed with SDF1, 30ng/ml for 
1 hour (FBL CXCR4+; yellow). Data. n.s. not significant, * P<0.05, ** P<0.01, ***P<0.001; One-
way ANOVA followed by Tukey’s multiple comparison post hoc test. Error bars are s.e.m. n = 15 
oim, n = 15 FBL transplanted mice. n = 14 FBL CXCR4+ transplanted mice. 
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At the bone mechanical level the total energy required to fracture determined with the 3-point 
bending test was used to measure the overall quality of the bone. Findings showed that oim 
transplanted with SDF1 primed hfMSC had increased bone quality compared to oim 
transplanted with unprimed cells (1.7mJ ± 0.2 s.e.m vs.1.0mJ ± 0.1, P<0.05 respectively) and 
compared to oim controls (0.7mJ ± 0.1, P<0.001), indicating mice transplanted with primed 
hfMSC were more resistant to fracture (Fig.47A). To assess bone plasticity the post-yield 
strain was measured. Results showed increased bone plasticity of oim treated with SDF1 
primed cells compared to oim transplanted with unprimed blood hfMSC (1.4mJ ± 0.2 vs. 
0.8mJ ± 0.1, P<0.01 respectively) (Fig.47B). Both primed and unprimed groups had 
improved bone plasticity compared to the non-transplanted oim controls (0.3mJ ± 0.1, 
P<0.001 and P<0.05 respectively). [Three-point bending experiments carried out with the 
help of Maximilien Vanleene in the Department of Bioengineering, Imperial College 
London]. These results show the improved chemotaxis of donor cells to oim bone translated 
to a greater improvement in the oim disease pathology. 
 
 
 
4.5.3. Discussion 
 
Our lab has developed a strategy to improve the therapeutic benefits of fetal cell therapy by 
increasing the migration of transplanted cells to damaged tissues by first priming donor cells 
with SDF1. Transplanted primed blood hfMSC had increased CXCR4 expression and were 
able to enhance the bone quality and plasticity of oim significantly more than unprimed cells, 
due to increased migration of donor cells to the target tissue. The improved bone parameters 
resulted in lower fracture rates compared to control oim and a trend towards less fractures 
compared to oim transplanted with unprimed cells. This demonstrates the importance of the 
SDF1-CXCR4 axis in the chemotactic response of blood hfMSC to bone and may be 
applicable to other cell types such as the e-CSC. These findings are in line with others that 
showed migration of MSC to fractures was CXCR4-dependent (Granero-Molto, Weis et al. 
2009), whilst bone formation by MSC was inhibited if SDF1 is blocked (Kitaori, Ito et al. 
2009)al 2009). Finally Lein et al. transduced bone marrow MSC with CXCR4 to increase cell 
surface expression and showed improved bone mass, strength and stiffness over non-
transduced cells when transplanted in a model of osteoporosis (Lien, Chih-Yuan Ho et al. 
2009). 
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Low engraftment levels is one of the main challenges of stem cell therapy, for example I 
found only 2-4% engraftment of e-CSC in the bone marrow. I showed e-CSC engraftment in 
oim bone directly correlated with improvements in bone mechanical parameters. Stem cells 
isolated from the fetal part of term chorionic villi have shown migration in response to SDF-
1, PDGF, HGF and monocyte chemotactic protein-1 (MCP-1) (Abumaree, Al Jumah et al. 
2012). Therefore the next step to enhance the therapeutic effects of e-CSC transplantation 
would be to apply the same principles as with the blood hfMSC and prime the cells with 
SDF1 then test if the migratory response is increased. 
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CHAPTER 5 – Discussion, Conclusions and Future Work 
 
  Gemma Nicole Jones 
130 
 
5.1. Chorionic stem cells are candidates for cell therapy 
Identifying a safe, suitable and readily obtainable supply of therapeutic cells is a major 
challenge in regenerative medicine. My work characterises and compares two potential 
candidates; first trimester and term human placental chorionic stem cells (e-CSC and l-CSC 
respectively), available from discarded tissues after chorionic villous sampling /termination 
of pregnancy during the first trimester of pregnancy, or at term.  
 
Human chorionic stem cells are relatively accessible and easy to isolate in large numbers, can 
be sourced from surplus tissues at routine prenatal diagnostic procedures or at term delivery 
and thus used without ethical restrictions for allogeneic and autologous applications 
(Abdulrazzak, Moschidou et al. 2010). I have shown that the chorionic stem cells have an 
intermediate phenotype between MSC and hESC, showing features of both, and can be safely 
transplanted intra-peritoneal in neonatal oim mice and subcutaneously in a murine skin 
wound model without forming tumours. Others have shown these cells have potential for 
clinical use as both e-CSC (Poloni, Maurizi et al. 2011) and l-CSC (Fariha, Chua et al. 2011) 
can maintain a normal karyotype after long term expansion. The lack of telomerase activity 
and hTERT expression in e-CSC (Poloni, Maurizi et al. 2011) and l-CSC (Fariha, Chua et al. 
2011; Koo, Park et al. 2012) means undifferentiated cells are unlikely to transform into 
cancer cells when transplanted, although they do not self-renew and will senesce in culture. 
In addition e-CSC and l-CSC, like fetal liver MSC (Gotherstrom, Ringden et al. 2004), have 
low immunogenicity as they do not express HLA class II and their expression of HLA class I 
is low, which means an immune reaction is unlikely following allogeneic use (Le Blanc, 
Tammik et al. 2003). 
 
In addition to testing the repair capacity of chorionic stem cells, steps towards establishing 
the safety of placenta-derived cells are underway with preclinical testing. No adverse clinical 
signs were seen after administration of allogeneic term placenta derived stem cells in 
NOD/SCID mice (Ramot, Meiron et al. 2009) or when delivered by intramuscular injection 
to mice with critical limb ischemia (Prather, Toren et al. 2009). Likewise, transplantation of 
e-CSC into nude mice did not cause tumour formation and cells repopulated depleted 
hematopoietic tissues (Spitalieri, Cortese et al. 2009). Although I did not test tumorigenicity 
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in immune-deficient mice, I found no tumour formation in any of the mice transplanted with 
either e-CSC or l-CSC.  
 
Finally, placenta derived stem cells isolated at term have already been used safely in clinical 
trials, although fetal origin of the cells was not tested. For example, these cells were safely 
infused in a patient with acute myeloid leukemia (Brooke, Rossetti et al. 2009). Placental cell 
therapy has also been used safely in Phase I clinical trials by Celgene Cellular Therapeutics 
of 12 patients with Crohn’s disease, utilising the immuno-modulatory properties of l-CSC, no 
major toxicities were reported (Health. 2013). Finally term placenta derived stem cells are 
currently in Phase III clinical trials by Israel’s Pluristem Therapeutics for patients with 
critical limb ischemia and peripheral artery disease (Trounson, Thakar et al. 2011). Clinical 
trials using e-CSC as well as rigorous quality control standards are now needed to generate 
GMP-grade cells and test their long-term safety for use in allogeneic or autologous cell 
therapy, as well as for cell or tissue banking (Portmann-Lanz, Schoeberlein et al. 2006; Si, 
Zhao et al. 2011; Poloni, Maurizi et al. 2012).   
 
5.2. The more primitive characteristics of e-CSC are advantageous for 
cell therapy 
I showed in vitro that the phenotype of CSC changes during development, with e-CSC 
offering advantages relevant for cell therapy when compared with their term counterparts 
such as smaller size, faster growth kinetics, later senescence and greater osteogenic and 
adipogenic differentiation potency. These differences translate into greater repair potential of 
e-CSC over l-CSC in two different mouse models; skin wound repair and osteogenesis 
imperfecta.  
 
I hypothesised that the ability of transplanted cells to cross the trans-endothelial barrier of 
blood vessels and home to the target tissue sites may be aided by a smaller cell, which has 
less resistance to pass through the endothelium. However, engraftment of donor cells in oim 
bone was not significantly different 8 weeks after transplantation of e-CSC or l-CSC 
therefore the larger size of l-CSC did not appear to be the limiting factor to its therapeutic 
effects. Furthermore others have shown l-CSC can successfully migrate through the blood-
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brain barrier of rats (Kholodenko, Yarygin et al. 2012) and engraft in bone immune-deficient 
model of medullary myeloma bone disease (Li, Ling et al. 2011). It is also unlikely that the 
faster intrinsic growth kinetics of e-CSC over l-CSC were responsible for the differences in 
bone mechanical properties measured in the bone of e-CSC and l-CSC transplanted oim, 
since engraftment of donor cells was similar. Although, the increased expansion potential of 
e-CSC may be an advantage for its long term survival and functionality in host tissues.  
 
Instead my results suggest the greater inherent osteogenic differentiation potency of e-CSC 
compared to l-CSC translated to better results when these cells were transplanted in oim 
mice. In vitro e-CSC showed enhanced osteogenic differentiation with higher levels of 
osteogenic gene expression and more collagen type I protein produced than l-CSC. Similarly 
in vivo transplanted e-CSC showed higher expression of human specific osteogenic genes 
than l-CSC indicating more osteogenic differentiation, which corresponded with greater bone 
plasticity. Analysis of e-CSC transplanted oim also showed the production of COL1A2 and 
late osteoblast markers by donor cells indicating their differentiation to functional osteoblasts. 
Therefore the differentiation potency of donor cells seems to be important for the 
effectiveness of cell therapy and may in part explain why e-CSC were better than l-CSC in 
improving the mechanical properties of oim bones. 
 
Strategies to increase exogenous cell osteogenesis and increase production of COL1A2 could 
further improve the ability of e-CSC to treat OI, and could also be used to enhance the 
treatment success of l-CSC. In the literature various protocols have been tested to enhance 
osteogenic differentiation of MSC, which could be applicable. It has been found that 
spermine, found in platelet-rich plasma, increased Runx2 expression in MSC and 
subsequently enhanced osteoblastogenesis, resulting in more maturation of osteoblasts 
(Guidotti, Facchini et al. 2013). Histone deacetylase (HDAC) inhibitors, which are 
modulators of cell fate, also promote osteogenesis capacity of adult MSC and could be used 
to pre-treat cells before transplantation in orthopaedic applications (Ye, Fan et al. 2012; Hu, 
Zhang et al. 2013). Whilst Vitamin MK-7 co-supplementation with vitamin D3 has been 
shown to increase osteogenesis and angiogenesis genes in adult MSC and has potential for 
use with cell therapy (Gigante, Bruge et al. 2012). Alternatively bone healing has been shown 
to be promoted when irradiated with low-intensity laser therapy (Ebrahimi, Moslemi et al. 
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2012), or electromagnetic field stimulation, which enhanced chondrogenesis and osteogenesis 
of adipose derived stem cells (Chen, Lin et al. 2012). Further research with adipose derived 
stromal cells showed that the CD90+ cells have greater osteogenic capacity, and could be a 
potential candidate for selection prior to transplantation (Chung, Liu et al. 2012). 
  
5.3. Investigation of the trophic mechanisms of tissue repair 
My findings provide some insight into the mechanisms of action of e-CSC showing their 
osteoblast differentiation in oim bone. I also show that transplanted e-CSC may have an 
effect on endogenous chondrogenesis, which was associated with increased bone plasticity. 
This reflects the findings of Horwitz et al. in oim mice, that showed bone marrow MSC 
indirectly increased endogenous chondrocyte proliferation at the growth plate (Otsuru, 
Gordon et al. 2012). The concept that transplanted cells can influence endogenous progenitor 
cells is not new and has been reported in a wide range of other models. For example, 
transplanted bone marrow stem cells increased host pancreatic β cells in a diabetic mouse 
model (Urban, Kiss et al. 2008) and increased angiogenesis via endogenous endothelial 
differentiation in a primate model of myocardial infarction (Yoshioka, Ageyama et al. 2005), 
whilst transplanted neural progenitors increased endogenous neurogenesis in a rat model of 
stroke (Jin, Xie et al. 2011). These effects have been shown to be mediated by direct 
exchange of cytoplasmic components across cellular contacts (Plotnikov, Khryapenkova et al. 
2008; Cselenyak, Pankotai et al. 2010), but also release of soluble factors (Ankrum and Karp 
2010). 
 
Paracrine action by transplanted cells, such as release of trophic factors, has also been shown 
to aid tissue repair by reducing tissue inflammation, apoptosis and fibrosis and increasing 
tissue angiogenesis (Togel, Weiss et al. 2007; Zhang, Mal et al. 2007). My findings 
demonstrated tissue repair 7 days after transplantation of e-CSC into a skin wound mouse 
model, which was likely the result of beneficial paracrine factors affecting the endogenous 
differentiation and tissue repair. To test if soluble factors released by the transplanted cells 
were responsible for tissue repair, conditioned media from e-CSC could be applied instead to 
the cells. 
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Critically, more analysis of the paracrine effects of e-CSC in tissue regeneration in the skin 
wound model and oim is needed to understand how the cell phenotype translates to 
therapeutic benefits in vivo and to understand the fundamental mechanisms of action. In order 
to address this it would be essential to measure local and systemic growth factors produced 
by the transplanted cells (e.g. those that may affect bone and cartilage growth such as HIF-1, 
IGF-1, β-FGF, CTGF and PDGF), as well as to measure levels of inflammatory cytokines to 
determine if the exogenous cells had an anti-inflammatory response. Investigation into levels 
of proangiogenic molecules and quantification of blood vessels would indicate the effect of 
transplanted cells on angiogenesis. Whilst measurements of anti-apoptotic factors would 
show if transplanted cells promoted endogenous cell survival and proliferation, which would 
be beneficial to tissue repair (Phinney 2007; Dominici, Rasini et al. 2009). Comparing the 
number and activity of immune cells at sites of tissue repair (e.g. fractures) in transplanted 
and non-transplanted mice would also give an indication of the effect of transplanted cells on 
the immune response of the mice. 
 
Adult BM-MSC are known to be immune-modulatory with suppression of T-cell activation 
and proliferation, natural killer cell cytoxicity, B-cell maturation and induction of regulatory 
T-cells (Francois and Galipeau 2012). This property is an advantage for application in 
autoimmune diseases such as type I diabetes (Fiorina, Jurewicz et al. 2009), multiple sclerosis 
(Martino, Franklin et al. 2010; Tyndall 2010), rheumatoid arthritis (Bouffi, Djouad et al. 
2009) and graft versus host disease (Trento and Dazzi 2010; Francois and Galipeau 2012), 
although obtaining sufficient numbers of cells is difficult. Immune-suppressive properties 
have been demonstrated in both term and first trimester placenta derived stem cells 
(Cargnoni, Gibelli et al. 2009; Karlsson, Erkers et al. 2012; Lee, Jung et al. 2012; Poloni, 
Maurizi et al. 2012). However, a comparative study of the two CSC populations with adult 
BM-MSC is now needed to assess if a more primitive phenotype is an advantage or 
disadvantage in terms of immunosuppressive capacity.  
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5.4. Enhanced effectiveness of cell therapy by altering stem cell 
properties 
I showed that the effects of cell therapy in oim could be improved by priming blood hfMSC 
with SDF1 prior to transplantation, which upregulated the expression of external CXCR4 and 
subsequently led to increased homing of donor cells to bone. Preliminary tests have shown e-
CSC does not respond in the same way to SDF-1 priming, with external CXCR4 levels 
remaining the same after incubation with SDF-1. Subsequent ongoing work within the group 
is investigating if increasing the number of cells transplanted results in increased engraftment 
within the oim bone.  
 
The CXCR7 receptor also plays an important role in chemokine SDF-1 mediated migration 
and is required for cell growth, survival, endothelial adhesion and transendothelial migration 
(Burns, Summers et al. 2006; Mazzinghi, Ronconi et al. 2008). CXCR7 may therefore be an 
additional target, alongside CXCR4, to increase stem cell homing to the site of tissue repair. 
For example, hypoxic pre-conditioning has been shown to upregulate CXCR4 and CXCR7 in 
bone marrow MSC, which led to improved migration, adhesion and survival of MSC (Liu, 
Xue et al. 2010) and improved therapeutic potential of MSC (Hu, Yu et al. 2008; Rosova, 
Dao et al. 2008). This can also be achieved using chemicals or acidosis that induce hypoxia-
inducible factor-1, desferrioxamine and cobalt chloride (Liu, Xue et al. 2010; Cencioni, 
Melchionna et al. 2011). Alternatively a combination of gene and cell therapy could be used 
to upregulate expression of the Cxcr4 and Cxcr7 genes in the donor cells. The Cox2 gene 
could also be targeted, due to its role in MSC recruitment (Lau, Kothari et al. 2013). The 
successful transfer of genes into CSC using vectors has already been carried out in l-CSC 
(Han, Li et al. 2012), but has yet to be determined for e-CSC. 
 
5.5. Reprogramming e-CSC to pluripotency for wider cell therapy and 
tissue engineering applications 
My findings showed e-CSC endogenously expressed basal levels of the key pluripotency 
genes required for reprogramming; Klf4, Sox2 and c-Myc and the variant 1 isoform of Oct4A, 
critical for self renewal of pluripotent cells (Atlasi, Mowla et al. 2008; Ryan, Pettit et al. 
2011), albeit at a considerably lower level of expression than hESC.  
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Induced pluripotent stem cells (iPSC) have raised the possibility to generate unlimited patient 
specific pluripotent stem cells for use in a wide range of regenerative medicine settings, as 
well as for investigation of disease pathologies and drug screening. They were first generated 
using retroviral vectors to ectopically express four key pluripotency genes (Oct4A, Klf4, Sox2 
and c-Myc) from fibroblasts (Takahashi and Yamanaka 2006). However, viral integration 
methods have low efficiency, risk viral induced tumorigenicity from random integration and 
lack stability of the phenotype, whilst non-integration methods show promise but remain both 
inefficient and technically challenging (Mukherjee and Thrasher 2011). 
 
Recent work from Dr Pascale Guillot’s group has shown that first and second trimester 
human amniotic fluid stem cells (AFSC) can be reprogrammed to functional pluripotency 
without ectopic expression of transcription factors (Moschidou, Mukherjee et al. 2012; 
Moschidou, Mukherjee et al. 2012), due to the endogenous expression of Oct4A, Sox2, Klf4 
and c-Myc in the parental population. This means AFSC are ideal to generate patient specific 
iPSC, which can be rapidly grown to sufficient numbers for application in cell therapy or 
tissue engineering, whilst maintaining an identity that can differentiate to all the lineages of 
the three germ layers (Li, Zhou et al. 2009; Ye, Chang et al. 2009; Galende, Karakikes et al. 
2010). Induced pluripotent AFSC were generated by expansion of cells on Matrigel in low 
growth factor media supplemented with β-FGF and HDAC inhibitor valproic acid (VPA) 
(Moschidou, Drews et al. 2012; Moschidou and Guillot 2012; Moschidou, Mukherjee et al. 
2012; Moschidou, Mukherjee et al. 2012). In combination with environmental cues HDAC 
inhibitors upregulate gene transcription by increasing acetylation of histones and causing 
chromatin relaxation (Han, Lu et al. 2007). Identifying other clinically available sources that 
can be reprogrammed using only small molecules will further advance the movement of this 
field to the clinic and maximise the tissue types that can be banked for later therapeutic use. 
 
As a small side project with a BSc student [Hyein Chun] we investigated if the human 
chorionic stem cells could also be grown under hESC conditions and if, like the AFSC, had 
potential to be reprogrammed using small molecule supplementation. Our findings so far 
show that e-CSC, but not l-CSC, can survive and be expanded on Matrigel in low growth 
factor media supplemented with β-FGF (Nutristem, Sigma). The e-CSC formed compact 
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colonies on top of large fibroblastic flat colonies (Appendix 3A), as was the case for AFSC 
(Moschidou, Mukherjee et al. 2012; Moschidou, Mukherjee et al. 2012). Various epigenetic 
modifying chemical compounds were supplemented into the hESC media and e-CSC were 
assessed for cell survival and pluripotency gene expression. The HDAC inhibitor VPA 
(1mM) or the DNA methyltransferase inhibitor RG108 (100µM) compounds upregulated 
basal expression levels of Oct4A, Sox2 and Nanog in the e-CSC with minimal cell death 
(Appendix 3B) [Supervised work of Hyein Chun, December 2012]. Further analysis, 
including teratoma formation, is now required to determine if e-CSC have been 
reprogrammed to full pluripotency using this method. 
 
If successful it will be important to test if the reprogrammed cells can be fully differentiated 
to c-MYC negative cells that can be safely applied in regenerative medicine and to assess 
their differentiation potency. For applications in autoimmune diseases determining if the 
reprogrammed cells could be reverted to an MSC phenotype with immune-suppressive 
properties would provide a practical alternative to adult BM-MSC. These reprogrammed cells 
could also have wide applications in gene targeted therapy, once the feasibility and safety of 
vector gene transfer in the reprogrammed cells has been assessed, since they do not contain 
any previous viral integration. This greatly broadens the opportunities to use e-CSC safely in 
cell based therapies to treat a wide variety of disease pathologies as well as in tissue 
engineering. In combination with the fact e-CSC can be harvested during pregnancy, without 
causing harm to the fetus, these cells offer huge benefits over using adult bone marrow for 
use in prenatal and neonatal autologous or allogeneic therapy. 
 
 
5.6. Conclusion 
My work investigated the evolution of the stemness characteristics of chorionic stem cells 
during fetal development and demonstrates the therapeutic benefits of e-CSC to treat OI in a 
mouse model. Strategies to improve the therapeutic effects of these cells in OI are required 
before human trials if cell therapy using first trimester chorionic stem cells can become a 
standardized treatment for OI. 
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Appendix 1 – Controls for characterisation of MSC phenotype in CSC 
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Figure 48 – Controls used for MSC characterisation. 
(a) Human first trimester fetal bone marrow mesenchymal stem cells are negative for CD14, CD34, 
CD45 and HLA II, with some expression of HLA I and were used as a positive control for expression 
of CD105, CD73, CD44, Vimentin, CD29 and CD90. (b) Human umbilical vein endothelial cells 
were used as a positive control for expression of CD14, CD34 and CD45. (c) Interferon 
gamma stimulated human umbilical vein endothelial cells were used as a positive control for 
expression of HLA-ABC (HLA I) and HLA-DP, DQ, DR (HLA II). All genes stained with FITC 
(green). Nuclei stained with DAPI (blue). All scale bars are 100 µm. 
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Appendix 2 – Controls for investigation of PGC origin in CSC 
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Figure 49 – Positive controls for PGC markers. 
(a) Gene expression of loading control Gapdh for human second trimester amniotic fluid stem cells 
(AFSC), which were used as a positive control of c-kit expression in Figure 20. (b)  Gene expression 
of loading control β-actin for mouse testes, which were used as a positive control of Vasa expression 
in Figure 20. (c) Representative images of confocal immuno-fluorescence for protein expression of 
PGC markers; SSEA1, VASA, BLIMP1, FRAGILIS, STELLA, TNAP, PUM2, NANOS3 and DAZL 
using positive control first trimester AFSC, which exhibits characteristics of PGC (Moschidou, 
Mukherjee et al. 2012) (d) Representative flow cytometry for PGC markers in positive control first 
trimester AFSC (isotype control in black).  
  Gemma Nicole Jones 
161 
 
Appendix 3 – Reprogramming e-CSC using small molecules 
Reprogramming chemical
R
el
at
iv
e 
R
N
A
ex
pr
es
si
on
 (
%
 h
E
S
C
)
Basal RG VPA
0.001
0.01
0.1
1
10
100
1000
10000 OCT4
SOX2
NANOG
B
A
Large flat
fibroblast-
like cells
Compact
colony of
small round
cells
 
Figure 50 – Small molecule supplementation upregulates pluripotency genes 
(a) Photograph of morphology of e-CSC after 1 month of growth and passaging in low growth factor 
medium supplemented with β-FGF. Scale bar is 200 µm. (b) Quantitative real time PCR results 
showing increase in expression of Oct4A (orange), Sox2 (green) and Nanog (pink) following 7 days 
growth of e-CSC in low growth factor media supplemented with β-FGF and small molecules; RG108 
(RG) or valproic acid (VPA), or without media supplementation (Basal). Expression is normalised to 
Gapdh and given as a percentage relative to human embryonic stem cell levels (hESC). 
